<?xml version='1.0' encoding='UTF-8'?>
		<PROJECTS xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<row><APPLICATION_ID>9184925</APPLICATION_ID><ACTIVITY>K08</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>K08AR063696</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-193</FOA_NUMBER><FULL_PROJECT_NUM>3K08AR063696-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:1000\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Arthritis]]></CATEGORY><CATEGORY><![CDATA[Autoimmune Disease]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Rheumatoid Arthritis]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>030811269</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BRIGHAM AND WOMEN'S HOSPITAL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021156110</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Rheumatoid arthritis (RA) is a destructive autoimmune disease of the joints affecting 0.5-1% of the US population. Critical to RA development is activation of the fibroblast cells resident inside the joint, which amplify inflammation and drive cartilage and bone erosion. Understanding the pathways that promote activation and accumulation joint fibroblasts may provide new therapeutic targets to prevent long-term joint destruction in RA.]]></PHR><PIS><PI><PI_NAME>NOSS, ERIKA HEIDI</PI_NAME><PI_ID>10207048</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MAO, SU-YAU </PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2013</PROJECT_START><PROJECT_END>06/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[1-Phosphatidylinositol 3-Kinase]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Arthritis]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[Autoimmune Process]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood Platelets]]></TERM><TERM><![CDATA[bone erosion]]></TERM><TERM><![CDATA[cadherin-11]]></TERM><TERM><![CDATA[Cadherins]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Cartilage]]></TERM><TERM><![CDATA[Cell Adhesion Molecules]]></TERM><TERM><![CDATA[Cell Differentiation process]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Co-Immunoprecipitations]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[Flow Cytometry]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth Factor Receptors]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human PDGFRL protein]]></TERM><TERM><![CDATA[Hyperplasia]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immunofluorescence Immunologic]]></TERM><TERM><![CDATA[In Situ]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammation Mediators]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Arthritis]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[joint destruction]]></TERM><TERM><![CDATA[joint function]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mitogen-Activated Protein Kinase Kinases]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[PDGF receptor tyrosine kinase]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Platelet-Derived Growth Factor Receptor]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Activation]]></TERM><TERM><![CDATA[receptor expression]]></TERM><TERM><![CDATA[Receptor Protein-Tyrosine Kinases]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Rheumatoid Arthritis]]></TERM><TERM><![CDATA[Rheumatology]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[Stromal Cells]]></TERM><TERM><![CDATA[Synovial Membrane]]></TERM><TERM><![CDATA[Synovitis]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Tissue Model]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[tumor]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cadherin-11 growth factor receptor interactions in RA fibroblast hyperplasia]]></PROJECT_TITLE><SERIAL_NUMBER>063696</SERIAL_NUMBER><STUDY_SECTION>AMS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>926</DIRECT_COST_AMT><INDIRECT_COST_AMT>74</INDIRECT_COST_AMT><TOTAL_COST>1000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9015764</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK052574</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK052574-17</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:256218\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Networking and Information Technology R&D]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[AITAC assists and trains investigators in the morphologic analysis and advanced imaging of the Gl tract and 
liver, to advance the DDRCC's mission. We provide training in a wide array of histologic and immunohistochemical 
techniques, access to unique imaging capabilities, and sophisticated image analysis tools. We 
provide services to 49 Full and 11 Associate DDRCC members in a highly cost-effective manner.]]></PHR><PIS><PI><PI_NAME>RUBIN, DEBORAH C.</PI_NAME><PI_ID>1859991</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Animal Diseases]]></TERM><TERM><![CDATA[animal tissue]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Computer software]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[Electron Microscopy]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Histologic]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[human tissue]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[imaging system]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[in vivo imaging]]></TERM><TERM><![CDATA[investigator training]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Microscope]]></TERM><TERM><![CDATA[Microscopic]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[quantitative imaging]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Staining method]]></TERM><TERM><![CDATA[Stains]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tissue Embedding]]></TERM><TERM><![CDATA[tissue processing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Transmission Electron Microscopy]]></TERM><TERM><![CDATA[two-photon]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Washington]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core C: Advanced Imaging and Tissue Analysis Core]]></PROJECT_TITLE><SERIAL_NUMBER>052574</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8152</SUBPROJECT_ID><SUPPORT_YEAR>17</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>168012</DIRECT_COST_AMT><INDIRECT_COST_AMT>88206</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>256218</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9189395</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>397</CFDA_CODE><CORE_PROJECT_NUM>P30CA006516</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-11-005</FOA_NUMBER><FULL_PROJECT_NUM>3P30CA006516-51S4</FULL_PROJECT_NUM><FUNDING_ICs>NCI:200000\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>076580745</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[DANA-FARBER CANCER INST]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>022155450</ORG_ZIPCODE><PHR><![CDATA[RELEVANCE: The primary goal of the Center is to promote collaborative interactions that will lead to new approaches to cancer prevention, diagnosis and treatment.]]></PHR><PIS><PI><PI_NAME>BENZ, EDWARD J</PI_NAME><PI_ID>1887430</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PTAK, KRZYSZTOF </PROGRAM_OFFICER_NAME><PROJECT_START>03/10/1997</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Advanced Malignant Neoplasm]]></TERM><TERM><![CDATA[anticancer research]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Boston]]></TERM><TERM><![CDATA[Cancer Center]]></TERM><TERM><![CDATA[Cancer Center Support Grant]]></TERM><TERM><![CDATA[cancer prevention]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Comprehensive Cancer Center]]></TERM><TERM><![CDATA[Conduct Clinical Trials]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Dana-Farber Cancer Institute]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[forging]]></TERM><TERM><![CDATA[General Hospitals]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health Sciences]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Israel]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Massachusetts]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[NCI-Designated Cancer Center]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Pediatric Hospitals]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Public Health Schools]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Resource Sharing]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Talents]]></TERM><TERM><![CDATA[Transcend]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cancer Center Support Grant]]></PROJECT_TITLE><SERIAL_NUMBER>006516</SERIAL_NUMBER><STUDY_SECTION>NCI</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Subcommittee G - Education ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>51</SUPPORT_YEAR><SUFFIX>S4</SUFFIX><DIRECT_COST_AMT>200000</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>200000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9188904</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>R01GM113046</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01GM113046-02</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:368113\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Glycans, also known as polysaccharides, are involved in a variety of physiological and pathological processes in humans, ranging from normal to neoplastic development. Cell-surface glycans undergo drastic changes during disease progression and have great potential to be used as biomarkers for disease diagnosis. However, few methods exist to detect these glycans in live cells and tissue samples. This project is aimed to develop highly specific, sensitive, and low cost techniques to label complex glycans on the surface of live cells and apply them towards the labeling of human tumor samples in a method termed `CHoMP' (Chemoenzymatic Histology of Membrane Polysaccharides), which may be translated into a clinical diagnostic tool to guide cancer therapies.   
      

]]></PHR><PIS><PI><PI_NAME>WU, PENG </PI_NAME><PI_ID>8650265</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MARINO, PAMELA </PROGRAM_OFFICER_NAME><PROJECT_START>08/15/2015</PROJECT_START><PROJECT_END>07/31/2019</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Chemoenzymatic methods for the detection of cell-surface glycans]]></PROJECT_TITLE><SERIAL_NUMBER>113046</SERIAL_NUMBER><STUDY_SECTION>SBCA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Synthetic and Biological Chemistry A Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>224583</DIRECT_COST_AMT><INDIRECT_COST_AMT>143530</INDIRECT_COST_AMT><TOTAL_COST>368113</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8975192</APPLICATION_ID><ACTIVITY>R25</ACTIVITY><ADMINISTERING_IC>ES</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>113</CFDA_CODE><CORE_PROJECT_NUM>R25ES025060</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF VETERINARY MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-13-104</FOA_NUMBER><FULL_PROJECT_NUM>5R25ES025060-02</FULL_PROJECT_NUM><FUNDING_ICs>NIEHS:58965\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>EAST LANSING</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>193247145</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MICHIGAN STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>MI</ORG_STATE><ORG_ZIPCODE>488242600</ORG_ZIPCODE><PHR><![CDATA[Public Health Relevance: A summer research program in environmental health and toxicology will provide opportunities for underrepresented minority students to receive first time mentored introductory experiences in laboratory research. Coupled with professional development activities aimed at improving both verbal and written scientific communication, introduction to research career opportunities in environmental health and ethical conduct of research, the proposed program should prepare the student for a more extensive subsequent research experience. The ultimate goal is to increase the number of under-represented minority scientists engaged in environmental health and toxicology research.]]></PHR><PIS><PI><PI_NAME>ATCHISON, WILLIAM D</PI_NAME><PI_ID>1879154</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HUMBLE, MICHAEL C</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2014</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Ally]]></TERM><TERM><![CDATA[Asian Americans]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Career Choice]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disabled Persons]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Ecology]]></TERM><TERM><![CDATA[Educational Activities]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[environmental agent]]></TERM><TERM><![CDATA[Environmental Health]]></TERM><TERM><![CDATA[environmental toxicology]]></TERM><TERM><![CDATA[Ethics]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[gene environment interaction]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[graduate student]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Hispanic Americans]]></TERM><TERM><![CDATA[Hispanics]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Laboratory Research]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[lead exposure]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Michigan]]></TERM><TERM><![CDATA[Migrant Workers]]></TERM><TERM><![CDATA[Minority Groups]]></TERM><TERM><![CDATA[Minority-Serving Institution]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[National Institute of Environmental Health Sciences]]></TERM><TERM><![CDATA[National Institute of Neurological Disorders and Stroke]]></TERM><TERM><![CDATA[Native Americans]]></TERM><TERM><![CDATA[Neurosciences]]></TERM><TERM><![CDATA[New Mexico]]></TERM><TERM><![CDATA[news]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Pesticides]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[posters]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Puerto Rico]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[role model]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Societies]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stream]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Texas]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Toxic Environmental Substances]]></TERM><TERM><![CDATA[Toxicology]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[undergraduate research]]></TERM><TERM><![CDATA[undergraduate student]]></TERM><TERM><![CDATA[Underrepresented Minority]]></TERM><TERM><![CDATA[underrepresented minority student]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[First Time Summer Research Experience in Environmental Health Sciences]]></PROJECT_TITLE><SERIAL_NUMBER>025060</SERIAL_NUMBER><STUDY_SECTION>ZES1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>54597</DIRECT_COST_AMT><INDIRECT_COST_AMT>4368</INDIRECT_COST_AMT><TOTAL_COST>58965</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9016530</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK034987</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK034987-31</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:77520\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Networking and Information Technology R&D]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CHAPEL HILL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>608195277</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF NORTH CAROLINA CHAPEL HILL]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>275990001</ORG_ZIPCODE><PHR><![CDATA[Conducting high quality clinical translational and epidemiological research requires a sophisticated 
bioinformatics platform to collect, store and analyze the data. Investigators need ready access to consultation 
in study design, data management and biostatistics. The Biostatistics and Bioinformatics core has the 
personnel and expertise to enhance the quality and the integrity of research conducted by CGIBD members.]]></PHR><PIS><PI><PI_NAME>SANDLER, ROBERT S.</PI_NAME><PI_ID>1863678</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biometry]]></TERM><TERM><![CDATA[Biostatistics Core]]></TERM><TERM><![CDATA[Budgets]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[computer science]]></TERM><TERM><![CDATA[Computer software]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[data management]]></TERM><TERM><![CDATA[data modeling]]></TERM><TERM><![CDATA[Data Sources]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Epidemiologic Studies]]></TERM><TERM><![CDATA[Epidemiologist]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Informatics]]></TERM><TERM><![CDATA[Internet]]></TERM><TERM><![CDATA[Licensing]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[model development]]></TERM><TERM><![CDATA[Names]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Registries]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Software Tools]]></TERM><TERM><![CDATA[sound]]></TERM><TERM><![CDATA[Specialist]]></TERM><TERM><![CDATA[Statistical Data Interpretation]]></TERM><TERM><![CDATA[Statistical Study]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Systems Development]]></TERM><TERM><![CDATA[Systems Integration]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Translational Research]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core B: Biostatistics and Bioinformatics Core]]></PROJECT_TITLE><SERIAL_NUMBER>034987</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8182</SUBPROJECT_ID><SUPPORT_YEAR>31</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>49661</DIRECT_COST_AMT><INDIRECT_COST_AMT>27859</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>77520</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9144495</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>08/10/2015</BUDGET_START><BUDGET_END>12/31/2015</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>R01GM108647</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>7R01GM108647-02</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:221000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DUARTE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>32</ORG_DISTRICT><ORG_DUNS>027176833</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CITY OF HOPE/BECKMAN RESEARCH INSTITUTE]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>910103000</ORG_ZIPCODE><PHR><![CDATA[Project Narrative:
 The TET2/OGT complex plays an important role in gene transcription regulation. However, the molecular
mechanism of the TET2/OGT complex in transcription regulation remains elusive. In this proposal, we plan to
examine: 1) The role of the TET2/OGT complex in H2B ubiquitination; 2) The role of the TET2/OGT complex in
histone acetylation; 3) The functional interaction between the TET2/OGT complex and the TET1/SIN3A
complex. The results are likely to reveal novel mechanisms of epigenetic modifications in transcription.]]></PHR><PIS><PI><PI_NAME>YU, XIAOCHUN </PI_NAME><PI_ID>8855757</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BARSKI, OLEG </PROGRAM_OFFICER_NAME><PROJECT_START>01/01/2015</PROJECT_START><PROJECT_END>12/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Affinity Chromatography]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Chromatin]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[CpG dinucleotide]]></TERM><TERM><![CDATA[Cytosine]]></TERM><TERM><![CDATA[demethylation]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Methylation]]></TERM><TERM><![CDATA[DNA Modification Methylases]]></TERM><TERM><![CDATA[embryonic stem cell]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[gene repression]]></TERM><TERM><![CDATA[Gene Silencing]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Genomic DNA]]></TERM><TERM><![CDATA[HDAC1 gene]]></TERM><TERM><![CDATA[Histone Acetylation]]></TERM><TERM><![CDATA[histone acetyltransferase]]></TERM><TERM><![CDATA[Histone H2B]]></TERM><TERM><![CDATA[histone modification]]></TERM><TERM><![CDATA[Histones]]></TERM><TERM><![CDATA[Hypermethylation]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Lysine]]></TERM><TERM><![CDATA[methyl group]]></TERM><TERM><![CDATA[Methylation]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[O-GlcNAc transferase]]></TERM><TERM><![CDATA[oxidation]]></TERM><TERM><![CDATA[peptide O-linked N-acetylglucosamine-beta-N-acetylglucosaminidase]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Promoter Regions (Genetics)]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Pyrimidine]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Tail]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Transcription Initiation Site]]></TERM><TERM><![CDATA[Transcriptional Activation]]></TERM><TERM><![CDATA[Transcriptional Regulation]]></TERM><TERM><![CDATA[Ubiquitination]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Functional analysis of the TET2/OGT complex in epigenetic modifications]]></PROJECT_TITLE><SERIAL_NUMBER>108647</SERIAL_NUMBER><STUDY_SECTION>CG</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cancer Genetics Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>130000</DIRECT_COST_AMT><INDIRECT_COST_AMT>91000</INDIRECT_COST_AMT><TOTAL_COST>221000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9019626</APPLICATION_ID><ACTIVITY>R03</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>12/24/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>R03HD087111</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-13-304</FOA_NUMBER><FULL_PROJECT_NUM>1R03HD087111-01</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:77250\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Basic Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Sleep Research]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>EVANSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHOLOGY]]></ORG_DEPT><ORG_DISTRICT>09</ORG_DISTRICT><ORG_DUNS>160079455</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NORTHWESTERN UNIVERSITY]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>602013149</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Sleep is important for neurological and psychological health, as well as memory processes and the incubation stage of problem solving, perhaps through a common mechanisms. The proposed project tests whether targeted memory reactivation during specific sleep stages enhances solving of previously presented problems. The research could lead to a method for facilitating creative problem solving, and to better understanding the mechanisms involved.   
      

]]></PHR><PIS><PI><PI_NAME>BEEMAN, MARK E</PI_NAME><PI_ID>1863743</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MANN KOEPKE, KATHY M</PROGRAM_OFFICER_NAME><PROJECT_START>12/24/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aging]]></TERM><TERM><![CDATA[Anecdotes]]></TERM><TERM><![CDATA[awake]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Cognitive deficits]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Confusion]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Electroencephalography]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Incubated]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[memory consolidation]]></TERM><TERM><![CDATA[memory process]]></TERM><TERM><![CDATA[mental age]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Problem Solving]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Route]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleep Stages]]></TERM><TERM><![CDATA[Slow-Wave Sleep]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[sound]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Walkers]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Targeted problem reactivation and incubation during slow-wave sleep]]></PROJECT_TITLE><SERIAL_NUMBER>087111</SERIAL_NUMBER><STUDY_SECTION>CP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cognition and Perception Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>50000</DIRECT_COST_AMT><INDIRECT_COST_AMT>27250</INDIRECT_COST_AMT><TOTAL_COST>77250</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9191581</APPLICATION_ID><ACTIVITY>K08</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>02/29/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>K08AR063668</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-193</FOA_NUMBER><FULL_PROJECT_NUM>3K08AR063668-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:1000\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Autoimmune Disease]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Lupus]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>ANN ARBOR</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>073133571</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MICHIGAN]]></ORG_NAME><ORG_STATE>MI</ORG_STATE><ORG_ZIPCODE>481091276</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Systemic Lupus Erythematosus is a devastating autoimmune disease that affects up to 0.5% of the US population. It results in severe organ damage, elevated risk of cardiovascular disease, and disfiguring scars. Current therapies are globally immunosuppressive and cause significant morbidity. In order to improve patient care and create better treatments, an improved understanding of the mechanisms that drive lupus development is required. This proposal strives to create a pathway by which the candidate can develop an integrated knowledge of the mechanisms of systemic and cutaneous lupus and begin to dissect the role of the inflammasome and innate immunity in this disease. The results of this work will provide novel targets for treatment development and lead to improved patient care and outcomes.]]></PHR><PIS><PI><PI_NAME>KAHLENBERG, JOANNE MICHELLE</PI_NAME><PI_ID>10972743</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MANCINI, MARIE </PROGRAM_OFFICER_NAME><PROJECT_START>03/01/2013</PROJECT_START><PROJECT_END>02/28/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acceleration]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Career Choice]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cicatrix]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cutaneous]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Cytokine Activation]]></TERM><TERM><![CDATA[Dermatitis]]></TERM><TERM><![CDATA[Dermatologic]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Development Plans]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease model]]></TERM><TERM><![CDATA[Dissection]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Exanthema]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[human subject]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[Immunosuppressive Agents]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo Model]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Infiltrate]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Interferon Type I]]></TERM><TERM><![CDATA[Interferons]]></TERM><TERM><![CDATA[Interleukin-18]]></TERM><TERM><![CDATA[Internal Medicine]]></TERM><TERM><![CDATA[International]]></TERM><TERM><![CDATA[keratinocyte]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Lupus]]></TERM><TERM><![CDATA[lupus cutaneous]]></TERM><TERM><![CDATA[Lupus Erythematosus, Cutaneous, Subacute]]></TERM><TERM><![CDATA[lupus prone mice]]></TERM><TERM><![CDATA[lupus-like]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical Research]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Michigan]]></TERM><TERM><![CDATA[Mites]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Natural Immunity]]></TERM><TERM><![CDATA[Nephritis]]></TERM><TERM><![CDATA[neutrophil]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[oral communication]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[Prevention strategy]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[prognostic]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research and development]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rheumatology]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Running]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[skin disorder]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[systemic autoimmune disease]]></TERM><TERM><![CDATA[Systemic disease]]></TERM><TERM><![CDATA[Systemic Lupus Erythematosus]]></TERM><TERM><![CDATA[Systems Biology]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Transcriptional Regulation]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Tumor Necrosis Factor-alpha]]></TERM><TERM><![CDATA[Ultraviolet Rays]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Western Blotting]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Role of Innate Immunity in Systemic and Cutaneous Lupus]]></PROJECT_TITLE><SERIAL_NUMBER>063668</SERIAL_NUMBER><STUDY_SECTION>AMS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>926</DIRECT_COST_AMT><INDIRECT_COST_AMT>74</INDIRECT_COST_AMT><TOTAL_COST>1000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9023035</APPLICATION_ID><ACTIVITY>R15</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/22/2015</BUDGET_START><BUDGET_END>11/30/2018</BUDGET_END><CFDA_CODE>395</CFDA_CODE><CORE_PROJECT_NUM>R15CA202618</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[BIOMED ENGR/COL ENGR/ENGR STA]]></ED_INST_TYPE><FOA_NUMBER>PA-13-313</FOA_NUMBER><FULL_PROJECT_NUM>1R15CA202618-01</FULL_PROJECT_NUM><FUNDING_ICs>NCI:431999\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Breast Cancer]]></CATEGORY><CATEGORY><![CDATA[Cancer]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>PROVO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ENGINEERING (ALL TYPES)]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>009094012</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BRIGHAM YOUNG UNIVERSITY]]></ORG_NAME><ORG_STATE>UT</ORG_STATE><ORG_ZIPCODE>846021001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The research proposed here is relevant to public health because an understanding of 14-3-3? regulation and survival pathways will enhance our ability to rationally target the pro-tumor effects of 14-3-3? in human cancer and thereby improve outcomes for cancer patients. This work is pertinent to the NCI's goal of elucidating the basic mechanisms of cancer biology in order to ultimately eliminate suffering and death due to cancer.   
      

]]></PHR><PIS><PI><PI_NAME>ANDERSEN, JOSHUA LYON</PI_NAME><PI_ID>8831097</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KONDAPAKA, SUDHIR B</PROGRAM_OFFICER_NAME><PROJECT_START>12/22/2015</PROJECT_START><PROJECT_END>11/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acetylation]]></TERM><TERM><![CDATA[Anthracyclines]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Autophagocytosis]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Proteins]]></TERM><TERM><![CDATA[Breast Cancer Cell]]></TERM><TERM><![CDATA[Cancer Biology]]></TERM><TERM><![CDATA[Cancer Patient]]></TERM><TERM><![CDATA[Catabolic Process]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cellular Stress]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[chemotherapy]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cytotoxic Chemotherapy]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deacetylase]]></TERM><TERM><![CDATA[ERBB2 gene]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[HDAC6 gene]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[IGF1R gene]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Ischemia]]></TERM><TERM><![CDATA[Lysine]]></TERM><TERM><![CDATA[malignant breast neoplasm]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mammary Neoplasms]]></TERM><TERM><![CDATA[Manuscripts]]></TERM><TERM><![CDATA[MAP Kinase Gene]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular and Cellular Biology]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[neoplastic cell]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Nutrient]]></TERM><TERM><![CDATA[Oncogenic]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[PI3K/AKT]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[taxane]]></TERM><TERM><![CDATA[Taxane Compound]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Transforming Growth Factor beta]]></TERM><TERM><![CDATA[triple-negative invasive breast carcinoma]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[tumor growth]]></TERM><TERM><![CDATA[tumor microenvironment]]></TERM><TERM><![CDATA[tumor xenograft]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Xenograft procedure]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The regulation and targeting of cell survival pathways in cancer]]></PROJECT_TITLE><SERIAL_NUMBER>202618</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>299999</DIRECT_COST_AMT><INDIRECT_COST_AMT>132000</INDIRECT_COST_AMT><TOTAL_COST>431999</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9194039</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2014</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GPS003079</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-10-133</FOA_NUMBER><FULL_PROJECT_NUM>3U2GPS003079-05S2</FULL_PROJECT_NUM><FUNDING_ICs>COGH:227109\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NAIROBI</ORG_CITY><ORG_COUNTRY>KENYA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>360301993</ORG_DUNS><ORG_FIPS>KE</ORG_FIPS><ORG_NAME><![CDATA[HOPE WORLDWIDE KENYA]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>WHEELER, MALINDA </PI_NAME><PI_ID>9100529</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2010</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[PS10-10133: Supporting the Scale-up of Combination HIV/AIDS Prevention Services f]]></PROJECT_TITLE><SERIAL_NUMBER>003079</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>227109</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9177824</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>393</CFDA_CODE><CORE_PROJECT_NUM>R01CA117907</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>7R01CA117907-10</FULL_PROJECT_NUM><FUNDING_ICs>NCI:91446\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>AURORA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>041096314</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF COLORADO DENVER]]></ORG_NAME><ORG_STATE>CO</ORG_STATE><ORG_ZIPCODE>800452570</ORG_ZIPCODE><PHR><![CDATA[One of the most common genetic alterations in cancer cells is the functional inactivation of the tumor suppressor protein p53. The goal of this research project is to decipher the molecular mechanisms regulating the genes acting downstream of p53, which may enable the design of novel therapeutic strategies.]]></PHR><PIS><PI><PI_NAME>ESPINOSA, JOAQUIN M.</PI_NAME><PI_ID>8235921</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>JOHNSON, RONALD L</PROGRAM_OFFICER_NAME><PROJECT_START>05/26/2006</PROJECT_START><PROJECT_END>10/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[addiction]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Apoptotic]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[Autophagocytosis]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[cancer cell]]></TERM><TERM><![CDATA[CCCTC-binding factor]]></TERM><TERM><![CDATA[Cell Cycle Arrest]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cell Fate Control]]></TERM><TERM><![CDATA[Cell Separation]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chromatin]]></TERM><TERM><![CDATA[cofactor]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Deacetylation]]></TERM><TERM><![CDATA[deep sequencing]]></TERM><TERM><![CDATA[demethylation]]></TERM><TERM><![CDATA[Deposition]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Binding]]></TERM><TERM><![CDATA[DNA-Binding Proteins]]></TERM><TERM><![CDATA[Dominant-Negative Mutation]]></TERM><TERM><![CDATA[Enhancers]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gene Expression Regulation]]></TERM><TERM><![CDATA[gene repression]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic Screening]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Histone Deacetylation]]></TERM><TERM><![CDATA[Histone H3]]></TERM><TERM><![CDATA[Histones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human MDM2 protein]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[knock-down]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Lysine]]></TERM><TERM><![CDATA[Malignant Epithelial Cell]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Modern Medicine]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[nutlin 3]]></TERM><TERM><![CDATA[Oncogene Proteins]]></TERM><TERM><![CDATA[Oncogenes]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Polycomb]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[PRC1 Protein]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Protein p53]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Repression]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[senescence]]></TERM><TERM><![CDATA[small hairpin RNA]]></TERM><TERM><![CDATA[Squamous cell carcinoma]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tertiary Protein Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[therapy design]]></TERM><TERM><![CDATA[therapy development]]></TERM><TERM><![CDATA[TP53 gene]]></TERM><TERM><![CDATA[Trans-Activation (Genetics)]]></TERM><TERM><![CDATA[Transcript]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transcriptional Regulation]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[Tumor Suppressor Proteins]]></TERM><TERM><![CDATA[Untranslated RNA]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Mechanisms of Gene-Specific Transcriptional Regulation Within the p53 Network]]></PROJECT_TITLE><SERIAL_NUMBER>117907</SERIAL_NUMBER><STUDY_SECTION>CAMP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cancer Molecular Pathobiology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>10</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>58808</DIRECT_COST_AMT><INDIRECT_COST_AMT>32638</INDIRECT_COST_AMT><TOTAL_COST>91446</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8989979</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>394</CFDA_CODE><CORE_PROJECT_NUM>R01CA183749</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[BIOMED ENGR/COL ENGR/ENGR STA]]></ED_INST_TYPE><FOA_NUMBER>PAR-13-169</FOA_NUMBER><FULL_PROJECT_NUM>5R01CA183749-02</FULL_PROJECT_NUM><FUNDING_ICs>NCI:270931\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Dental/Oral and Craniofacial Disease]]></CATEGORY><CATEGORY><![CDATA[Diagnostic Radiology]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>MINNEAPOLIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOMEDICAL ENGINEERING]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>555917996</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MINNESOTA]]></ORG_NAME><ORG_STATE>MN</ORG_STATE><ORG_ZIPCODE>554552070</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Optimizing cancer photodynamic therapy (PDT) using photoacoustic lifetime imaging (PALI) Project Narrative The proposed work will lay the scientific and technological foundations for non-invasive imaging of oxygen distribution in cancer tumors. Low oxygen level (hypoxia) in tumors greatly inhibits cancer therapy and indicates a poor prognosis. Successful implementation of the technology would allow the oncologist to use tumor oxygen information to significantly improve the efficacy of photodynamic therapy of head and neck cancers.]]></PHR><PIS><PI><PI_NAME>ASHKENAZI, SHAI </PI_NAME><PI_ID>8765538</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ZHANG, YANTIAN </PROGRAM_OFFICER_NAME><PROJECT_START>12/22/2014</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[Animal Cancer Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blood capillaries]]></TERM><TERM><![CDATA[Blood flow]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Breathing]]></TERM><TERM><![CDATA[Cancer Biology]]></TERM><TERM><![CDATA[cancer diagnosis]]></TERM><TERM><![CDATA[Cancer Model]]></TERM><TERM><![CDATA[cancer therapy]]></TERM><TERM><![CDATA[Canis familiaris]]></TERM><TERM><![CDATA[case-by-case basis]]></TERM><TERM><![CDATA[Cell Hypoxia]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[chemotherapy]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical application]]></TERM><TERM><![CDATA[Clinical Assessment Tool]]></TERM><TERM><![CDATA[Clinical Treatment]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[common treatment]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Computers]]></TERM><TERM><![CDATA[Consumption]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[data acquisition]]></TERM><TERM><![CDATA[Dependency (Psychology)]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drops]]></TERM><TERM><![CDATA[Dyes]]></TERM><TERM><![CDATA[Electrodes]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Felis catus]]></TERM><TERM><![CDATA[Fiber Optics]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gases]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Head and Neck Cancer]]></TERM><TERM><![CDATA[head and neck cancer patient]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[image guided]]></TERM><TERM><![CDATA[Image Reconstructions]]></TERM><TERM><![CDATA[imaging agent]]></TERM><TERM><![CDATA[imaging modality]]></TERM><TERM><![CDATA[imaging probe]]></TERM><TERM><![CDATA[imaging system]]></TERM><TERM><![CDATA[Imaging Techniques]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Lasers]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Lighting]]></TERM><TERM><![CDATA[Localized Malignant Neoplasm]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[malignant mouth neoplasm]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Medical Imaging]]></TERM><TERM><![CDATA[Methylene blue]]></TERM><TERM><![CDATA[minimally invasive]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mouth Neoplasms]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Needles]]></TERM><TERM><![CDATA[Nitrogen]]></TERM><TERM><![CDATA[non-invasive imaging]]></TERM><TERM><![CDATA[Oncologist]]></TERM><TERM><![CDATA[Oral cavity]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[outcome forecast]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Penetration]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[photoacoustic imaging]]></TERM><TERM><![CDATA[Photosensitizing Agents]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Physiologic pulse]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[preclinical study]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proliferating]]></TERM><TERM><![CDATA[PUVA Photochemotherapy]]></TERM><TERM><![CDATA[Radiation therapy]]></TERM><TERM><![CDATA[Radiosurgery]]></TERM><TERM><![CDATA[Reading]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Relapse]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Systems Development]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Temperature]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapy outcome]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tissue oxygenation]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[Treatment outcome]]></TERM><TERM><![CDATA[treatment planning]]></TERM><TERM><![CDATA[Treatment Protocols]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[Tumor Oxygenation]]></TERM><TERM><![CDATA[tumor progression]]></TERM><TERM><![CDATA[Ultrasonography]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Optimizing cancer photodynamic therapy using photoacoustic lifetime imaging]]></PROJECT_TITLE><SERIAL_NUMBER>183749</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>205875</DIRECT_COST_AMT><INDIRECT_COST_AMT>65056</INDIRECT_COST_AMT><TOTAL_COST>270931</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8974828</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK039994</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>4R01DK039994-26</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:354895\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Autoimmune Disease]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Organ Transplantation]]></CATEGORY><CATEGORY><![CDATA[Transplantation]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SEATTLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>09</ORG_DISTRICT><ORG_DUNS>041332172</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PACIFIC NORTHWEST RESEARCH INSTITUTE]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>981224302</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The studies proposed in this competitive renewal focus on identifying mechanisms that are responsible for b- cell and a-cell fates after intrahepatic transplantation in humans. These putative mechanisms primarily involve inappropriate b-cell and a-cell secretory responses during hypoglycemia that occur because the cells are exposed to increased intrahepatic glycogenolysis and consequent increased interstitial glucose flux. Establishment of these mechanisms will provide convincing arguments that inclusion of non-hepatic sites will improve metabolic outcomes of autoislet, and by extension, alloislet, transplantation.]]></PHR><PIS><PI><PI_NAME>ROBERTSON, RODERICK PAUL</PI_NAME><PI_ID>1883600</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ARREAZA-RUBIN, GUILLERMO </PROGRAM_OFFICER_NAME><PROJECT_START>12/01/1988</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[adrenergic]]></TERM><TERM><![CDATA[Adrenergic Agents]]></TERM><TERM><![CDATA[Allografting]]></TERM><TERM><![CDATA[Alpha Cell]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Arginine]]></TERM><TERM><![CDATA[attenuation]]></TERM><TERM><![CDATA[Autoimmune Process]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Beta Cell]]></TERM><TERM><![CDATA[Bicycling]]></TERM><TERM><![CDATA[blood glucose regulation]]></TERM><TERM><![CDATA[C-Peptide]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemosensitization]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[chronic pancreatitis]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[diabetic patient]]></TERM><TERM><![CDATA[Drug Metabolic Detoxication]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Fasting]]></TERM><TERM><![CDATA[feeding]]></TERM><TERM><![CDATA[Flushing]]></TERM><TERM><![CDATA[functional decline]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Glucagon]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[glucose production]]></TERM><TERM><![CDATA[Glycogen]]></TERM><TERM><![CDATA[glycogenolysis]]></TERM><TERM><![CDATA[Glycosylated hemoglobin A]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hepatic]]></TERM><TERM><![CDATA[Hormonal]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hyperglycemia]]></TERM><TERM><![CDATA[Hypoglycemia]]></TERM><TERM><![CDATA[Immunosuppressive Agents]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Infusion procedures]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[insulin secretion]]></TERM><TERM><![CDATA[insulin sensitivity]]></TERM><TERM><![CDATA[Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[interstitial]]></TERM><TERM><![CDATA[intrahepatic]]></TERM><TERM><![CDATA[Intravenous]]></TERM><TERM><![CDATA[islet]]></TERM><TERM><![CDATA[Islets of Langerhans Transplantation]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Longitudinal Studies]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[metabolic abnormality assessment]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pancreas Transplantation]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Radio]]></TERM><TERM><![CDATA[Refractory]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Secretory Cell]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Somatostatin]]></TERM><TERM><![CDATA[Stomach]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Total Pancreatectomy]]></TERM><TERM><![CDATA[Toxic Environmental Substances]]></TERM><TERM><![CDATA[Transplant Recipients]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[transplantation typing]]></TERM><TERM><![CDATA[Travel]]></TERM><TERM><![CDATA[type I diabetic]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Pancreas and Islet Transplantation in Humans]]></PROJECT_TITLE><SERIAL_NUMBER>039994</SERIAL_NUMBER><STUDY_SECTION>CIDO</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Clinical and Integrative Diabetes and Obesity Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>26</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>195750</DIRECT_COST_AMT><INDIRECT_COST_AMT>159145</INDIRECT_COST_AMT><TOTAL_COST>354895</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9028857</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK104772</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01DK104772-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:518868\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Basic Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Depression]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Obesity]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>030811269</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BRIGHAM AND WOMEN'S HOSPITAL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021156110</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Difficulty losing weight and maintaining weight loss may be due in part to biological factors which favor increased intake of palatable foods in response to stress, including hormones such as ghrelin which act on brain reward regions to signal food reward sensitivity and attainment. In the proposed study, we plan to determine whether, following short-term psychosocial stress, ghrelin is associated with brain activity in response to palatable food and to monetary reward in individuals with chronic stress-related overconsumption of palatable foods. An improved mechanistic explanation for the relationship between stress and overeating will potentially inform the design of more effective intervention.   
      

]]></PHR><PIS><PI><PI_NAME>HOLSEN, LAURA MCGRATH</PI_NAME><PI_ID>6701826</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LAUGHLIN, MAREN R</PROGRAM_OFFICER_NAME><PROJECT_START>12/23/2015</PROJECT_START><PROJECT_END>11/30/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Amygdaloid structure]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Factors]]></TERM><TERM><![CDATA[Body Weight decreased]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[burden of illness]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Chemosensitization]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Chronic stress]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Desire for food]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Dimerization]]></TERM><TERM><![CDATA[Dopamine]]></TERM><TERM><![CDATA[Dopamine D1 Receptor]]></TERM><TERM><![CDATA[Dopamine D2 Receptor]]></TERM><TERM><![CDATA[dopaminergic neuron]]></TERM><TERM><![CDATA[Eating]]></TERM><TERM><![CDATA[effective intervention]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Functional Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[ghrelin]]></TERM><TERM><![CDATA[GHS-R1a]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[hedonic]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hyperphagia]]></TERM><TERM><![CDATA[Hypothalamic structure]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[increased appetite]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intake]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mood Disorders]]></TERM><TERM><![CDATA[Moods]]></TERM><TERM><![CDATA[Nucleus Accumbens]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[prognostic]]></TERM><TERM><![CDATA[prognostic value]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Psychosocial Stress]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[putamen]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[reward circuitry]]></TERM><TERM><![CDATA[Rewards]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Suicide]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Ventral Tegmental Area]]></TERM><TERM><![CDATA[Weight]]></TERM><TERM><![CDATA[Weight Gain]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Ghrelin Modulation of Mesolimbic Reward Signaling in Stress-induced Hyperphagia]]></PROJECT_TITLE><SERIAL_NUMBER>104772</SERIAL_NUMBER><STUDY_SECTION>APDA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Adult Psychopathology and Disorders of Aging Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>292320</DIRECT_COST_AMT><INDIRECT_COST_AMT>226548</INDIRECT_COST_AMT><TOTAL_COST>518868</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8983221</APPLICATION_ID><ACTIVITY>IK1</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>IK1RX001820</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-15-008</FOA_NUMBER><FULL_PROJECT_NUM>1IK1RX001820-01A1</FULL_PROJECT_NUM><FUNDING_ICs>VA:99404\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PORTLAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>089461255</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PORTLAND VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>OR</ORG_STATE><ORG_ZIPCODE>972392964</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
Exposure to high-intensity blast waves is one of the most prevalent dangers facing military service members in recent conflicts. Though survival rates are vastly improved over previous military encounters, blast-exposed warfighters often report lingering neurological symptoms affecting multiple sensory systems as well as cognitive processes. These deficits may stem from a common source of neural dysfunction. Using behavioral and electrophysiological techniques, this research project will investigate the hypothesis that blast exposure degrades the brain's normal ability to ignore irrelevant sensory information, thus making it more difficult or blast-exposed Veterans to focus on information of interest. We predict that such poor filtering of sensory information is linked to common symptoms such as poor speech understanding in noise. Our intention is to improve knowledge regarding chronic neurological consequences of blast exposure in the hopes of informing future efforts to assess and rehabilitate blast-related symptoms in the Veteran population.   
   
      

]]></PHR><PIS><PI><PI_NAME>PAPESH, MELISSA </PI_NAME><PI_ID>12156019</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Afghanistan]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Auditory]]></TERM><TERM><![CDATA[auditory rehabilitation]]></TERM><TERM><![CDATA[Auditory system]]></TERM><TERM><![CDATA[Auditory Threshold]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[behavior measurement]]></TERM><TERM><![CDATA[behavior test]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Blast Cell]]></TERM><TERM><![CDATA[Blast Injuries]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Data]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cognitive function]]></TERM><TERM><![CDATA[cognitive process]]></TERM><TERM><![CDATA[Cognitive Therapy]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Comprehension]]></TERM><TERM><![CDATA[Conflict (Psychology)]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Hearing]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Intention]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Iraq]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Leeks (dietary)]]></TERM><TERM><![CDATA[Linear Regressions]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Melissa]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[memory recall]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Military Personnel]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[Neurobehavioral Manifestations]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[Noise]]></TERM><TERM><![CDATA[noise perception]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Post-Traumatic Stress Disorders]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Questionnaires]]></TERM><TERM><![CDATA[Reaction Time]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[selective attention]]></TERM><TERM><![CDATA[Sensory]]></TERM><TERM><![CDATA[sensory gating]]></TERM><TERM><![CDATA[sensory system]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Shadowing (Histology)]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[sound]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Speech]]></TERM><TERM><![CDATA[Speech Perception]]></TERM><TERM><![CDATA[speech processing]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Stream]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Survival Rate]]></TERM><TERM><![CDATA[sustained attention]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Test Result]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Effects of Blast Exposure on Sensory Gating and Speech Perception in Noise]]></PROJECT_TITLE><SERIAL_NUMBER>001820</SERIAL_NUMBER><STUDY_SECTION>RRD9</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Blank ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9151035</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DA</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>279</CFDA_CODE><CORE_PROJECT_NUM>R01DA031852</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R01DA031852-05</FULL_PROJECT_NUM><FUNDING_ICs>NIDA:301221\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE ON DRUG ABUSE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BINGHAMTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>22</ORG_DISTRICT><ORG_DUNS>090189965</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STATE UNIVERSITY OF NY,BINGHAMTON]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>139026000</ORG_ZIPCODE><PHR><![CDATA[Behavior addictions, including the abuse of or dependence on drugs of abuse, cause substantial personal and social costs. Unfortunately, prevention and cessation treatments are few and of limited efficacy. With that in mind, understanding the genetic architecture of risk for addictions raises new avenues, not just for quantifying liability,
but for developing biomarkers that can be the target of prevention trials. Moreover, identification
of the molecular genetic mediators of addictions raises new potential treatment targets.]]></PHR><PIS><PI><PI_NAME>JENTSCH, J. DAVID </PI_NAME><PI_ID>7356157</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>POLLOCK, JONATHAN D</PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2015</PROJECT_START><PROJECT_END>04/30/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Genetic influences on inhibitory control and cocaine sensitivity]]></PROJECT_TITLE><SERIAL_NUMBER>031852</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>194336</DIRECT_COST_AMT><INDIRECT_COST_AMT>106885</INDIRECT_COST_AMT><TOTAL_COST>301221</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9197728</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000532</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-139</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000532-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:1000000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WASHINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>98</ORG_DISTRICT><ORG_DUNS>007041168</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ELIZABETH GLASER PEDIATRIC AIDS FDN]]></ORG_NAME><ORG_STATE>DC</ORG_STATE><ORG_ZIPCODE>200364028</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>DITEKEMENA, JOHN  </PI_NAME><PI_ID>10930867</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[PROVIDING A COMPREHESIVE CONTINUM OF HIV/AIDS CARE AND TREATEMENT SERVICES IN THE]]></PROJECT_TITLE><SERIAL_NUMBER>000532</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1000000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9184923</APPLICATION_ID><ACTIVITY>K08</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/10/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>K08AR064834</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-193</FOA_NUMBER><FULL_PROJECT_NUM>3K08AR064834-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:1000\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Arthritis]]></CATEGORY><CATEGORY><![CDATA[Autoimmune Disease]]></CATEGORY><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Rheumatoid Arthritis]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LA JOLLA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>804355790</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA SAN DIEGO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>920930934</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The proposed studies have direct significance for understanding mechanism of rheumatoid arthritis and may lead to novel therapeutic approaches. Rheumatoid arthritis is a chronic, debilitating condition and affects about 1% of the population in United States. There is a need for more effective, safer and affordable therapies.]]></PHR><PIS><PI><PI_NAME>GUMA, MONICA </PI_NAME><PI_ID>11566340</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MAO, SU-YAU </PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2013</PROJECT_START><PROJECT_END>08/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aggressive behavior]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[Arthritis]]></TERM><TERM><![CDATA[articular cartilage]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[California]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Cartilage]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Choline]]></TERM><TERM><![CDATA[Choline Kinase]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical phenotype]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Degenerative polyarthritis]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Development Plans]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Enzyme-Linked Immunosorbent Assay]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Fellowship]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammation Mediators]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Informatics]]></TERM><TERM><![CDATA[Invaded]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[joint destruction]]></TERM><TERM><![CDATA[joint injury]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[K/BxN model]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[kinase inhibitor]]></TERM><TERM><![CDATA[knock-down]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Magnetic Resonance Spectroscopy]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Matrix Metalloproteinases]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[metabolomics]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutic intervention]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[patient oriented research]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacotherapy]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Phospholipids]]></TERM><TERM><![CDATA[Phosphorylcholine]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[post-doctoral training]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[Prognostic Marker]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Institute]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rheumatoid Arthritis]]></TERM><TERM><![CDATA[Rheumatology]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[Spain]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Synovial Membrane]]></TERM><TERM><![CDATA[Synovitis]]></TERM><TERM><![CDATA[systemic autoimmune disease]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissue Sample]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Toxicology]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[tumorigenesis]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Universities]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Choline kinase: a novel target for rheumatoid arthritis]]></PROJECT_TITLE><SERIAL_NUMBER>064834</SERIAL_NUMBER><STUDY_SECTION>AMS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>926</DIRECT_COST_AMT><INDIRECT_COST_AMT>74</INDIRECT_COST_AMT><TOTAL_COST>1000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9056074</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/22/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK105689</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01DK105689-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:567233\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Autoimmune Disease]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>042250712</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PENNSYLVANIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191046205</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Beta cell failure underlies the development of all forms of diabetes; however, the high hopes for cell replacement therapy have been tempered by the poor efficiency of generating the mature beta cell phenotype in efforts to guide differentiation or
reprogramming of other cell types. We have identified two factors that work together to regulate the formation and maturation of beta cell progenitors. The information we generate may be useful to improve directed differentiation and reprogramming strategies to generate new fully functional &#223; cells from stem cells, progenitor cells, or other non-&#223; cells.      

]]></PHR><PIS><PI><PI_NAME>GANNON, MAUREEN A</PI_NAME><PI_ID>1970983</PI_ID></PI><PI><PI_NAME>STOFFERS, DORIS A. (contact)</PI_NAME><PI_ID>1870129 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SATO, SHERYL M</PROGRAM_OFFICER_NAME><PROJECT_START>12/22/2015</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Beta Cell]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Birth]]></TERM><TERM><![CDATA[Cell Count]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cell Lineage]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Double Effect]]></TERM><TERM><![CDATA[Ductal Epithelial Cell]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Embryonic Development]]></TERM><TERM><![CDATA[Endocrine]]></TERM><TERM><![CDATA[Endoderm]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Epithelium]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[gain of function]]></TERM><TERM><![CDATA[Gene Activation]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Epistasis]]></TERM><TERM><![CDATA[Glucagon]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Heterozygote]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human embryonic stem cell]]></TERM><TERM><![CDATA[Hyperglycemia]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[intestinal epithelium]]></TERM><TERM><![CDATA[islet]]></TERM><TERM><![CDATA[Islets of Langerhans]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Neonatal]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pancreas]]></TERM><TERM><![CDATA[pancreas development]]></TERM><TERM><![CDATA[Pancreatic duct]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[premature]]></TERM><TERM><![CDATA[Primitive foregut structure]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Replacement Therapy]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[stem cell differentiation]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[synergism]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[transcriptomics]]></TERM><TERM><![CDATA[transdifferentiation]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Formation and maturation of endocrine pancreas progenitors]]></PROJECT_TITLE><SERIAL_NUMBER>105689</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>402479</DIRECT_COST_AMT><INDIRECT_COST_AMT>164754</INDIRECT_COST_AMT><TOTAL_COST>567233</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9003047</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK041301</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK041301-27</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:388894\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ROZENGURT, JUAN ENRIQUE</PI_NAME><PI_ID>6774619</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Center for Translational Science Activities]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Extramural Activities]]></TERM><TERM><![CDATA[Feasibility Studies]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gastroenterology]]></TERM><TERM><![CDATA[gastrointestinal system]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Training and Education]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Pilot and Feasibility Program]]></PROJECT_TITLE><SERIAL_NUMBER>041301</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7946</SUBPROJECT_ID><SUPPORT_YEAR>27</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>309485</DIRECT_COST_AMT><INDIRECT_COST_AMT>79409</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>388894</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9046864</APPLICATION_ID><ACTIVITY>R44</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>395</CFDA_CODE><CORE_PROJECT_NUM>R44CA203336</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-071</FOA_NUMBER><FULL_PROJECT_NUM>1R44CA203336-01</FULL_PROJECT_NUM><FUNDING_ICs>NCI:282451\</FUNDING_ICs><FUNDING_MECHANISM>SBIR-STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Immunization]]></CATEGORY><CATEGORY><![CDATA[Orphan Drug]]></CATEGORY><CATEGORY><![CDATA[Pancreatic Cancer]]></CATEGORY><CATEGORY><![CDATA[Patient Safety]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY><CATEGORY><![CDATA[Vaccine Related]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>AUBURNDALE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>192959851</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ADVANTAGENE, INC]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>024661923</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Pancreatic adenocarcinoma has a 5-year survival rate of less than 5%, the lowest of all major cancers, with more than 37,000 deaths in the US each year. Pancreatic cancer is a major focus of the Recalcitrant Cancer Research Act, recently passed to encourage research support for this deadly cancer. This application proposes a multi-pronged approach with an aggressive chemoradiation regimen combined with a viral immuno-oncology product for pancreatic cancer. The goal is to increase the resection rate and 2-year survival without further compromising quality of life. The project builds on a completed Phase 1a trial with Gene Mediated Cytotoxic Immunotherapy (GMCI) combined with chemoradiation and surgery that established a safe dose level and demonstrated immune stimulation in pancreatic cancer. This Fast-Track grant proposal seeks to build on these results with a follow-on Phase 1b/2 clinical trial. Our clinical objective is to increase the number of patients that may undergo potentially curative resections and prevent development of metastases; thus, potentially achieve long-term clinical benefit. Our commercial goal is to develop a new therapeutic product for pancreatic cancer.]]></PHR><PIS><PI><PI_NAME>AGUILAR, LAURA K</PI_NAME><PI_ID>1927661</PI_ID></PI><PI><PI_NAME>AGUILAR-CORDOVA, ESTUARDO  (contact)</PI_NAME><PI_ID>6187479 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>EVANS, GREGORY </PROGRAM_OFFICER_NAME><PROJECT_START>12/23/2015</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[anticancer research]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Apoptotic]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[CD8B1 gene]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[chemoradiation]]></TERM><TERM><![CDATA[chemotherapy]]></TERM><TERM><![CDATA[Chemotherapy-Oncologic Procedure]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Protocols]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[commercialization]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[cytotoxic]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disorder control]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Dose-Limiting]]></TERM><TERM><![CDATA[efficacy evaluation]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Excision]]></TERM><TERM><![CDATA[expectation]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Fluorouracil]]></TERM><TERM><![CDATA[gemcitabine]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunotherapy]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Malignant Glioma]]></TERM><TERM><![CDATA[Malignant neoplasm of pancreas]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Measurable]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Metastatic Pancreatic Adenocarcinoma]]></TERM><TERM><![CDATA[Micrometastasis]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Myelogenous]]></TERM><TERM><![CDATA[Necrosis]]></TERM><TERM><![CDATA[Neoadjuvant Therapy]]></TERM><TERM><![CDATA[Neoplasm Metastasis]]></TERM><TERM><![CDATA[neoplastic cell]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[nucleotide analog]]></TERM><TERM><![CDATA[oncology]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[oxaliplatin]]></TERM><TERM><![CDATA[palliative]]></TERM><TERM><![CDATA[palliative chemotherapy]]></TERM><TERM><![CDATA[Pancreatic Adenocarcinoma]]></TERM><TERM><![CDATA[pancreatic neoplasm]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[phase 2 study]]></TERM><TERM><![CDATA[Phase II Clinical Trials]]></TERM><TERM><![CDATA[phase II trial]]></TERM><TERM><![CDATA[Phase Transition]]></TERM><TERM><![CDATA[preclinical study]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prodrugs]]></TERM><TERM><![CDATA[Progression-Free Survivals]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Radiation]]></TERM><TERM><![CDATA[Radiosurgery]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Regulatory T-Lymphocyte]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resectable]]></TERM><TERM><![CDATA[Residual Neoplasm]]></TERM><TERM><![CDATA[Residual state]]></TERM><TERM><![CDATA[Residual Tumors]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[standard of care]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Suppressor-Effector T-Lymphocytes]]></TERM><TERM><![CDATA[Survival Rate]]></TERM><TERM><![CDATA[Systemic disease]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[treatment planning]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[Tumor Antigens]]></TERM><TERM><![CDATA[Tumor Debulking]]></TERM><TERM><![CDATA[Unresectable]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[valacyclovir]]></TERM><TERM><![CDATA[Viral]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation]]></PROJECT_TITLE><SERIAL_NUMBER>203336</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>282451</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9176057</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>EY</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>867</CFDA_CODE><CORE_PROJECT_NUM>K23EY022673</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7K23EY022673-05</FULL_PROJECT_NUM><FUNDING_ICs>NEI:228593\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL EYE INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>073757627</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSP OF PHILADELPHIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191044318</ORG_ZIPCODE><PHR><![CDATA[Low-grade gliomas, the most common type of brain tumor in children, can cause severe vision loss in some, but not all of the children with these tumors. Treatment with chemotherapy is only initiated after vision loss has occurred, but unfortunately young children with these tumors are frequently uncooperative with their vision testing. The goal of this project is to use novel ophthalmologic imaging methods that do not require patient cooperation as a surrogate marker of vision which may allow for early detection and treatment of impending vision loss.]]></PHR><PIS><PI><PI_NAME>AVERY, ROBERT ANDREW</PI_NAME><PI_ID>10524940</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>AGARWAL, NEERAJ </PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2015</PROJECT_START><PROJECT_END>07/31/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Visual outcome measures in children with optic Pathway gliomas]]></PROJECT_TITLE><SERIAL_NUMBER>022673</SERIAL_NUMBER><STUDY_SECTION>ZEY1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>211660</DIRECT_COST_AMT><INDIRECT_COST_AMT>16933</INDIRECT_COST_AMT><TOTAL_COST>228593</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198086</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000548</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-GH-11-191</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000548-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:1019003\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CORAL GABLES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[FAMILY MEDICINE]]></ORG_DEPT><ORG_DISTRICT>27</ORG_DISTRICT><ORG_DUNS>052780918</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MIAMI SCHOOL OF MEDICINE]]></ORG_NAME><ORG_STATE>FL</ORG_STATE><ORG_ZIPCODE>331462926</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>DODARD, MICHEL JOSEPH</PI_NAME><PI_ID>10919719</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[IMPROVEMENT OF INTEGRATED HIV CLINICAL-BASED SERVICES]]></PROJECT_TITLE><SERIAL_NUMBER>000548</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1019003</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9197389</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>R21NS085772</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-261</FOA_NUMBER><FULL_PROJECT_NUM>6R21NS085772-03</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:79546\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2014</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Gap junction (GJ) mediated electrical synaptic transmission is considered an essential form of interneuronal communication. It contributes to important functional processes in diverse regions of the mammalian CNS and has been linked to a variety of neurological conditions. Plasticity of electrical synapses underlies important functions by reconfiguring networks of electrically coupled neurons, whose disruption might contribute to neurological dysfunction. In contrast to chemical synapses, less is known regarding the molecular mechanisms that regulate the strength of electrical synapses. This proposal focuses on understanding mechanisms underlying plastic changes in GJ communication observed at mixed, electrical and chemical, synapses that couple auditory afferents to the teleost Mauthner cells, at which GJs are formed by fish homologs of the widespread mammalian GJ protein connexin36 (Cx36) and where it is possible to analyze cellular and subcellular mechanisms in-vivo. We propose to investigate the contribution of trafficking of GJ channels as a possible mechanism for regulating the strength of electrical transmission. For this purpose, we will take this unique model synapse to a new level of analysis by investigating their properties in larval zebrafish, whose transparency will make it possible to track individual molecules within living cells, in vivo. The amenability of zebrafish larvae to image the movement of fluorescently tagged GJ channels in-vivo will permit monitoring active synapses undergoing plasticity, thus providing an unprecedented window for the analysis of this modality of transmission at which detailed molecular mechanisms could be investigated combining electrophysiology and live imaging with powerful genetic manipulations. Finally, the development of this zebrafish model will provide a new powerful tool to study molecular aspects of Cx36-mediated synapses (prevalent in mammals) that could lead to the identification of novel therapeutic opportunities for the treatment of various neurological conditions.]]></PHR><PIS><PI><PI_NAME>PEREDA, ALBERTO E</PI_NAME><PI_ID>1972924</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>STEWART, RANDALL R</PROGRAM_OFFICER_NAME><PROJECT_START>09/16/2013</PROJECT_START><PROJECT_END>08/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Generation of transgenic zebrafish to study electrical synaptic transmission]]></PROJECT_TITLE><SERIAL_NUMBER>085772</SERIAL_NUMBER><STUDY_SECTION>NTRC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neurotransporters, Receptors, and Calcium Signaling Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>47633</DIRECT_COST_AMT><INDIRECT_COST_AMT>31913</INDIRECT_COST_AMT><TOTAL_COST>79546</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198373</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000243</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-152</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000243-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:1203176\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WASHINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>98</ORG_DISTRICT><ORG_DUNS>040054827</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[POPULATION SERVICES INTERNATIONAL]]></ORG_NAME><ORG_STATE>DC</ORG_STATE><ORG_ZIPCODE>200363605</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>SCOTT, BILLY </PI_NAME><PI_ID>10917199</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1152, S. AFRICA:  Planning, Implementation and Evaluation of Comprehensive HIV Prevention Programs ]]></PROJECT_TITLE><SERIAL_NUMBER>000243</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1203176</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9188038</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH001053</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-13-311</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH001053-03S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:3500000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MEKELLE</ORG_CITY><ORG_COUNTRY>ETHIOPIA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>850499538</ORG_DUNS><ORG_FIPS>ET</ORG_FIPS><ORG_NAME><![CDATA[TIGRAY REGIONAL HEALTH BUREAU]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE>007</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>TEKLU, TSIGEM </PI_NAME><PI_ID>11789284</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2013</PROJECT_START><PROJECT_END>09/29/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH13-1311: STRENGTHENING LOCAL OWNERSHIP FOR THE SUSTAINABLE PROVISION OF ]]></PROJECT_TITLE><SERIAL_NUMBER>001053</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>3500000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9185062</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DA</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>279</CFDA_CODE><CORE_PROJECT_NUM>R01DA032552</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-10-129</FOA_NUMBER><FULL_PROJECT_NUM>6R01DA032552-05</FULL_PROJECT_NUM><FUNDING_ICs>NIDA:524356\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE ON DRUG ABUSE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[HIV remains an important cause of neurocognitive (NC) dysfunction, despite the introduction of HAART in the mid-1990's. Significant numbers of HIV infected drug users exhibit accelerated and more severe NC dysfunction compared to either HIV infected persons without a history of drug use, or to uninfected drug users. Because the risk of NC impairment is also elevated in opioid users regardless of HIV status, among HIV- infected opioid users there is an additive risk of NC impairment. To understand whether opiate agonist therapies, including methadone and buprenorphine, worsen or improve NC function and treatment outcomes, it is crucial to evaluate their relative impact on NC function in opioid users with and without HIV infection.]]></PHR><PIS><PI><PI_NAME>ARNSTEN, JULIA H (contact)</PI_NAME><PI_ID>1903755 (contact)</PI_ID></PI><PI><PI_NAME>RIVERA-MINDT, MONICA G</PI_NAME><PI_ID>7088043</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LIN, YU </PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2012</PROJECT_START><PROJECT_END>06/30/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Neurocognitive Effects of Opiate Agonist Treatment in HIV Infected Drug Users]]></PROJECT_TITLE><SERIAL_NUMBER>032552</SERIAL_NUMBER><STUDY_SECTION>BSCH</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Behavioral and Social Consequences of HIV/AIDS Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>391703</DIRECT_COST_AMT><INDIRECT_COST_AMT>132653</INDIRECT_COST_AMT><TOTAL_COST>524356</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9003044</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK041301</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK041301-27</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:99077\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[Our goals are to improve understanding, knowledge, and treatment of Gl disorders in a cost-effective and 
collaborative approach. Using patients and human samples to study pathogenesis and treatments increases 
the relevance to human diseases. The Human Studies Core space, equipment, expertise, and personnel 
required to provide these services are expensive but are shared for collaborative research with clinical, 
outcomes and translational researchers and their trainees in a cost-effective way.]]></PHR><PIS><PI><PI_NAME>JENSEN, DENNIS MICHAEL</PI_NAME><PI_ID>1872384</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acquired Immunodeficiency Syndrome]]></TERM><TERM><![CDATA[Amendment]]></TERM><TERM><![CDATA[Barrett Epithelium]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biopsy]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Budgets]]></TERM><TERM><![CDATA[Cancerous]]></TERM><TERM><![CDATA[capsule (pharmacologic)]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[cell motility]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[chronic pancreatitis]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Cohort Studies]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Colon]]></TERM><TERM><![CDATA[Colonic Polyps]]></TERM><TERM><![CDATA[Computer software]]></TERM><TERM><![CDATA[Consult]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Cyst Fluid]]></TERM><TERM><![CDATA[Cystic Lesion]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[data management]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Diarrhea]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dysplasia]]></TERM><TERM><![CDATA[Educational process of instructing]]></TERM><TERM><![CDATA[Endoscopic Retrograde Cholangiopancreatography]]></TERM><TERM><![CDATA[Endoscopy]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Esophagus motility]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Fine needle aspiration biopsy]]></TERM><TERM><![CDATA[Focus Groups]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Functional Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Gastrointestinal Diseases]]></TERM><TERM><![CDATA[Gastrointestinal Endoscopy]]></TERM><TERM><![CDATA[Gastrointestinal Hemorrhage]]></TERM><TERM><![CDATA[Gastrointestinal Intraepithelial Neoplasia]]></TERM><TERM><![CDATA[Gastrointestinal Motility]]></TERM><TERM><![CDATA[Gastrointestinal Neuroendocrine Neoplasm]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health Insurance Portability and Accountability Act]]></TERM><TERM><![CDATA[Health Services Accessibility]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[human tissue]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Immunohistochemistry]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Institutional Review Boards]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lasers]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Liquid substance]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Microscopy]]></TERM><TERM><![CDATA[Multicenter Studies]]></TERM><TERM><![CDATA[Multicenter Trials]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Outcomes Research]]></TERM><TERM><![CDATA[Outpatients]]></TERM><TERM><![CDATA[Pancreas]]></TERM><TERM><![CDATA[Pancreatic Diseases]]></TERM><TERM><![CDATA[Pancreatitis]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[patient registry]]></TERM><TERM><![CDATA[Patient risk]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peptic Esophagitis]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[pre-doctoral]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[protocol development]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Research Technics]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Review Literature]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Satiation]]></TERM><TERM><![CDATA[secondary outcome]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Small Intestines]]></TERM><TERM><![CDATA[Specialist]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Stem Cell Research]]></TERM><TERM><![CDATA[Stomach]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tissue Sample]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core C: Human Studies Core]]></PROJECT_TITLE><SERIAL_NUMBER>041301</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7943</SUBPROJECT_ID><SUPPORT_YEAR>27</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>79473</DIRECT_COST_AMT><INDIRECT_COST_AMT>19604</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>99077</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9015761</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>P30DK052574</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK052574-17</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:1029375\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Research supported through the WU DDRCC has and will continue to have a profound impact on understanding the pathophysiology of digestive disease and the role of host-environment interactions. The WU DDRCC also promotes scientific collaboration and synergies that ultimately will identify new therapeutic opportunities with the potential for rapid translation into clinical trials for patients with digestive diseases.]]></PHR><PIS><PI><PI_NAME>DAVIDSON, NICHOLAS </PI_NAME><PI_ID>8179452</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PERRIN, PETER J</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2000</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[biobank]]></TERM><TERM><![CDATA[Cancer Biology]]></TERM><TERM><![CDATA[Categories]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Environmental Risk Factor]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human Genetics]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[lectures]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Metadata]]></TERM><TERM><![CDATA[microbiome]]></TERM><TERM><![CDATA[microorganism interaction]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mucosal Immunity]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Nutrient]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[stem cell biology]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Washington]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Regulatory Factors in the GI Tract]]></PROJECT_TITLE><SERIAL_NUMBER>052574</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>17</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>675000</DIRECT_COST_AMT><INDIRECT_COST_AMT>354375</INDIRECT_COST_AMT><TOTAL_COST>1029375</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9034389</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/18/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI109439</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>1R21AI109439-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:273000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Immunization]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Orphan Drug]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY><CATEGORY><![CDATA[Vaccine Related]]></CATEGORY><CATEGORY><![CDATA[Vector-Borne Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>PORT SAINT LUCIE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>605758754</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[TORREY PINES INST FOR MOLECULAR STUDIES]]></ORG_NAME><ORG_STATE>FL</ORG_STATE><ORG_ZIPCODE>349872352</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Chagas disease and its causative agent, Trypanosoma cruzi, constitute a prominent human health problem in Central and South America. In addition, increased travel and immigration has brought the disease to the United States, Europe and other countries around the world. The identification of the immunogenic T. cruzi antigens involved in the human immune response to natural infection, as proposed in this application, will contribute in the design of novel Chagas vaccines.   
   
      

]]></PHR><PIS><PI><PI_NAME>PINILLA, CLEMENCIA </PI_NAME><PI_ID>7354284</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WALI, TONU M.</PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Antibody Response]]></TERM><TERM><![CDATA[Antigenic Specificity]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Archives]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Central America]]></TERM><TERM><![CDATA[Chagas Cardiomyopathy]]></TERM><TERM><![CDATA[Chagas Disease]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[Europe]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[immunogenic]]></TERM><TERM><![CDATA[immunogenicity]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[In-Migration]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Japan]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Malaria]]></TERM><TERM><![CDATA[memory CD4 T lymphocyte]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Mitogens]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel vaccines]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Peptide Library]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Peripheral Blood Mononuclear Cell]]></TERM><TERM><![CDATA[Phytohemagglutinins]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[prophylactic]]></TERM><TERM><![CDATA[Protein Databases]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteome]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[repository]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Scanning]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Sorting - Cell Movement]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[South America]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[T cell response]]></TERM><TERM><![CDATA[T memory cell]]></TERM><TERM><![CDATA[T-Cell Activation]]></TERM><TERM><![CDATA[T-Cell Immunologic Specificity]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic vaccine]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Travel]]></TERM><TERM><![CDATA[Trypanosoma cruzi]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[vaccine candidate]]></TERM><TERM><![CDATA[vaccine development]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Vascular blood supply]]></TERM><TERM><![CDATA[vector]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[T cell driven antigen discovery for vaccine candidates for human Chagas disease]]></PROJECT_TITLE><SERIAL_NUMBER>109439</SERIAL_NUMBER><STUDY_SECTION>VMD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Vaccines Against Microbial Diseases ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>150000</DIRECT_COST_AMT><INDIRECT_COST_AMT>123000</INDIRECT_COST_AMT><TOTAL_COST>273000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9016531</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK034987</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK034987-31</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:293207\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CHAPEL HILL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>608195277</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF NORTH CAROLINA CHAPEL HILL]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>275990001</ORG_ZIPCODE><PHR><![CDATA[The Gnotobiotic Animal Core provides resources for CGIBD members and external investigators to 
study mechanisms of host/microbial interactions by precisely manipulating the commensal enteric microbiota. 
Investigators can compare host responses and microbial interactions in mice that are germ free (sterile), 
monoassociated (single microbial species), colonized with defined groups of bacterial, fungal or viral species or 
transplanted with of complex groups of microbiota from various phenotypes of mice or humans, for example, 
control or inflamed hosts. Results of these studies can identify microbial and host elements that mediate host 
protection, epithelial and immune development, inflammation, infection, neoplasia and recovery from injury.]]></PHR><PIS><PI><PI_NAME>SARTOR, RYAN B</PI_NAME><PI_ID>1861652</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[animal tissue]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Enteral]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Gene Deletion]]></TERM><TERM><![CDATA[Genetic Engineering]]></TERM><TERM><![CDATA[Genetically Engineered Mouse]]></TERM><TERM><![CDATA[Germ-Free]]></TERM><TERM><![CDATA[Gnotobiotic]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[microbial host]]></TERM><TERM><![CDATA[microorganism interaction]]></TERM><TERM><![CDATA[Mouse Strains]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutant Strains Mice]]></TERM><TERM><![CDATA[Neoplasms]]></TERM><TERM><![CDATA[North Carolina]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Sterility]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Veterinary Medicine]]></TERM><TERM><![CDATA[Viral]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core C: Gnotobiotic Core]]></PROJECT_TITLE><SERIAL_NUMBER>034987</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8183</SUBPROJECT_ID><SUPPORT_YEAR>31</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>264558</DIRECT_COST_AMT><INDIRECT_COST_AMT>28649</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>293207</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9191606</APPLICATION_ID><ACTIVITY>K08</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/10/2015</BUDGET_START><BUDGET_END>01/31/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>K08AR063813</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-193</FOA_NUMBER><FULL_PROJECT_NUM>3K08AR063813-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:531\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Congenital Structural Anomalies]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Immunization]]></CATEGORY><CATEGORY><![CDATA[Osteogenesis Imperfecta]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>076593722</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSPITAL CORPORATION]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021155724</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Osteogenesis Imperfecta (OI) is a disorder of low bone mass and frequent fractures for which current medical therapies are limited. Increasing low density lipoprotein receptor related-protein 5 (LRP5) signaling improves bone density and strength in two mouse models of OI by increasing bone formation. This proposal aims to define how LRP5 signaling improves bone strength in mouse models of OI, to define which types of mutations are most likely to benefit from therapies targeting the LRP5 pathway, and to identify therapeutic strategies using mouse models of OI that will provide the most benefit to human patients.]]></PHR><PIS><PI><PI_NAME>JACOBSEN, CHRISTINA MARIE</PI_NAME><PI_ID>9822703</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHEN, FAYE H</PROGRAM_OFFICER_NAME><PROJECT_START>02/01/2013</PROJECT_START><PROJECT_END>01/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adolescence]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Anabolism]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antibody Therapy]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Birth]]></TERM><TERM><![CDATA[bisphosphonate]]></TERM><TERM><![CDATA[bone]]></TERM><TERM><![CDATA[Bone Density]]></TERM><TERM><![CDATA[bone health]]></TERM><TERM><![CDATA[bone mass]]></TERM><TERM><![CDATA[Bone Matrix]]></TERM><TERM><![CDATA[bone strength]]></TERM><TERM><![CDATA[bone turnover]]></TERM><TERM><![CDATA[Cell Surface Receptors]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Collagen]]></TERM><TERM><![CDATA[Collagen Type I]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Early treatment]]></TERM><TERM><![CDATA[endoplasmic reticulum stress]]></TERM><TERM><![CDATA[Fracture]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetically Engineered Mouse]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hereditary Disease]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune Tolerance]]></TERM><TERM><![CDATA[immunogenicity]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Lactation]]></TERM><TERM><![CDATA[LDL-Receptor Related Protein 1]]></TERM><TERM><![CDATA[lipoprotein receptor related protein 5]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Minerals]]></TERM><TERM><![CDATA[Missense Mutation]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[neutralizing monoclonal antibodies]]></TERM><TERM><![CDATA[Osteoblasts]]></TERM><TERM><![CDATA[Osteoclasts]]></TERM><TERM><![CDATA[Osteogenesis]]></TERM><TERM><![CDATA[Osteogenesis Imperfecta]]></TERM><TERM><![CDATA[Osteopenia]]></TERM><TERM><![CDATA[Pathological fracture]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase II Clinical Trials]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Placenta]]></TERM><TERM><![CDATA[Post-Translational Protein Processing]]></TERM><TERM><![CDATA[postnatal]]></TERM><TERM><![CDATA[prenatal]]></TERM><TERM><![CDATA[prenatal therapy]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[pup]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[skeletal]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[targeted treatment]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Therapeutic Monoclonal Antibodies]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[treatment strategy]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Targeting the Lrp5 Pathway To Increase Bone Strength In Osteogenesis Imperfecta]]></PROJECT_TITLE><SERIAL_NUMBER>063813</SERIAL_NUMBER><STUDY_SECTION>AMS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>492</DIRECT_COST_AMT><INDIRECT_COST_AMT>39</INDIRECT_COST_AMT><TOTAL_COST>531</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8982235</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>EY</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>867</CFDA_CODE><CORE_PROJECT_NUM>R01EY014370</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>4R01EY014370-09</FULL_PROJECT_NUM><FUNDING_ICs>NEI:307800\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL EYE INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Eye Disease and Disorders of Vision]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>DETROIT</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[OPHTHALMOLOGY]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>001962224</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WAYNE STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>MI</ORG_STATE><ORG_ZIPCODE>482024050</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Diabetic retinopathy, a slow progressing, is the most frequent cause of blindness among young adults. Despite the cutting edge research to explore how the disease develops, the exact molecular and cellular mechanisms underlying this lesion remain elusive. This proposal is focused on understanding potential damaging mechanisms responsible for the development of diabetic retinopathy through systematic analysis of MMP-9 mediated damage of retinal capillary cells. We will test the role of histone modifications in the activationof MMP-9, leading to mitochondrial dysfunction, and the development of diabetic retinopathy. The application will use biochemical, molecular and epigenetic techniques, and represents the first attempt to examine the potential role of epigenetic modifications of MMP-9 in its activation in diabetes. Data from this study are expected to identify novel drug targets for halting the progression of this blinding disease in human diabetes.]]></PHR><PIS><PI><PI_NAME>KOWLURU, RENU A.</PI_NAME><PI_ID>2107015</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SHEN, GRACE L</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2002</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Apoptotic]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Blindness]]></TERM><TERM><![CDATA[Blood capillaries]]></TERM><TERM><![CDATA[capillary]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Complications of Diabetes Mellitus]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Deacetylation]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diabetic mouse]]></TERM><TERM><![CDATA[Diabetic Retinopathy]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Down-Regulation]]></TERM><TERM><![CDATA[Drug Targeting]]></TERM><TERM><![CDATA[Endothelial Cells]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Gelatinase B]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[glycemic control]]></TERM><TERM><![CDATA[GTP-Binding Proteins]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Histone Acetylation]]></TERM><TERM><![CDATA[Histone Deacetylase]]></TERM><TERM><![CDATA[Histone H3]]></TERM><TERM><![CDATA[histone methylation]]></TERM><TERM><![CDATA[histone modification]]></TERM><TERM><![CDATA[Histones]]></TERM><TERM><![CDATA[HRAS gene]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hyperglycemia]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[in vivo Model]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[knockout gene]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Lysine]]></TERM><TERM><![CDATA[MAP Kinase Gene]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Mitochondrial DNA]]></TERM><TERM><![CDATA[mitochondrial dysfunction]]></TERM><TERM><![CDATA[MMP9 gene]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Weight]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[NF-kappa B]]></TERM><TERM><![CDATA[NF-Kappa B p65]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[p65]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Plasmids]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Promoter Regions (Genetics)]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Retina]]></TERM><TERM><![CDATA[Retinal]]></TERM><TERM><![CDATA[retinal apoptosis]]></TERM><TERM><![CDATA[retinal damage]]></TERM><TERM><![CDATA[Retinal Diseases]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stream]]></TERM><TERM><![CDATA[Superoxides]]></TERM><TERM><![CDATA[targeted treatment]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[young adult]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Role of H-Ras in Retinal Cell Death in Diabetes]]></PROJECT_TITLE><SERIAL_NUMBER>014370</SERIAL_NUMBER><STUDY_SECTION>DPVS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>09</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>202500</DIRECT_COST_AMT><INDIRECT_COST_AMT>105300</INDIRECT_COST_AMT><TOTAL_COST>307800</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9151875</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/17/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>R01AR067187</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>7R01AR067187-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:195816\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PITTSBURGH</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[DERMATOLOGY]]></ORG_DEPT><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>004514360</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PITTSBURGH AT PITTSBURGH]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>152132303</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  Despite the clear importance of humoral responses to skin health and disease, the mechanisms that generate antibody responses to cutaneous antigen are very poorly studied. We hypothesize that during both steady-state and inflammatory conditions, LC are a key cell type that drives differentiation of T follicular helper cells and provides intact antigen to B cells. Understanding how antibodies against cutaneous antigen form is critical to understanding immunity to skin pathogens as well as the etiology of antibody- mediated skin diseases.]]></PHR><PIS><PI><PI_NAME>KAPLAN, DANIEL H</PI_NAME><PI_ID>1930431</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CIBOTTI, RICARDO </PROGRAM_OFFICER_NAME><PROJECT_START>04/06/2015</PROJECT_START><PROJECT_END>03/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Ablation]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antibody Formation]]></TERM><TERM><![CDATA[Antibody Response]]></TERM><TERM><![CDATA[Antigen Presentation]]></TERM><TERM><![CDATA[Antigen Targeting]]></TERM><TERM><![CDATA[Antigen-Presenting Cells]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Atopic Dermatitis]]></TERM><TERM><![CDATA[Autoimmune Process]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bulla]]></TERM><TERM><![CDATA[Candida albicans]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Cutaneous]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Dendrites]]></TERM><TERM><![CDATA[Dendritic Cells]]></TERM><TERM><![CDATA[Dermal]]></TERM><TERM><![CDATA[Dermis]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Ectromelia]]></TERM><TERM><![CDATA[Epidermis]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[fungus]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Gnotobiotic]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Helper-Inducer T-Lymphocyte]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Humoral Immunities]]></TERM><TERM><![CDATA[immune function]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunization]]></TERM><TERM><![CDATA[Immunoglobulin M]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Infectious Ectromelia]]></TERM><TERM><![CDATA[Infectious Skin Diseases]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[ITGAM gene]]></TERM><TERM><![CDATA[Job's Syndrome]]></TERM><TERM><![CDATA[Langerhans cell]]></TERM><TERM><![CDATA[langerin]]></TERM><TERM><![CDATA[lymph nodes]]></TERM><TERM><![CDATA[Lymphoid Tissue]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[microorganism]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[new therapeutic target]]></TERM><TERM><![CDATA[nonhuman primate]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[resistance mechanism]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[skin disorder]]></TERM><TERM><![CDATA[Stratum corneum]]></TERM><TERM><![CDATA[Structure of germinal center of lymph node]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[X-Linked Agammaglobulinemia]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Skin Dendritic Cells and Humoral Immunity]]></PROJECT_TITLE><SERIAL_NUMBER>067187</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>157420</DIRECT_COST_AMT><INDIRECT_COST_AMT>38396</INDIRECT_COST_AMT><TOTAL_COST>195816</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9135108</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>12/24/2015</BUDGET_START><BUDGET_END>05/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL086324</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-15-322</FOA_NUMBER><FULL_PROJECT_NUM>3R01HL086324-07S1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:28450\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Infant Mortality/ (LBW)]]></CATEGORY><CATEGORY><![CDATA[Lung]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Perinatal - Birth - Preterm (LBW)]]></CATEGORY><CATEGORY><![CDATA[Perinatal - Neonatal Respiratory Distress Syndrome]]></CATEGORY><CATEGORY><![CDATA[Perinatal Period - Conditions Originating in Perinatal Period]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LA JOLLA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PEDIATRICS]]></ORG_DEPT><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>804355790</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA SAN DIEGO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>920930934</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Preterm birth is among the most important clinical problems affecting children. Bronchopulmonary dysplasia is a frequent complication of extremely preterm birth, and its incidence has not decreased despite advances in neonatal care. Therefore, new insight into the mechanisms of bronchopulmonary dysplasia pathogenesis and discovery of new therapeutic strategies is critical to improve the long-term health of children born preterm.]]></PHR><PIS><PI><PI_NAME>PRINCE, LAWRENCE S</PI_NAME><PI_ID>7598551</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BLAISDELL, CAROL J</PROGRAM_OFFICER_NAME><PROJECT_START>12/24/2015</PROJECT_START><PROJECT_END>05/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[activating transcription factor]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Alveolus]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Bronchopulmonary Dysplasia]]></TERM><TERM><![CDATA[caspase]]></TERM><TERM><![CDATA[Caspase Inhibitor]]></TERM><TERM><![CDATA[Cell model]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Child health care]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Data]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Complication]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Developmental Gene]]></TERM><TERM><![CDATA[Discipline of obstetrics]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA-Protein Interaction]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[extreme prematurity]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[fetal]]></TERM><TERM><![CDATA[Fetal Lung]]></TERM><TERM><![CDATA[fibroblast growth factor 10]]></TERM><TERM><![CDATA[gain of function]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Regulation]]></TERM><TERM><![CDATA[Genetic Transcription]]></TERM><TERM><![CDATA[Growth Factor]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hospitalization]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Infant]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammation Mediators]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Knock-in Mouse]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[lung development]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Macrophage Activation]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mesenchymal]]></TERM><TERM><![CDATA[Mesenchyme]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[molecular modeling]]></TERM><TERM><![CDATA[Molecular Models]]></TERM><TERM><![CDATA[Morphogenesis]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[neonatal care]]></TERM><TERM><![CDATA[Neonatology]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[Premature Birth]]></TERM><TERM><![CDATA[Premature Infant]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[receptor expression]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Respiratory physiology]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Sp1 Transcription Factor]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Toll-like receptors]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[Transcription Repressor/Corepressor]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[FGF-10 Expression in a Fetal Mouse Lung Model of Bronchopulmonary Dysplasia]]></PROJECT_TITLE><SERIAL_NUMBER>086324</SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>07</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>22314</DIRECT_COST_AMT><INDIRECT_COST_AMT>6136</INDIRECT_COST_AMT><TOTAL_COST>28450</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9030953</APPLICATION_ID><ACTIVITY>I21</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I21RX001363</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-13-011</FOA_NUMBER><FULL_PROJECT_NUM>5I21RX001363-02</FULL_PROJECT_NUM><FUNDING_ICs>VA:92971\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHICAGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>010299204</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[JESSE BROWN VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>606123728</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
   
Components with reduced stiffness are commonly prescribed in lower-limb prostheses to change the mechanical response of the prosthesis to an applied load, providing shock absorption and reducing forces transmitted to the residual limb during gait. However, these components do not generally decrease ground reaction forces during gait, a commonly used indicator of shock absorption. Previous reports of increased subject preference for reduced-stiffness components indicate that these components are influencing the limb- prosthesis system. However, this influence has not been documented consistently in any biomechanical gait parameter. The proposed study is intended to lay the groundwork for a more complete understanding of how prosthetic components function in vivo. The anticipated results would inform prosthetic practice and design by indicating which levels of prosthetic stiffness are effective for improving the gait and quality of life of persons with lower-limb amputations, an integral part of the VA's Patient Care Mission.   
      

]]></PHR><PIS><PI><PI_NAME>GARD, STEVEN A.</PI_NAME><PI_ID>6719056</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2014</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[absorption]]></TERM><TERM><![CDATA[Ankle]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[attenuation]]></TERM><TERM><![CDATA[Beds]]></TERM><TERM><![CDATA[Biomechanics]]></TERM><TERM><![CDATA[Body Weight]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[expectation]]></TERM><TERM><![CDATA[Financial compensation]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gait]]></TERM><TERM><![CDATA[gait examination]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heel]]></TERM><TERM><![CDATA[Hip region structure]]></TERM><TERM><![CDATA[Impact evaluation]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[indium arsenide]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[kinematics]]></TERM><TERM><![CDATA[Knee]]></TERM><TERM><![CDATA[Leg]]></TERM><TERM><![CDATA[limb amputation]]></TERM><TERM><![CDATA[Limb Prosthesis]]></TERM><TERM><![CDATA[Limb structure]]></TERM><TERM><![CDATA[Lower Extremity]]></TERM><TERM><![CDATA[Manufacturer Name]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[Pelvis]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Prosthesis]]></TERM><TERM><![CDATA[Prosthesis Design]]></TERM><TERM><![CDATA[prosthesis wearer]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[residual limb]]></TERM><TERM><![CDATA[Residual state]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Shock]]></TERM><TERM><![CDATA[Side]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[soft tissue]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Walking]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Effect of prosthesis stiffness on impact force during in vivo step loads and gait]]></PROJECT_TITLE><SERIAL_NUMBER>001363</SERIAL_NUMBER><STUDY_SECTION>RRDS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9134327</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>12/24/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL057181</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-15-322</FOA_NUMBER><FULL_PROJECT_NUM>3R01HL057181-20A1S1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:22195\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Cardiovascular]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Heart Disease]]></CATEGORY><CATEGORY><![CDATA[Human Genome]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAN FRANCISCO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>099992430</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[J. DAVID GLADSTONE INSTITUTES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>941582261</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This project will determine the mechanisms by which a non-muscle cell converts toward a cardiac muscle cell upon introduction of a discrete number of genes that regulate DNA. This approach has promise for cardiac regenerative approaches to heart disease using endogenous cells already in the heart, but requires additional innovation and improvements that will be dependent on a better understanding of the mechanism involved in cell fate conversion.   
      

]]></PHR><PIS><PI><PI_NAME>SRIVASTAVA, DEEPAK </PI_NAME><PI_ID>1974450</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SCHRAMM, CHARLENE A.</PROGRAM_OFFICER_NAME><PROJECT_START>12/24/2015</PROJECT_START><PROJECT_END>03/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acetylation]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Calcium Oscillations]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac development]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[cardiac regeneration]]></TERM><TERM><![CDATA[cardiogenesis]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[chromatin immunoprecipitation]]></TERM><TERM><![CDATA[combinatorial]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Dermal]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Methylation]]></TERM><TERM><![CDATA[Enhancers]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[histone methylation]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Letters]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Promotor (Genetics)]]></TERM><TERM><![CDATA[protein protein interaction]]></TERM><TERM><![CDATA[Proxy]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[regenerative]]></TERM><TERM><![CDATA[Reporter]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Sequences]]></TERM><TERM><![CDATA[Sarcomeres]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Somatic Cell]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[transcription factor]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Troponin T]]></TERM><TERM><![CDATA[Viral]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cardiogenesis: Molecular Mechanisms]]></PROJECT_TITLE><SERIAL_NUMBER>057181</SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>20</SUPPORT_YEAR><SUFFIX>A1S1</SUFFIX><DIRECT_COST_AMT>17780</DIRECT_COST_AMT><INDIRECT_COST_AMT>4415</INDIRECT_COST_AMT><TOTAL_COST>22195</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9006752</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK107579</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF NURSING]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01DK107579-01</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:709015\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY><CATEGORY><![CDATA[Comparative Effectiveness Research]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Health Services]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Obesity]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>TEMPE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>09</ORG_DISTRICT><ORG_DUNS>943360412</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ARIZONA STATE UNIVERSITY-TEMPE CAMPUS]]></ORG_NAME><ORG_STATE>AZ</ORG_STATE><ORG_ZIPCODE>852876011</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Obesity and type 2 diabetes are critical public health issues in youth. This study will test the effects and estimate the cost-effectiveness of a culturally-grounded community-based lifestyle intervention on type 2 diabetes risk among obese Latino adolescents with prediabetes.   
      

]]></PHR><PIS><PI><PI_NAME>SHAIBI, GABRIEL QUANTUM</PI_NAME><PI_ID>9237718</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LINDER, BARBARA </PROGRAM_OFFICER_NAME><PROJECT_START>12/23/2015</PROJECT_START><PROJECT_END>11/30/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adolescence]]></TERM><TERM><![CDATA[Adolescent]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[behavior change]]></TERM><TERM><![CDATA[Behavior Therapy]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Body Composition]]></TERM><TERM><![CDATA[Body Weight decreased]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[Centers for Disease Control and Prevention (U.S.)]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Community Health]]></TERM><TERM><![CDATA[contextual factors]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cost effectiveness]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Diabetes prevention]]></TERM><TERM><![CDATA[diabetes prevention program]]></TERM><TERM><![CDATA[diabetes risk]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Eating Behavior]]></TERM><TERM><![CDATA[Effectiveness of Interventions]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[Ethics]]></TERM><TERM><![CDATA[Exercise]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[fitness]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[glucose tolerance]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health behavior]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[health literacy]]></TERM><TERM><![CDATA[Health Services Accessibility]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[insulin sensitivity]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[intervention effect]]></TERM><TERM><![CDATA[Latino]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Life Expectancy]]></TERM><TERM><![CDATA[lifestyle intervention]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Longevity]]></TERM><TERM><![CDATA[Low income]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[nutrition education]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pancreas]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[peer]]></TERM><TERM><![CDATA[Personal Satisfaction]]></TERM><TERM><![CDATA[Physical activity]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Prediabetes syndrome]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Preventive Intervention]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Risk Marker]]></TERM><TERM><![CDATA[Risk Reduction]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Self Efficacy]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[social cognitive theory]]></TERM><TERM><![CDATA[Social support]]></TERM><TERM><![CDATA[Societies]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[treatment as usual]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Visceral]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Youth]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Preventing Diabetes in Latino Youth]]></PROJECT_TITLE><SERIAL_NUMBER>107579</SERIAL_NUMBER><STUDY_SECTION>PRDP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Psychosocial Risk and Disease Prevention Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>472750</DIRECT_COST_AMT><INDIRECT_COST_AMT>236265</INDIRECT_COST_AMT><TOTAL_COST>709015</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198294</APPLICATION_ID><ACTIVITY>R43</ACTIVITY><ADMINISTERING_IC>EY</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/25/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2014</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>867</CFDA_CODE><CORE_PROJECT_NUM>R43EY024792</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-234</FOA_NUMBER><FULL_PROJECT_NUM>3R43EY024792-01S2</FULL_PROJECT_NUM><FUNDING_ICs>NEI:22399\</FUNDING_ICs><FUNDING_MECHANISM>SBIR-STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL EYE INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAN DIEGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>078667568</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[E AND B TECHNOLOGIES, LLC]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>921302784</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Novel caveolin modulators as therapeutics for uveitis Project Narrative This research seeks to develop a treatment for uveitis, a difficult to treat condition tht drives 5-20% of blindness. Because uveitis often affects people at working age, it can cause significant disability. A treatment for uveitis that both improves visual function and reduces the burden of treatment would improve the lives of patients.]]></PHR><PIS><PI><PI_NAME>EVELETH, DAVID D</PI_NAME><PI_ID>11765667</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WUJEK, JEROME R</PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2014</PROJECT_START><PROJECT_END>08/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Adverse event]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[analog]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Autoimmune encephalitis]]></TERM><TERM><![CDATA[autoimmune uveitis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blindness]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Caveolae]]></TERM><TERM><![CDATA[Caveolins]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drug Kinetics]]></TERM><TERM><![CDATA[Edema]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[Extravasation]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genus Mycobacterium]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gold]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Sciences]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hybrid Cells]]></TERM><TERM><![CDATA[Immunomodulators]]></TERM><TERM><![CDATA[Immunosuppressive Agents]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[inflammatory modulation]]></TERM><TERM><![CDATA[intravitreal injection]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[migration]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Oregon]]></TERM><TERM><![CDATA[Oryctolagus cuniculus]]></TERM><TERM><![CDATA[Outcome Measure]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research clinical testing]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Retinal]]></TERM><TERM><![CDATA[retinal damage]]></TERM><TERM><![CDATA[RIII Mouse]]></TERM><TERM><![CDATA[Route]]></TERM><TERM><![CDATA[Saturn's Moon Phoebe]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Toxicology]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Uveitis]]></TERM><TERM><![CDATA[Vascular Permeabilities]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[Visual impairment]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Novel caveolin modulators as therapeutics for uveitis]]></PROJECT_TITLE><SERIAL_NUMBER>024792</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>S2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>22399</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9197449</APPLICATION_ID><ACTIVITY>T15</ACTIVITY><ADMINISTERING_IC>LM</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>879</CFDA_CODE><CORE_PROJECT_NUM>T15LM011270</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-LM-11-001</FOA_NUMBER><FULL_PROJECT_NUM>3T15LM011270-04S2</FULL_PROJECT_NUM><FUNDING_ICs>NLM:32382\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL LIBRARY OF MEDICINE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>COLUMBUS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[MISCELLANEOUS]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>832127323</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[OHIO STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>432101016</ORG_ZIPCODE><PHR><![CDATA[The Ohio State University Clinical and Translational Research Informatics Training Program (CTRIP)
The purpose of the proposed project, entitled The Ohio State University Clinical and Translational
Research Informatics Training Program (CTRIP) is to establish a Biomedical Informatics training initiative
that focuses upon the emergent and rapidly growing sub-domains of Translational Bioinformatics (TBI) and
Clinical Research Informatics (CRI). This program will catalyze the formation and dissemination of an
informatics workforce capable of advancing clinical and translational research in order to speed the process by
which new basic science discoveries and translated into actionable therapies for human diseases.]]></PHR><PIS><PI><PI_NAME>EMBI, PETER J</PI_NAME><PI_ID>7582057</PI_ID></PI><PI><PI_NAME>JANIES, DANIEL A</PI_NAME><PI_ID>7837593</PI_ID></PI><PI><PI_NAME>PAYNE, PHILIP R.O. (contact)</PI_NAME><PI_ID>8934691 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>FLORANCE, VALERIE </PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2012</PROJECT_START><PROJECT_END>06/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Academic Medical Centers]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[biomedical informatics]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Educational Curriculum]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Housing]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Informatics]]></TERM><TERM><![CDATA[informatics training]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Instruction]]></TERM><TERM><![CDATA[knowledge base]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Ohio]]></TERM><TERM><![CDATA[post-doctoral training]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[pre-doctoral]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Research Methodology]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[trend]]></TERM><TERM><![CDATA[Universities]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The OSU Clinical and Translational Research Informatics Training Program (CTRIP)]]></PROJECT_TITLE><SERIAL_NUMBER>011270</SERIAL_NUMBER><STUDY_SECTION>ZLM1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX>S2</SUFFIX><DIRECT_COST_AMT>29983</DIRECT_COST_AMT><INDIRECT_COST_AMT>2399</INDIRECT_COST_AMT><TOTAL_COST>32382</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9195156</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>R01GM057454</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>6R01GM057454-17</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:250502\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[This project will study the mechanisms used by membrane-enveloped alphaviruses to enter cells and to assemble and exit from cells. Alphaviruses include important human pathogens that cause serious diseases and are potential biodefense threats, and for which there are no antiviral therapies. The alphaviruses are highly developed experimental systems that also teach us about the general functions of membrane-enveloped viruses and cellular membrane processes.]]></PHR><PIS><PI><PI_NAME>KIELIAN, MARGARET </PI_NAME><PI_ID>1866114</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SAKALIAN, MICHAEL </PROGRAM_OFFICER_NAME><PROJECT_START>02/01/1999</PROJECT_START><PROJECT_END>04/30/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Molecular Mechanisms of Alphavirus Entry and Exit]]></PROJECT_TITLE><SERIAL_NUMBER>057454</SERIAL_NUMBER><STUDY_SECTION>VIRB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Virology - B Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>17</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>150001</DIRECT_COST_AMT><INDIRECT_COST_AMT>100501</INDIRECT_COST_AMT><TOTAL_COST>250502</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9003045</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK041301</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK041301-27</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:125261\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Gene Therapy]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[By providing CURE: DDRCC researchers with highly specialized expertise and equipment for analysis and 
manipulation of gene and protein expression and high-throughput screening of therapeutic compounds, the 
Integrated Molecular Technologies Core supports our mission to investigate gastrointestinal biology and to 
develop new therapies for gastrointestinal disorders.]]></PHR><PIS><PI><PI_NAME>KASAHARA, NORIYUKI </PI_NAME><PI_ID>1866959</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cloning]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Custom]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[design and construction]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[drug candidate]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[expression vector]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[gastrointestinal disorder therapy]]></TERM><TERM><![CDATA[Gene Delivery]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genetic Engineering]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[high throughput screening]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Ice]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[instrumentation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Mammalian Cell]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Peptide Synthesis]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Protein Analysis]]></TERM><TERM><![CDATA[protein expression]]></TERM><TERM><![CDATA[protein function]]></TERM><TERM><![CDATA[Protein Inhibition]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Systems Biology]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Viral Vector]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core D: Integrated Molecular Technologies]]></PROJECT_TITLE><SERIAL_NUMBER>041301</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7944</SUBPROJECT_ID><SUPPORT_YEAR>27</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>79475</DIRECT_COST_AMT><INDIRECT_COST_AMT>45786</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>125261</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9016532</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK034987</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK034987-31</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:83978\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CHAPEL HILL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>608195277</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF NORTH CAROLINA CHAPEL HILL]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>275990001</ORG_ZIPCODE><PHR><![CDATA[The public health relevance of the CGIBD Histology Core is based on the histopathological services 
conducted on human and animal tissues that allow scientists to translate research discoveries in digestive 
diseases.]]></PHR><PIS><PI><PI_NAME>KEKU, TEMITOPE O.</PI_NAME><PI_ID>1982368</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[animal tissue]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Cancer Histology]]></TERM><TERM><![CDATA[cellular imaging]]></TERM><TERM><![CDATA[clinical care]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[digital]]></TERM><TERM><![CDATA[digital imaging]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Fee-for-Service Plans]]></TERM><TERM><![CDATA[fluorescence microscope]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Histology]]></TERM><TERM><![CDATA[Histopathology]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[human tissue]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[Immunohistochemistry]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Laboratory Research]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Microscope]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Pancreas]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Scanning]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Slide]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translating]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core D: Histology and Imaging Core]]></PROJECT_TITLE><SERIAL_NUMBER>034987</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8184</SUBPROJECT_ID><SUPPORT_YEAR>31</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>53909</DIRECT_COST_AMT><INDIRECT_COST_AMT>30069</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>83978</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9114340</APPLICATION_ID><ACTIVITY>U18</ACTIVITY><ADMINISTERING_IC>FD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>08/24/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U18FD005644</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-FD-15-025</FOA_NUMBER><FULL_PROJECT_NUM>1U18FD005644-01</FULL_PROJECT_NUM><FUNDING_ICs>FDA:93129\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>FOOD AND DRUG ADMINISTRATION</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ALBANY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>20</ORG_DISTRICT><ORG_DUNS>806780565</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NY STATE DEPT OF AGRICULTURE/ MARKETS]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>122351000</ORG_ZIPCODE><PHR><![CDATA[FDA Drug Residue Avoidance Cooperative Agreement Proposal Narrative
RFA-FD-025
 The New York State Department of Agriculture and Markets / Division of Animal
Industry is proposing to enter into a cooperative agreement with the FDA to enhance our
current program promoting the prevention of illegal drug residues in food of animal origin. Our
current program is centered on the Food Safety and Drug Residue Avoidance Module, a
component of the New York State Cattle Health Assurance Program (NYSCHAP). This effort will
include outreach to current NYSCHAP participants to increase participation in the module as
well as efforts to expand NYSCHAP participation. Efforts will also be made to expand the
distribution of drug residue avoidance information to producers beyond NYSCHAP participants.
This will include development of a reference notebook with record keeping forms and guidance
useful at the producer level. Mass communication in the form of a webpage and email
newsletters will be key components of the project. In addition food animal veterinarians will
be targeted for outreach.
Producers who have been investigated by FDA for a drug residue will be offered an educational
visit. This would be done with the permission of the local FDA office and would be voluntary on
the part of the producer. We would also involve the attending veterinarian. The purpose of
this outreach is to offer practical guidance and materials to the violative producer to hopefully
result in a reduction in repeat violators.
Goals Year 1
? Develop webpage
? Develop content for notebook and produce and distribute 1000 copies
? 100 NYSCHAP producer contacts
? 9 CE seminars for veterinarians
? 30 veterinary practice meetings
? 20 post investigational educational visits
Goals Year 2 and 3
? Update webpage as necessary
? Update and produce notebooks, 1000 per year
? 100 NYSCHAP producer contacts
? 9 CE seminars for veterinarians
? 20 practice meetings
? 20 post investigational educational visits]]></PHR><PIS><PI><PI_NAME>SMITH, DAVID  </PI_NAME><PI_ID>14184769</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2015</PROJECT_START><PROJECT_END>08/31/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[FDA Drug Residue Avoidance Cooperative Agreement]]></PROJECT_TITLE><SERIAL_NUMBER>005644</SERIAL_NUMBER><STUDY_SECTION>ZFD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>93129</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9016299</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/20/2015</AWARD_NOTICE_DATE><BUDGET_START>12/20/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI121805</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>1R21AI121805-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:202500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cystic Fibrosis]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Lung]]></CATEGORY><CATEGORY><![CDATA[Orphan Drug]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY><CATEGORY><![CDATA[Tuberculosis]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BALTIMORE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>001910777</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[JOHNS HOPKINS UNIVERSITY]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>212051832</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: A significant proportion of cystic fibrosis patients are morbid with chronic Mycobacterium abscessus infection. The number of drug resistant Mycobacterium abscessus strains isolated from cystic fibrosis patients around the country is steadily increasing making it increasingly difficult to manage these infections. Therefore, new drugs and novel regimens are acutely needed to effectively treat these infections and this proposal is directly aimed at developing a novel regimen using carbapenems, a class of powerful antibiotics never used for treating Mycobacterium abscessus infection, by inhibiting a novel class of enzyme present in this pathogen.      

]]></PHR><PIS><PI><PI_NAME>LAMICHHANE, GYANU </PI_NAME><PI_ID>9751245</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BOYCE, JIM P.</PROGRAM_OFFICER_NAME><PROJECT_START>12/20/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acylation]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Anti-Bacterial Agents]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[antimicrobial]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Bacteriology]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[biapenem]]></TERM><TERM><![CDATA[Bioavailable]]></TERM><TERM><![CDATA[Carbapenems]]></TERM><TERM><![CDATA[Cefoxitin]]></TERM><TERM><![CDATA[Cephalosporins]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clavulanic Acids]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Country]]></TERM><TERM><![CDATA[crosslink]]></TERM><TERM><![CDATA[cystic fibrosis patients]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[doripenem]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[Drug usage]]></TERM><TERM><![CDATA[enzyme activity]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[fropenem]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Genus Mycobacterium]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Hospitals]]></TERM><TERM><![CDATA[Hydrolysis]]></TERM><TERM><![CDATA[Imipenem]]></TERM><TERM><![CDATA[in vitro Model]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Infection Control]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Lactamase]]></TERM><TERM><![CDATA[Lactams]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[Meropenem]]></TERM><TERM><![CDATA[Mycobacterium Infections]]></TERM><TERM><![CDATA[Mycobacterium tuberculosis]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Penicillin-Binding Proteins]]></TERM><TERM><![CDATA[Penicillins]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Peptidoglycan]]></TERM><TERM><![CDATA[Peptidyltransferase]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[resistant strain]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Sputum]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Virulence]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Towards a new regimen to treat mycobacterial infection in cystic fibrosis patients]]></PROJECT_TITLE><SERIAL_NUMBER>121805</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>125000</DIRECT_COST_AMT><INDIRECT_COST_AMT>77500</INDIRECT_COST_AMT><TOTAL_COST>202500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9015762</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK052574</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK052574-17</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:423104\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[The overall goal of the Administrative and Resource Access Core is to provide overall guidance and effective 
stewardship for the Digestive Disease Resource Core Center at Washington University.]]></PHR><PIS><PI><PI_NAME>DAVIDSON, NICHOLAS </PI_NAME><PI_ID>8179452</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Administrator]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Awareness]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Educational workshop]]></TERM><TERM><![CDATA[Electronics]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Financial Support]]></TERM><TERM><![CDATA[Fostering]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[National Institute of Diabetes and Digestive and Kidney Diseases]]></TERM><TERM><![CDATA[Online Systems]]></TERM><TERM><![CDATA[Organizational Objectives]]></TERM><TERM><![CDATA[Peer Review]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Qualifying]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Activity]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resource Allocation]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Seeds]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Systems Biology]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Washington]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Administrative and Resources Access Core and Enrichment Program]]></PROJECT_TITLE><SERIAL_NUMBER>052574</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8139</SUBPROJECT_ID><SUPPORT_YEAR>17</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>277445</DIRECT_COST_AMT><INDIRECT_COST_AMT>145659</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>423104</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9188036</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH001178</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-13-313</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH001178-03S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:1500000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ADDIS ABABA</ORG_CITY><ORG_COUNTRY>ETHIOPIA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>645271719</ORG_DUNS><ORG_FIPS>ET</ORG_FIPS><ORG_NAME><![CDATA[ETHIOPIAN PUBLIC HEALTH INSTITUTE]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE>1242</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>KEBEDE, AMHA </PI_NAME><PI_ID>11807747</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2013</PROJECT_START><PROJECT_END>09/29/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH13-1313: Expansion of PEPFAR Activities:  Strengthening Capacity for Laboratory Systems]]></PROJECT_TITLE><SERIAL_NUMBER>001178</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1500000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9004780</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/24/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI120973</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-AI-14-062</FOA_NUMBER><FULL_PROJECT_NUM>1R21AI120973-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:188759\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Emerging Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Malaria]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY><CATEGORY><![CDATA[Vector-Borne Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>ALBUQUERQUE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>007113228</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SANDIA CORP-SANDIA NATIONAL LABORATORIES]]></ORG_NAME><ORG_STATE>NM</ORG_STATE><ORG_ZIPCODE>871233453</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Early diagnosis of febrile illnesses is critical to guiding patient care and infection control, as exemplified by the 2013-2015 Ebola outbreak in West Africa. We propose to develop a simple, portable, inexpensive diagnostic test that can distinguish between 6 emerging viruses including Ebola virus, as well as malaria parasites, for use in low resource settings such as airports, field clinics, and triage centers.   
      

]]></PHR><PIS><PI><PI_NAME>MEAGHER, ROBERT JAMES</PI_NAME><PI_ID>11025105</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>REPIK, PATRICIA M.</PROGRAM_OFFICER_NAME><PROJECT_START>12/24/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Africa]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Antimalarials]]></TERM><TERM><![CDATA[Arboviruses]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[assay development]]></TERM><TERM><![CDATA[authority]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biomedical Engineering]]></TERM><TERM><![CDATA[Biotechnology]]></TERM><TERM><![CDATA[biothreat]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood specimen]]></TERM><TERM><![CDATA[Case Study]]></TERM><TERM><![CDATA[Cellular Phone]]></TERM><TERM><![CDATA[Chemistry]]></TERM><TERM><![CDATA[Chikungunya virus]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cold Chains]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Contact Tracing]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Data Reporting]]></TERM><TERM><![CDATA[Dengue Virus]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Diagnostic tests]]></TERM><TERM><![CDATA[Differential Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Outbreaks]]></TERM><TERM><![CDATA[Drops]]></TERM><TERM><![CDATA[Early Diagnosis]]></TERM><TERM><![CDATA[Ebola virus]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[Fatigue]]></TERM><TERM><![CDATA[Fever]]></TERM><TERM><![CDATA[Fever Chills]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[Fluorescent Probes]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Guinea]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Infection Control]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lassa virus]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Liberia]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Malaria]]></TERM><TERM><![CDATA[manufacturing scale-up]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Microfluidics]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[multiplex detection]]></TERM><TERM><![CDATA[Myalgia]]></TERM><TERM><![CDATA[Nausea]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nucleic Acids]]></TERM><TERM><![CDATA[Parasites]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathogen detection]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Plasmodium falciparum]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[prototype]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Qualifying]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Reagent]]></TERM><TERM><![CDATA[research clinical testing]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Viruses]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Sensitivity and Specificity]]></TERM><TERM><![CDATA[Sierra Leone]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Supportive care]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Texas]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Triage]]></TERM><TERM><![CDATA[Tube]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[West Nile virus]]></TERM><TERM><![CDATA[Wireless Technology]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Yellow fever virus]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Field-deployable Assay for Differential Diagnosis of Malaria and Viral Febrile Illnesses]]></PROJECT_TITLE><SERIAL_NUMBER>120973</SERIAL_NUMBER><STUDY_SECTION>ZAI1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>143943</DIRECT_COST_AMT><INDIRECT_COST_AMT>44816</INDIRECT_COST_AMT><TOTAL_COST>188759</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9193773</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>PS</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2014</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GPS002839</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-PS-10-133</FOA_NUMBER><FULL_PROJECT_NUM>3U2GPS002839-05S2</FULL_PROJECT_NUM><FUNDING_ICs>COGH:1492269\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NAIROBI</ORG_CITY><ORG_COUNTRY>KENYA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>366498744</ORG_DUNS><ORG_FIPS>KE</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF NAIROBI]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE>254</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>NJOROGE, PETER K</PI_NAME><PI_ID>14138829</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2010</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[PS10-10133: HIV PREV. AND CARE SERV. FOR MARPS IN CENTRAL PROVINCE]]></PROJECT_TITLE><SERIAL_NUMBER>002839</SERIAL_NUMBER><STUDY_SECTION>ZPS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1492269</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8974822</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>396</CFDA_CODE><CORE_PROJECT_NUM>R21CA191550</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-13-146</FOA_NUMBER><FULL_PROJECT_NUM>5R21CA191550-03</FULL_PROJECT_NUM><FUNDING_ICs>NCI:156893\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Colo-Rectal Cancer]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Nonembryonic - Non-Human]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>HERSHEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PEDIATRICS]]></ORG_DEPT><ORG_DISTRICT>15</ORG_DISTRICT><ORG_DUNS>129348186</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PENNSYLVANIA STATE UNIV HERSHEY MED CTR]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>170332360</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The major reason for the lack of satisfactory management of colorectal cancer is our poor understanding of the biology of colorectal tumorigenesis, especially the regulation of key signal transduction pathways and regulation of expression of oncogenes and tumor suppressors. Proposed studies on the role of CRD-BP in the regulation of Wnt signaling in intestinal tumorigenesis are highly significant not only for the understanding the biology of intestinal tumors, but also for the validation of a novel target for the therapy and/or prevention of intestinal tumorigenesis.]]></PHR><PIS><PI><PI_NAME>SPIEGELMAN, VLADIMIR S.</PI_NAME><PI_ID>8296951</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>STRASBURGER, JENNIFER </PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2014</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[American Cancer Society]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[ApcMin/+ mice]]></TERM><TERM><![CDATA[Apoptotic]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[c-myc Genes]]></TERM><TERM><![CDATA[c-myc Proto-Oncogenes]]></TERM><TERM><![CDATA[cancer cell]]></TERM><TERM><![CDATA[cancer diagnosis]]></TERM><TERM><![CDATA[Cancer Etiology]]></TERM><TERM><![CDATA[Cell Cycle Progression]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cell Size]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[chemotherapeutic agent]]></TERM><TERM><![CDATA[chemotherapy]]></TERM><TERM><![CDATA[colon cancer cell line]]></TERM><TERM><![CDATA[colon carcinogenesis]]></TERM><TERM><![CDATA[colon tumorigenesis]]></TERM><TERM><![CDATA[Colorectal Cancer]]></TERM><TERM><![CDATA[Colorectal Neoplasms]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Down-Regulation]]></TERM><TERM><![CDATA[Doxycycline]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[gastrointestinal epithelium]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[GLI gene]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[intestinal epithelium]]></TERM><TERM><![CDATA[Intestinal Neoplasms]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morphologic artifacts]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oncogenic]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[pleiotropism]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[recombinase]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA-Binding Proteins]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Second Primary Cancers]]></TERM><TERM><![CDATA[self-renewal]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signal Transduction Pathway]]></TERM><TERM><![CDATA[smoothened signaling pathway]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[targeted treatment]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Transfection]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[Tumor Suppressor Genes]]></TERM><TERM><![CDATA[tumorigenesis]]></TERM><TERM><![CDATA[tumorigenic]]></TERM><TERM><![CDATA[ubiquitin ligase]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[villin]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[CRD-BP-mediated regulation of Wnt signaling in intestinal tumorigenesis]]></PROJECT_TITLE><SERIAL_NUMBER>191550</SERIAL_NUMBER><STUDY_SECTION>ZCA1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>97875</DIRECT_COST_AMT><INDIRECT_COST_AMT>59018</INDIRECT_COST_AMT><TOTAL_COST>156893</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9188025</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000111</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-106</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000111-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:7500000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ADDIS ABABA</ORG_CITY><ORG_COUNTRY>ETHIOPIA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>850493439</ORG_DUNS><ORG_FIPS>ET</ORG_FIPS><ORG_NAME><![CDATA[OROMIA REGIONAL HEALTH BUREAU]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HABTAMU, ZELALEM </PI_NAME><PI_ID>11093589</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1106, STRENGTHENING LOCAL OWNERSHIP FOR SUSTAINABLE PROVISION OF HIV/AIDS SERVICES]]></PROJECT_TITLE><SERIAL_NUMBER>000111</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>7500000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9188023</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000833</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-12-222</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000833-04S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:3500000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ADDIS ABABA</ORG_CITY><ORG_COUNTRY>ETHIOPIA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>850514813</ORG_DUNS><ORG_FIPS>ET</ORG_FIPS><ORG_NAME><![CDATA[ADDIS ABABA CITY ADMIN HEALTH BUREAU]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE>30738</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>PAULOS, ALEMTSEHAY </PI_NAME><PI_ID>12556778</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2012</PROJECT_START><PROJECT_END>09/29/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH12-1222: STRENGTHENING LOCAL OWNERSHIP FOR SUSTAINABLE PROVISION OF HIV/AIDS SERVICES IN T]]></PROJECT_TITLE><SERIAL_NUMBER>000833</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>3500000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9189153</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>310</CFDA_CODE><CORE_PROJECT_NUM>R01DK049302</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>3R01DK049302-19S1</FULL_PROJECT_NUM><FUNDING_ICs>OD:69600\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cardiovascular]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Heart Disease]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Obesity]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>073130411</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MASSACHUSETTS GENERAL HOSPITAL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021142696</ORG_ZIPCODE><PHR><![CDATA[In this proposal, we will carefully study the regulation of a hormone called aldosterone in HIV-infection. Aldosterone may be increased in HIV-infection and may contribute to problems with sugar metabolism and increased risk of cardiovascular disease. We will also test whether eplerenone, a drug that decreases the body's response to aldosterone, may improve blood sugar and decrease risks for cardiovascular disease in HIV-infected patients with increased belly fat.]]></PHR><PIS><PI><PI_NAME>GRINSPOON, STEVEN K</PI_NAME><PI_ID>1886954</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BREMER, ANDREW </PROGRAM_OFFICER_NAME><PROJECT_START>09/30/1995</PROJECT_START><PROJECT_END>08/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abdominal fat]]></TERM><TERM><![CDATA[adipokines]]></TERM><TERM><![CDATA[adiponectin]]></TERM><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[Adrenal Glands]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aldosterone]]></TERM><TERM><![CDATA[Angiotensin II]]></TERM><TERM><![CDATA[Angiotensins]]></TERM><TERM><![CDATA[animal data]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[antiretroviral therapy]]></TERM><TERM><![CDATA[Applications Grants]]></TERM><TERM><![CDATA[Atherosclerosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior Therapy]]></TERM><TERM><![CDATA[Blood Glucose]]></TERM><TERM><![CDATA[blood glucose regulation]]></TERM><TERM><![CDATA[Blood Pressure]]></TERM><TERM><![CDATA[Body Composition]]></TERM><TERM><![CDATA[cardiometabolic risk]]></TERM><TERM><![CDATA[Cardiovascular Abnormalities]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[cardiovascular risk factor]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[CCL2 gene]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[diet and exercise]]></TERM><TERM><![CDATA[Double-Blind Method]]></TERM><TERM><![CDATA[Dyslipidemias]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[Endocrine]]></TERM><TERM><![CDATA[Endocrine system]]></TERM><TERM><![CDATA[eplerenone]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[glucose uptake]]></TERM><TERM><![CDATA[Glycosylated hemoglobin A]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Infections]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human data]]></TERM><TERM><![CDATA[Hydrocortisone]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[impaired glucose tolerance]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[inflammatory marker]]></TERM><TERM><![CDATA[Infusion procedures]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[insulin sensitivity]]></TERM><TERM><![CDATA[intimal medial thickening]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Life Style]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Magnetic Resonance Spectroscopy]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Mineralocorticoid Receptor]]></TERM><TERM><![CDATA[Mineralocorticoids]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Myocardial Infarction]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[novel strategies]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[open label]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[placebo controlled study]]></TERM><TERM><![CDATA[Placebos]]></TERM><TERM><![CDATA[Plasminogen Activator Inhibitor 1]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Renin]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Marker]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[salt intake]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[sugar]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Testosterone]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[urinary]]></TERM><TERM><![CDATA[vascular inflammation]]></TERM><TERM><![CDATA[Visceral]]></TERM><TERM><![CDATA[waist circumference]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Aldosterone Effects and Targeted Inhibition on Metabolic Indices in HIV-Infection]]></PROJECT_TITLE><SERIAL_NUMBER>049302</SERIAL_NUMBER><STUDY_SECTION>ACE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS Clinical Studies and Epidemiology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>19</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>40000</DIRECT_COST_AMT><INDIRECT_COST_AMT>29600</INDIRECT_COST_AMT><TOTAL_COST>69600</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8984556</APPLICATION_ID><ACTIVITY>IK2</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>IK2RX001512</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-15-009</FOA_NUMBER><FULL_PROJECT_NUM>1IK2RX001512-01A2</FULL_PROJECT_NUM><FUNDING_ICs>VA:181245\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SAN DIEGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>073358855</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA SAN DIEGO HEALTHCARE SYSTEM]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>921610002</ORG_ZIPCODE><PHR><![CDATA[Many Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn era
Veterans have suffered a mild traumatic brain injury (mTBI), and now cope with multiple post-
injury symptoms, including sleep disturbances (especially insomnia). Chronic insomnia in mTBI
patients has the potential to exacerbate other symptoms, delay recovery, and negatively affect
many of the cognitive, psychological, and neuromuscular sequelae of mTBI, thereby decreasing
quality of life. Although Cognitive-Behavioral Therapy for Insomnia (CBT-I) has been shown to
be an effective evidence-based treatment for insomnia, there are no published randomized
controlled trials evaluating the potential strengths and/or limitations of CBT-I in post-mTBI
patients. Therefore, assessing CBT-I in the context of mTBI holds promise to provide substantial
benefits in terms of improved rehabilitation outcomes in Veterans who have suffered mTBI.]]></PHR><PIS><PI><PI_NAME>ORFF, HENRY JOHN</PI_NAME><PI_ID>8403610</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>11/01/2015</PROJECT_START><PROJECT_END>10/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Academy]]></TERM><TERM><![CDATA[addiction]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Afghanistan]]></TERM><TERM><![CDATA[Alcohols]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Appointment]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biometry]]></TERM><TERM><![CDATA[blind]]></TERM><TERM><![CDATA[Brain Injuries]]></TERM><TERM><![CDATA[Budgets]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Chronic Insomnia]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Psychology]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cognitive rehabilitation]]></TERM><TERM><![CDATA[Cognitive Therapy]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[coping]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Distal]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Drug abuse]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Educational Background]]></TERM><TERM><![CDATA[Effect Modifiers (Epidemiology)]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Ethics]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Evidence based practice]]></TERM><TERM><![CDATA[Evidence based treatment]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Feeling suicidal]]></TERM><TERM><![CDATA[Fellowship]]></TERM><TERM><![CDATA[Freedom]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[High Prevalence]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Internships]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Iraq]]></TERM><TERM><![CDATA[Israel]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Letters]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Manuscripts]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Mental Depression]]></TERM><TERM><![CDATA[Mental disorders]]></TERM><TERM><![CDATA[Mental Health]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[mild traumatic brain injury]]></TERM><TERM><![CDATA[Minor]]></TERM><TERM><![CDATA[National Research Service Awards]]></TERM><TERM><![CDATA[neuromuscular]]></TERM><TERM><![CDATA[neuropsychological]]></TERM><TERM><![CDATA[Neuropsychology]]></TERM><TERM><![CDATA[Occupational]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Outcome Assessment (Health Care)]]></TERM><TERM><![CDATA[Outcome Measure]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Philadelphia]]></TERM><TERM><![CDATA[physical conditioning]]></TERM><TERM><![CDATA[Polysomnography]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Post-Concussion Syndrome]]></TERM><TERM><![CDATA[Post-Traumatic Stress Disorders]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[pre-doctoral]]></TERM><TERM><![CDATA[primary outcome]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Psychiatry]]></TERM><TERM><![CDATA[psychologic]]></TERM><TERM><![CDATA[Psychologist]]></TERM><TERM><![CDATA[Psychology]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Randomized Clinical Trials]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Regimen]]></TERM><TERM><![CDATA[Rehabilitation Outcome]]></TERM><TERM><![CDATA[Rehabilitation Research]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research and development]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[secondary outcome]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Sleep]]></TERM><TERM><![CDATA[Sleep Disorders]]></TERM><TERM><![CDATA[Sleep disturbances]]></TERM><TERM><![CDATA[Sleep Stages]]></TERM><TERM><![CDATA[Sleeplessness]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Societies]]></TERM><TERM><![CDATA[sound]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Telephone]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Traumatic Brain Injury]]></TERM><TERM><![CDATA[treatment effect]]></TERM><TERM><![CDATA[Treatment outcome]]></TERM><TERM><![CDATA[treatment response]]></TERM><TERM><![CDATA[trial comparing]]></TERM><TERM><![CDATA[unhealthy lifestyle]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[War]]></TERM><TERM><![CDATA[wound]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cognitive Behavioral Therapy for Insomnia for Veterans with History of TBI]]></PROJECT_TITLE><SERIAL_NUMBER>001512</SERIAL_NUMBER><STUDY_SECTION>RRD9</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Blank ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A2</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9188951</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>R01GM054179</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01GM054179-18</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:338078\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[Mutations in the gene that encodes the connexin26 ion channel protein are one of the most common causes of inherited deafness in the human population. In addition, a subset of mutations cause severe skin disorders and predispose patients to skin cancer (squamous cell carcinoma) and increased incidence of bacterial, viral, and fungal infections. This proposal investigates the underlying mechanisms causing these disorders.]]></PHR><PIS><PI><PI_NAME>VERSELIS, VYTAUTAS K</PI_NAME><PI_ID>1893653</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>NIE, ZHONGZHEN </PROGRAM_OFFICER_NAME><PROJECT_START>05/01/1996</PROJECT_START><PROJECT_END>06/30/2019</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Mechanisms of Gating and Permeation in Gap Junctions]]></PROJECT_TITLE><SERIAL_NUMBER>054179</SERIAL_NUMBER><STUDY_SECTION>NTRC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neurotransporters, Receptors, and Calcium Signaling Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>18</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>202442</DIRECT_COST_AMT><INDIRECT_COST_AMT>135636</INDIRECT_COST_AMT><TOTAL_COST>338078</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9055363</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK105821</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01DK105821-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:492368\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Kidney Disease]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>042250712</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PENNSYLVANIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191046205</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: African American have an approximately 3-5 fold increased risk of developing end stage renal disease. Recently, coding region polymorphisms in the apolipoprotein L1 (APOL1) gene has been identified that can explain this increased risk. The current proposal aims to examine the mechanism of APOL1 associated kidney disease.   
   
      

]]></PHR><PIS><PI><PI_NAME>SUSZTAK, KATALIN </PI_NAME><PI_ID>7733148</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>RASOOLY, REBEKAH S</PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[African American]]></TERM><TERM><![CDATA[African Trypanosomiasis]]></TERM><TERM><![CDATA[Albuminuria]]></TERM><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Apolipoproteins]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[clinical phenotype]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[cytotoxicity]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[disease-causing mutation]]></TERM><TERM><![CDATA[DNA Sequence Alteration]]></TERM><TERM><![CDATA[End stage renal failure]]></TERM><TERM><![CDATA[Epithelial Cells]]></TERM><TERM><![CDATA[Essential Genes]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Focal Segmental Glomerulosclerosis]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[gain of function mutation]]></TERM><TERM><![CDATA[Gene Frequency]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[glomerulosclerosis]]></TERM><TERM><![CDATA[High Density Lipoproteins]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[in vitro Model]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Kidney Diseases]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Liver]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle, Smooth, Vascular]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Nephrosclerosis]]></TERM><TERM><![CDATA[Nephrotic Syndrome]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[podocyte]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[risk variant]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sickle Cell Anemia]]></TERM><TERM><![CDATA[Smooth Muscle Myocytes]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Transcriptional Regulation]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Vascular Endothelial Cell]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[APOL1 associated kidney disease]]></PROJECT_TITLE><SERIAL_NUMBER>105821</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>307730</DIRECT_COST_AMT><INDIRECT_COST_AMT>184638</INDIRECT_COST_AMT><TOTAL_COST>492368</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9185041</APPLICATION_ID><ACTIVITY>K24</ACTIVITY><ADMINISTERING_IC>DA</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>279</CFDA_CODE><CORE_PROJECT_NUM>K24DA036955</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-195</FOA_NUMBER><FULL_PROJECT_NUM>6K24DA036955-03</FULL_PROJECT_NUM><FUNDING_ICs>NIDA:108397\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE ON DRUG ABUSE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This application for a K24 mid-career investigator award seeks to provide support to Dr. Chinazo Cunningham to provide excellent mentorship, effective leadership, and expand her current research to include comparative effectiveness research methods. Dr. Cunningham will mentor a range of junior investigators in the areas of drug abuse and HIV, with an emphasis on providing formal and inform mentorship to racial/ethnic minorities and women. Dr. Cunningham will use her existing research project as a foundation to provide much of her mentorship. In addition, expanding her research to include comparative effectiveness research focused on opioid use will allow her to conduct new research and provide additional mentorship that can ultimately improve health outcomes of drug users with and at-risk for HIV.]]></PHR><PIS><PI><PI_NAME>CUNNINGHAM, CHINAZO </PI_NAME><PI_ID>9213243</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LIN, YU </PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2014</PROJECT_START><PROJECT_END>03/31/2019</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Mentoring researchers on drug abuse and HIV]]></PROJECT_TITLE><SERIAL_NUMBER>036955</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>100368</DIRECT_COST_AMT><INDIRECT_COST_AMT>8029</INDIRECT_COST_AMT><TOTAL_COST>108397</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9187156</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000112</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-106</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000112-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:850000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HARAR</ORG_CITY><ORG_COUNTRY>ETHIOPIA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>850493324</ORG_DUNS><ORG_FIPS>ET</ORG_FIPS><ORG_NAME><![CDATA[HARARI REGIONAL HEALTH BUREAU]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HASSEN, MOHAMMED AHMED</PI_NAME><PI_ID>11092927</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1106: STRENGTHENING LOCAL OWNERSHIP FOR SUSTAINABLE PROVISION OF HIV/AIDS SERVICE]]></PROJECT_TITLE><SERIAL_NUMBER>000112</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>850000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8909603</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>EB</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>06/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END></BUDGET_END><CFDA_CODE>286</CFDA_CODE><CORE_PROJECT_NUM>F31EB020502</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-147</FOA_NUMBER><FULL_PROJECT_NUM>1F31EB020502-01</FULL_PROJECT_NUM><FUNDING_ICs>NIBIB:34194\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Injury (total) Accidents/Adverse Effects]]></CATEGORY><CATEGORY><![CDATA[Injury - Trauma - (Head and Spine)]]></CATEGORY><CATEGORY><![CDATA[Neurodegenerative]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Regenerative Medicine]]></CATEGORY><CATEGORY><![CDATA[Spinal Cord Injury]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Nonembryonic - Non-Human]]></CATEGORY><CATEGORY><![CDATA[Transplantation]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>STANFORD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOMEDICAL ENGINEERING]]></ORG_DEPT><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>009214214</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STANFORD UNIVERSITY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>943041222</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Materials-based stem cell therapies have shown promise in regenerating functional tissue, however, currently used materials generally lack the ability to dynamically interact with the transplanted stem cells. This project aims to develop a material that dynamically responds to neural stem cell differentiation by releasing compounds that improve neuron survival. This material will be used to deliver neural stem cells to sites of spinal
cord injury, with the goal of enhancing functional recovery.   
      

]]></PHR><PIS><PI><PI_NAME>MADL, CHRISTOPHER </PI_NAME><PI_ID>12312399</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ERIM, ZEYNEP </PROGRAM_OFFICER_NAME><PROJECT_START>12/23/2015</PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Alkynes]]></TERM><TERM><![CDATA[animal imaging]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Apoptotic]]></TERM><TERM><![CDATA[Axon]]></TERM><TERM><![CDATA[axon growth]]></TERM><TERM><![CDATA[Azides]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[behavior test]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cell Transplants]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemistry]]></TERM><TERM><![CDATA[Cicatrix]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[Contusions]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[data modeling]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[differential expression]]></TERM><TERM><![CDATA[Diffusion]]></TERM><TERM><![CDATA[Elastin]]></TERM><TERM><![CDATA[Engraftment]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Enzyme Kinetics]]></TERM><TERM><![CDATA[Extracellular Matrix]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Gel]]></TERM><TERM><![CDATA[Gelatinase A]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth Cones]]></TERM><TERM><![CDATA[Histology]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Hydrogels]]></TERM><TERM><![CDATA[Immunohistochemistry]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Situ]]></TERM><TERM><![CDATA[In Situ Nick-End Labeling]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Motivation]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[NAPVSIPQ peptide]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[Nerve]]></TERM><TERM><![CDATA[Nerve Regeneration]]></TERM><TERM><![CDATA[nerve stem cell]]></TERM><TERM><![CDATA[Neurites]]></TERM><TERM><![CDATA[neurodevelopment]]></TERM><TERM><![CDATA[neuron development]]></TERM><TERM><![CDATA[Neuronal Differentiation]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Neuroprotective Agents]]></TERM><TERM><![CDATA[neurotrophic factor]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[oxidative damage]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peptide Hydrolases]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Plants]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[protein expression]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Reactive Oxygen Species]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[Recovery of Function]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Rodent Model]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Serine Protease]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Spinal cord injury]]></TERM><TERM><![CDATA[Staining method]]></TERM><TERM><![CDATA[Stains]]></TERM><TERM><![CDATA[stem cell differentiation]]></TERM><TERM><![CDATA[stem cell fate]]></TERM><TERM><![CDATA[stem cell therapy]]></TERM><TERM><![CDATA[Stem cell transplant]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Support System]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[time use]]></TERM><TERM><![CDATA[tissue regeneration]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transplantation]]></TERM><TERM><![CDATA[Urokinase]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cell Responsive Hydrogels to Improve Functional Recovery after Spinal Cord Injury]]></PROJECT_TITLE><SERIAL_NUMBER>020502</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>34194</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>34194</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9197713</APPLICATION_ID><ACTIVITY>T32</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>07/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>T32GM079086</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-184</FOA_NUMBER><FULL_PROJECT_NUM>3T32GM079086-09S1</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:50614\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INSTITUTIONAL</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHICAGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>098987217</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF ILLINOIS AT CHICAGO]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>606127224</ORG_ZIPCODE><PHR><![CDATA[This program produces physician scientists who have both MD and PhD training, i.e., who receive both degrees at the completion of the program. MD-PhD graduates have deeper perceptions of medical significance in biology than do scientists without medical education, more comprehensive understanding of the limitations in medical practice, and greater ability to transfer basic scientific advances toward patient care advances. Thus, MD-PhD graduates are positioned to identify and pursue interdisciplinary approaches to important biomedical problems, and to help bridge the basic and clinical sciences.]]></PHR><PIS><PI><PI_NAME>TOBACMAN, LARRY S</PI_NAME><PI_ID>1897049</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PREUSCH, PETER </PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2007</PROJECT_START><PROJECT_END>06/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Training Programs]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Medical Scientist Training Program]]></PROJECT_TITLE><SERIAL_NUMBER>079086</SERIAL_NUMBER><STUDY_SECTION>BRT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[National Institute of General Medical Sciences Initial Review Group ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>09</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>48420</DIRECT_COST_AMT><INDIRECT_COST_AMT>2194</INDIRECT_COST_AMT><TOTAL_COST>50614</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9126783</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>09/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX002174</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-15-011</FOA_NUMBER><FULL_PROJECT_NUM>1I01RX002174-01</FULL_PROJECT_NUM><FUNDING_ICs>VA:406900\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HOUSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>09</ORG_DISTRICT><ORG_DUNS>078446044</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MICHAEL E DEBAKEY VA MEDICAL CENTER]]></ORG_NAME><ORG_STATE>TX</ORG_STATE><ORG_ZIPCODE>770304211</ORG_ZIPCODE><PHR><![CDATA[The Chronic Effects of Neurotrauma Consortium (CENC) Neuroimaging Core facilitates the collection, quality
control (QC), transfer, analysis, storage, and integration of structural and functional magnetic resonance
imaging (MRI) in Consortium projects utilizing imaging to study traumatic brain injury (TBI) in Veterans. The
Neuroimaging Core is comprised of both VA- and academic-affiliate resources; an expansion of existing Core
funds granted to the academic affiliate (Baylor College of Medicine) is needed due to the Consortium's growth
since its inception and the resultant change in the Core's scope of work. Specifically, expansion of the number
of Longitudinal Study sites and the addition of several new projects has substantially increased the Core's
responsibilities, including additional oversight, QC, analysis, and administrative duties for Michael E. DeBakey
VA Medical Center (MEDVAMC)-based Core investigators and staff. This expansion is necessary for the
continued efforts of the Consortium in addressing critical issues related to TBI and its associated comorbidities.]]></PHR><PIS><PI><PI_NAME>WILDE, ELISABETH A.</PI_NAME><PI_ID>8423277</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2015</PROJECT_START><PROJECT_END>09/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Advanced Development]]></TERM><TERM><![CDATA[Anatomy]]></TERM><TERM><![CDATA[Auditory]]></TERM><TERM><![CDATA[Autonomic Dysfunction]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Brain Concussion]]></TERM><TERM><![CDATA[Brain imaging]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cognitive change]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Computer Programs and Programming]]></TERM><TERM><![CDATA[Computer software]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Data Quality]]></TERM><TERM><![CDATA[Department of Defense]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Diffusion Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Functional Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Headache]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[Imaging Techniques]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Information Technology]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Long-Term Effects]]></TERM><TERM><![CDATA[Longevity]]></TERM><TERM><![CDATA[Longitudinal Studies]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Manuscripts]]></TERM><TERM><![CDATA[Medical center]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[mild traumatic brain injury]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Movement Disorders]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[Nerve Degeneration]]></TERM><TERM><![CDATA[Nervous System Trauma]]></TERM><TERM><![CDATA[Neurodegenerative Disorders]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Neuropsychology]]></TERM><TERM><![CDATA[Neurosciences]]></TERM><TERM><![CDATA[Neurosecretory Systems]]></TERM><TERM><![CDATA[novel marker]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Personal Satisfaction]]></TERM><TERM><![CDATA[Physics]]></TERM><TERM><![CDATA[Physiologic pulse]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[Prognostic Marker]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[psychologic]]></TERM><TERM><![CDATA[quality assurance]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Institute]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Rest]]></TERM><TERM><![CDATA[Seizures]]></TERM><TERM><![CDATA[Sensory]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Sleep Disorders]]></TERM><TERM><![CDATA[Sorting - Cell Movement]]></TERM><TERM><![CDATA[Spin Labels]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Supervision]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Thick]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Traumatic Brain Injury]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Update]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Visual]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Chronic Effects of Neurotrauma Consortium (CENC) Imaging Core]]></PROJECT_TITLE><SERIAL_NUMBER>002174</SERIAL_NUMBER><STUDY_SECTION>RRDB</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8879218</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/26/2015</AWARD_NOTICE_DATE><BUDGET_START>12/25/2015</BUDGET_START><BUDGET_END>12/24/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>F32MH101994</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-113</FOA_NUMBER><FULL_PROJECT_NUM>4F32MH101994-03</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:54194\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Autism]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Intellectual and Developmental Disabilities (IDD)]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>PHILADELPHIA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PSYCHIATRY]]></ORG_DEPT><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>042250712</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF PENNSYLVANIA]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>191046205</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Successful completion of the three aims will result in a new culturally sensitive tool for communication improvement, thereby advancing psychological and educational practice.  The proposed research also will advance science by providing evidenced-based practices in facilitating parent-teacher communication in special education settings using a consultation framework. This understanding is the necessary first step in future prevention and intervention studies targeting family-school partnerships, which has a pervasive impact on the cognitive, social, and behavioral health of children with ASD.]]></PHR><PIS><PI><PI_NAME>BEGUM, GAZI </PI_NAME><PI_ID>11646121</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HILL, LAUREN D.</PROGRAM_OFFICER_NAME><PROJECT_START>07/25/2013</PROJECT_START><PROJECT_END>12/24/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[behavioral health]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communication Programs]]></TERM><TERM><![CDATA[Communication Tools]]></TERM><TERM><![CDATA[Conflict (Psychology)]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Developmental Disabilities]]></TERM><TERM><![CDATA[Disabled Persons]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[Evidence based intervention]]></TERM><TERM><![CDATA[Evidence based practice]]></TERM><TERM><![CDATA[expectation]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Intervention Studies]]></TERM><TERM><![CDATA[Interview]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Legal]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Mining]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Pennsylvania]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Philadelphia]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Preventive Intervention]]></TERM><TERM><![CDATA[Problem Solving]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[psychiatric disability]]></TERM><TERM><![CDATA[psychologic]]></TERM><TERM><![CDATA[Psychologist]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[satisfaction]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[social skills]]></TERM><TERM><![CDATA[Special Education]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[teacher]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapy design]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Partners in Schools: A Program for Parents and Teachers of Children with Autism]]></PROJECT_TITLE><SERIAL_NUMBER>101994</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>54194</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>54194</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9003043</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK041301</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK041301-27</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:101436\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Autoimmune Disease]]></CATEGORY><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Inflammatory Bowel Disease]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Obesity]]></CATEGORY><CATEGORY><![CDATA[Pain Conditions - Chronic]]></CATEGORY><CATEGORY><![CDATA[Pain Research]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[The Animal Model Core plays a fundamental role to advance knowledge on several diseases including 
irritable bowel syndrome, inflammatory bowel diseases, constipation association with neurodegenerative 
disease and the interaction between the gut and the brain as it relates to food intake and metabolism. The 
unraveling of new mechanisms and testing new intervention using preclinical models will help to understand 
these disorders and advance therapeutic venues.]]></PHR><PIS><PI><PI_NAME>TACHE, YVETTE FRANCE</PI_NAME><PI_ID>1887321</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Body Composition]]></TERM><TERM><![CDATA[Body Fluids]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[cell motility]]></TERM><TERM><![CDATA[Central obesity]]></TERM><TERM><![CDATA[chemical genetics]]></TERM><TERM><![CDATA[Colitis]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Colonoscopy]]></TERM><TERM><![CDATA[Conscious]]></TERM><TERM><![CDATA[Constipation]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Drug Delivery Systems]]></TERM><TERM><![CDATA[Eating]]></TERM><TERM><![CDATA[Energy Metabolism]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Euthanasia]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[Feeding behaviors]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[gastrointestinal system]]></TERM><TERM><![CDATA[Genetic Models]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory Bowel Diseases]]></TERM><TERM><![CDATA[Inflammatory disease of the intestine]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Irritable Bowel Syndrome]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[miniaturize]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[motility disorder]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Neurodegenerative Disorders]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Parkinson Disease]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Permeability]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Pre-Clinical Model]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resource Sharing]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Visceral pain]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core B; Animal Models Core]]></PROJECT_TITLE><SERIAL_NUMBER>041301</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7942</SUBPROJECT_ID><SUPPORT_YEAR>27</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>81345</DIRECT_COST_AMT><INDIRECT_COST_AMT>20091</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>101436</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9195167</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>01/31/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>R01GM104459</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GM-13-002</FOA_NUMBER><FULL_PROJECT_NUM>6R01GM104459-04</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:254917\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The rapid development and deployment of high-throughput, genome-wide technologies coupled to advances in our understanding of transcription, the regulatory strategies of epigenetics and nuclear architecture, and the roles of non-coding RNA (ncRNA) in human biology and disease has licensed new, challenging approaches to functionally link GWAS disease risk loci to various molecular pathways. In this application, we propose to apply these approaches to test a novel paradigm for global transcriptional program changes underlying disease susceptibility detected by GWAS in humans, employing the 9p21 region as a model. Three-dimensional enhancer:promoter interactions, global patterns of altered transcription, gene relocations between functionally distinct subnuclear architectural structures and roles of eRNAs will be investigated. Based on the preliminary data and given all the permissive technologies currently operational in our laboratories, we believe that this project, central to exploiting the insights emanating from contemporary genetic studies of disease susceptibility, will provide critical insights into new strategies for disease prevention and therapeutic approaches, as well as making central contributions to the problem of enhancer-dependent gene transcription programs. The goal is to provide novel targets to prevent or inhibit disease-associated events and perhaps senescence in human cells. The 9p21, model will therefore provide an experimental blueprint for study of any GWAS locus. 
 
 
 
 
DESCRIPTION (provided by applicant): More than 1,000 published GWAS have collectively reported significant associations of ~4,000 SNPs for more than 200 traits/diseases. The challenge is to move SNP associations to biological insights and then to translate these insights, achieving better clinical outcomes. This ambitious goal requires an inclusive and effective strategy to solve the molecular basis by which these variants confer disease susceptibility. To date, the vast majority of the associations noted in GWAS for disease phenotypes have been with variants located within gene deserts, the 99% of the genome that does not encode known proteins and where our understanding of functional consequences and causality is at best rudimentary. Recent findings indicate that altering DNA sequence in evolutionarily conserved non-coding regions can be as deleterious as altering coding regions. Therefore, it is not surprising that disease-causing variants will reside in the gene desert regions. The greatest challenge in the post-GWAS era is to understand the regulatory principles of risk variants in gene desert regions and the mechanisms underlying the risk conferred by these loci. The goal of this proposal is to accelerate post-GWAS functional characterization, uncovering initial global principles for the functional characterization of disease risk loci by focusing on altered function 
in transcription based on the actions of enhancer RNAs. Employing the 9p21 region as a model, we will establish how disease-associated common sequence variants alter the functions of regulatory regions and address the molecular mechanisms by which these effects are exerted. These studies will integrate disease susceptibility-associated sequence variations into the emerging three-dimensional network of long-distance genomic region interactions, establish local and global alterations in gene transcription, and explore the key role of enhancer-RNAs harboring sequence variations at GWAS loci. The primary significance will be the discovery of a novel functional consequences and an epigenomic molecular mechanism underlying GWAS loci in disease, with the opportunity for exploiting these new mechanistic and therapeutic insights for preventative approaches to the chronic diseases associated with aging.]]></PHR><PIS><PI><PI_NAME>SUH, YOUSIN </PI_NAME><PI_ID>7669621</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KRASNEWICH, DONNA M</PROGRAM_OFFICER_NAME><PROJECT_START>04/05/2013</PROJECT_START><PROJECT_END>01/31/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[New Methods to Uncover Global Transcriptional Programs for Disease Risk Variants]]></PROJECT_TITLE><SERIAL_NUMBER>104459</SERIAL_NUMBER><STUDY_SECTION>ZGM1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>201875</DIRECT_COST_AMT><INDIRECT_COST_AMT>53042</INDIRECT_COST_AMT><TOTAL_COST>254917</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198595</APPLICATION_ID><ACTIVITY>U01</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>10/01/2015</BUDGET_START><BUDGET_END>08/14/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U01GH000048</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-10-003</FOA_NUMBER><FULL_PROJECT_NUM>3U01GH000048-06S1</FULL_PROJECT_NUM><FUNDING_ICs>NCHHSTP:58579\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BETHESDA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>144676566</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[HENRY M. JACKSON FDN FOR THE ADV MIL/MED]]></ORG_NAME><ORG_STATE>MD</ORG_STATE><ORG_ZIPCODE>208171888</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HAPNER, ARTHUR W</PI_NAME><PI_ID>14312308</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>10/01/2015</PROJECT_START><PROJECT_END>08/14/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH10-003:  Conducting Public Health Research in Kenya (U01)]]></PROJECT_TITLE><SERIAL_NUMBER>000048</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>06</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>58579</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198703</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>04/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH001150</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-13-340</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH001150-02S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:300000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CAPE TOWN</ORG_CITY><ORG_COUNTRY>SOUTH AFRICA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>635909489</ORG_DUNS><ORG_FIPS>SF</ORG_FIPS><ORG_NAME><![CDATA[MEDICAL RESEARCH COUNCIL OF SOUTH AFRICA]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>STEFAN, CRISTINA </PI_NAME><PI_ID>12617876</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2014</PROJECT_START><PROJECT_END>03/31/2019</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH13-1340, STRENGTHENING STRATEGIC INFORMATION, PROGRAM IMPLEMENTATION]]></PROJECT_TITLE><SERIAL_NUMBER>001150</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>300000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9010674</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL130452</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01HL130452-01</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:387500\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Cardiovascular]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Heart Disease]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Obesity]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LA JOLLA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>52</ORG_DISTRICT><ORG_DUNS>804355790</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA SAN DIEGO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>920930934</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Proposed studies will help us to gain insights into mechanisms by which adipocyte-derived microRNAs are involved in pathogenic cardiac remodeling in distinct disease settings. These findings will pave the way for potential therapeutic
use of antagomirs to treat these diseases. Proposed studies will also impact our general understanding of signal transduction and communication between organs.   
   
      

]]></PHR><PIS><PI><PI_NAME>CHEN, JU </PI_NAME><PI_ID>1859740</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WANG, LAN-HSIANG </PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Ablation]]></TERM><TERM><![CDATA[Adipocytes]]></TERM><TERM><![CDATA[Adipose tissue]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Cardiac]]></TERM><TERM><![CDATA[Cardiac Myocytes]]></TERM><TERM><![CDATA[Cardiomyopathies]]></TERM><TERM><![CDATA[Cell Communication]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[clinical application]]></TERM><TERM><![CDATA[Coculture Techniques]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Endocrine Glands]]></TERM><TERM><![CDATA[experimental analysis]]></TERM><TERM><![CDATA[Experimental Models]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Glycogen]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Heart Hypertrophy]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[human FRAP1 protein]]></TERM><TERM><![CDATA[Hypertrophy]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[insulin sensitivity]]></TERM><TERM><![CDATA[insulin sensitizing drugs]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Knockout Mice]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[lipid metabolism]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Muscle Cells]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Nuclear]]></TERM><TERM><![CDATA[Nuclear Hormone Receptors]]></TERM><TERM><![CDATA[Nucleotides]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peroxisome Proliferator-Activated Receptors]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[receptor expression]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[rosiglitazone]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Therapeutic Uses]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[Transport Vesicles]]></TERM><TERM><![CDATA[Untranslated RNA]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Ventricular]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Adipocytes and cardiac remodeling]]></PROJECT_TITLE><SERIAL_NUMBER>130452</SERIAL_NUMBER><STUDY_SECTION>MIM</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Myocardial Ischemia and Metabolism Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>250000</DIRECT_COST_AMT><INDIRECT_COST_AMT>137500</INDIRECT_COST_AMT><TOTAL_COST>387500</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9003046</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK041301</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK041301-27</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:128141\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Nanotechnology]]></CATEGORY><CATEGORY><![CDATA[Regenerative Medicine]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Induced Pluripotent Stem Cell]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Induced Pluripotent Stem Cell - Human]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Induced Pluripotent Stem Cell - Non-Human]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Nonembryonic - Human]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Nonembryonic - Non-Human]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[The availability of state-of-the-art equipment and resources for sophisticated imaging approaches and of 
technologies to isolate stem cells and induce enteroendocrine differentiation in vitro, has a significant impact 
on the Center program by allowing investigations of cellular processes and signaling mechanisms regulating 
Gl functions and of the molecular basis of Gl disorders, critical for advanced diagnosis and efficient therapy.]]></PHR><PIS><PI><PI_NAME>STERNINI, CATIA </PI_NAME><PI_ID>1955992</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Bioluminescence]]></TERM><TERM><![CDATA[Biosensor]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Separation]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Confocal Microscopy]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Digital Photography]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Embryo]]></TERM><TERM><![CDATA[Energy Transfer]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[Epithelial Cells]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetically Engineered Mouse]]></TERM><TERM><![CDATA[Gland]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human stem cells]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Image Analysis]]></TERM><TERM><![CDATA[Imagery]]></TERM><TERM><![CDATA[Immunohistochemistry]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[intestinal epithelium]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[light microscopy]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Monoclonal Antibodies]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Myopathy]]></TERM><TERM><![CDATA[Nanotechnology]]></TERM><TERM><![CDATA[Neurobiology]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Pluripotent Stem Cells]]></TERM><TERM><![CDATA[polyclonal antibody]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Quantum Dots]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[retroviral transduction]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[Smooth muscle (tissue)]]></TERM><TERM><![CDATA[stem cell biology]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Training]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core E: Imaging and Stem Cell Biology Core]]></PROJECT_TITLE><SERIAL_NUMBER>041301</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>7945</SUBPROJECT_ID><SUPPORT_YEAR>27</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>81345</DIRECT_COST_AMT><INDIRECT_COST_AMT>46796</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>128141</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9113334</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>08/01/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>R01NS085002</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R01NS085002-03</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:292109\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHICAGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROLOGY]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>005436803</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[NORTHWESTERN UNIVERSITY AT CHICAGO]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>606113152</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This study investigates cerebral vascular mechanisms leading to cognitive and mobility impairment in older adults. Cognitive and mobility impairments are a significant public health problem among elderly people. Cerebrovascular disease is a major contributor to these clinical outcomes. A better understanding of vascular mechanisms which proceed cognitive and mobility impairment will advance our knowledge of this process and help us identify more effective preventions and treatments.]]></PHR><PIS><PI><PI_NAME>SOROND, FARZANEH A</PI_NAME><PI_ID>1912496</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CORRIVEAU, RODERICK A</PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2015</PROJECT_START><PROJECT_END>04/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[age related]]></TERM><TERM><![CDATA[aging population]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Blood Vessels]]></TERM><TERM><![CDATA[Boston]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain imaging]]></TERM><TERM><![CDATA[cerebral microbleeds]]></TERM><TERM><![CDATA[Cerebrovascular Circulation]]></TERM><TERM><![CDATA[Cerebrovascular Disorders]]></TERM><TERM><![CDATA[Cerebrum]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical assessments]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[Cognitive]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Dementia]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diffusion Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[Doppler Ultrasound]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[falls]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[functional outcomes]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gait]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[gray matter]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Hyperemia]]></TERM><TERM><![CDATA[Impaired cognition]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[meter]]></TERM><TERM><![CDATA[Microvascular Dysfunction]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[motor impairment]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[population based]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Preventive Intervention]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[Spin Labels]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Vascular Diseases]]></TERM><TERM><![CDATA[white matter]]></TERM><TERM><![CDATA[White Matter Hyperintensity]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cerebral Small Vessels in Motor and Cognitive Decline]]></PROJECT_TITLE><SERIAL_NUMBER>085002</SERIAL_NUMBER><STUDY_SECTION>ASG</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Aging Systems and Geriatrics Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>201344</DIRECT_COST_AMT><INDIRECT_COST_AMT>90765</INDIRECT_COST_AMT><TOTAL_COST>292109</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9165938</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>02/29/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>R01NS074702</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R01NS074702-05</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:4853\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2014</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>STANFORD</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROSURGERY]]></ORG_DEPT><ORG_DISTRICT>18</ORG_DISTRICT><ORG_DUNS>009214214</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[STANFORD UNIVERSITY]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>943041222</ORG_ZIPCODE><PHR><![CDATA[Many patients with temporal lobe epilepsy have repeated spontaneous seizures that cannot be controlled with
existing drug therapies. Spontaneous seizures may be caused by persistently altered circuits that emerge after
precipitating insults. The project will determine whether transiently inhibiting pathologically super-connected
neurons using cutting-edge optical techniques can prevent the generation of seizures.]]></PHR><PIS><PI><PI_NAME>SOLTESZ, IVAN </PI_NAME><PI_ID>1896710</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>FUREMAN, BRANDY E</PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>02/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Optogenetic hub cell control for no seizures, no side-effects temporal lobe epilepsy]]></PROJECT_TITLE><SERIAL_NUMBER>074702</SERIAL_NUMBER><STUDY_SECTION>ZNS1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>3071</DIRECT_COST_AMT><INDIRECT_COST_AMT>1782</INDIRECT_COST_AMT><TOTAL_COST>4853</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9015765</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK052574</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK052574-17</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:255232\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[Extending basic research findings to human digestive disease and translating these findings to the clinical 
setting is a major goal of the Washington University DDRCC. The Biobank Core promotes, facilitates, and 
accelerates studies of human digestive disease by functioning as both an repository of archival specimens 
linked with relevant clinical data and as a platform studies in humans.]]></PHR><PIS><PI><PI_NAME>NEWBERRY, RODNEY D</PI_NAME><PI_ID>2046010</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[biobank]]></TERM><TERM><![CDATA[Categories]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Data]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Consent]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Enrollment]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gastrointestinal Diseases]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Genotype]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[high throughput analysis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Institutional Review Boards]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Metadata]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Observational Study]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Qualifying]]></TERM><TERM><![CDATA[repository]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Retrospective Studies]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Specimen Handling]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Washington]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core D: Biobank Core]]></PROJECT_TITLE><SERIAL_NUMBER>052574</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8153</SUBPROJECT_ID><SUPPORT_YEAR>17</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>167365</DIRECT_COST_AMT><INDIRECT_COST_AMT>87867</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>255232</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9198132</APPLICATION_ID><ACTIVITY>UR1</ACTIVITY><ADMINISTERING_IC>TI</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2014</BUDGET_START><BUDGET_END>09/29/2015</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>UR1TI024228</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-TI-12-008</FOA_NUMBER><FULL_PROJECT_NUM>3UR1TI024228-03S1</FULL_PROJECT_NUM><FUNDING_ICs>CSAT:59087\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2013</FY><IC_NAME>Center for Substance Abuse Treatment</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SALT LAKE CITY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>02</ORG_DISTRICT><ORG_DUNS>009095365</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF UTAH]]></ORG_NAME><ORG_STATE>UT</ORG_STATE><ORG_ZIPCODE>841128930</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>SEARCY, MARJEAN </PI_NAME><PI_ID>7024896</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KOPSTEIN, ANDREA </PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2012</PROJECT_START><PROJECT_END>09/29/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Region 8 Addiction Technology Transfer Center]]></PROJECT_TITLE><SERIAL_NUMBER>024228</SERIAL_NUMBER><STUDY_SECTION>ZOA1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Earmark ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8984134</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/11/2015</AWARD_NOTICE_DATE><BUDGET_START>09/14/2015</BUDGET_START><BUDGET_END>09/13/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>F32GM116423</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-149</FOA_NUMBER><FULL_PROJECT_NUM>1F32GM116423-01</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:52406\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BERKELEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>078576738</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>947208050</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Iron plays an important role in the function of many enzymes that are critical for cellular function, and for the health of the body as a whole. Iron containing
proteins are involved in harvesting the oxygen we breathe, Vitamin D synthesis, and in the creation of small molecules like Nitric Oxide (NO), which affect the heart and immune system. These proposed studies aim to how NO is formed from the amino acid Arginine by the Nitric Oxide Synthase using novel methodology that will have applications in other health-related enzyme studies, helping to understand how proteins do their work at an atomic level.   
   
   
      

]]></PHR><PIS><PI><PI_NAME>FULLER, FRANKLIN DEAN</PI_NAME><PI_ID>12469041</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>FLICKER, PAULA F.</PROGRAM_OFFICER_NAME><PROJECT_START>09/14/2015</PROJECT_START><PROJECT_END>09/13/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[absorption]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Arginine]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Breathing]]></TERM><TERM><![CDATA[Catalysis]]></TERM><TERM><![CDATA[Cell Communication]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Respiration]]></TERM><TERM><![CDATA[chemical synthesis]]></TERM><TERM><![CDATA[Chemical-Induced Change]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[cryogenics]]></TERM><TERM><![CDATA[Crystallography]]></TERM><TERM><![CDATA[cytochrome c oxidase]]></TERM><TERM><![CDATA[Cytochrome P450]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dioxygen]]></TERM><TERM><![CDATA[Dioxygenases]]></TERM><TERM><![CDATA[disorder control]]></TERM><TERM><![CDATA[Drug Targeting]]></TERM><TERM><![CDATA[Electronics]]></TERM><TERM><![CDATA[Electrons]]></TERM><TERM><![CDATA[emission spectroscopy]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[enzyme substrate]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[free-electron laser]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Harvest]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heart]]></TERM><TERM><![CDATA[Heme]]></TERM><TERM><![CDATA[Heme Iron]]></TERM><TERM><![CDATA[Hemeproteins]]></TERM><TERM><![CDATA[Human body]]></TERM><TERM><![CDATA[Hydroxyl Radical]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Iron]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lifting]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[metalloenzyme]]></TERM><TERM><![CDATA[Metals]]></TERM><TERM><![CDATA[method development]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Nitric Oxide]]></TERM><TERM><![CDATA[Nitric Oxide Synthase]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[optical spectra]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Oxidants]]></TERM><TERM><![CDATA[Oxidation-Reduction]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Oxygenases]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Photons]]></TERM><TERM><![CDATA[Physiologic pulse]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Radiation]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Reactive Oxygen Species]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Roentgen Rays]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Spectrum Analysis]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Superoxides]]></TERM><TERM><![CDATA[Suspension substance]]></TERM><TERM><![CDATA[Suspensions]]></TERM><TERM><![CDATA[Synchrotrons]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Temperature]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transition Elements]]></TERM><TERM><![CDATA[Triplet Multiple Birth]]></TERM><TERM><![CDATA[Vasodilation]]></TERM><TERM><![CDATA[Vitamin D]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[X ray spectroscopy]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[X-ray spectroscopy of Highly Reactive Catalytic Intermediates in Oxygen Activating Metallo-Enzymes]]></PROJECT_TITLE><SERIAL_NUMBER>116423</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>52406</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>52406</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9012685</APPLICATION_ID><ACTIVITY>F32</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>11/19/2015</AWARD_NOTICE_DATE><BUDGET_START>12/22/2015</BUDGET_START><BUDGET_END>12/21/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>F32AI116355</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-149</FOA_NUMBER><FULL_PROJECT_NUM>5F32AI116355-02</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:56042\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Immunization]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY><CATEGORY><![CDATA[Vaccine Related]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>076593722</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSPITAL CORPORATION]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021155724</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Current HIV vaccine-development strategies focus on inducing broadly neutralizing antibodies (bnAbs) that target a wide range of viral variants. This research proposal seeks to determine pathways of antibody affinity maturation that have led to specific bnAbs and to track the co-evolution in an infected individual of virus and antibody response. It is expected that this information can suggest characteristics of vaccine immunogens that might elicit comparable responses via shorter pathways.   
      

]]></PHR><PIS><PI><PI_NAME>FERA, DANIELA </PI_NAME><PI_ID>11738238</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KUO, LILLIAN S.</PROGRAM_OFFICER_NAME><PROJECT_START>12/22/2014</PROJECT_START><PROJECT_END>12/21/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antibody Affinity]]></TERM><TERM><![CDATA[Antibody Binding Sites]]></TERM><TERM><![CDATA[Antibody Response]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[B-Lymphocytes]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Binding Sites]]></TERM><TERM><![CDATA[Carbohydrates]]></TERM><TERM><![CDATA[Cell Separation]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Cloning]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Crystallization]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dissociation]]></TERM><TERM><![CDATA[Epitopes]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[glycosylation]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Hemagglutinin]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Envelope Protein gp120]]></TERM><TERM><![CDATA[HIV vaccine]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immune system]]></TERM><TERM><![CDATA[Immunoglobulin Variable Region]]></TERM><TERM><![CDATA[Immunologic Deficiency Syndromes]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Influenza]]></TERM><TERM><![CDATA[influenzavirus]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Interferometry]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[molecular dynamics]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[neutralizing antibody]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Polysaccharides]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Race]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Siblings]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Trees]]></TERM><TERM><![CDATA[Vaccination]]></TERM><TERM><![CDATA[vaccine development]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Antibodies]]></TERM><TERM><![CDATA[Virion]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[virus envelope]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Interplay between antibody affinity maturation and HIV evolution in a single host]]></PROJECT_TITLE><SERIAL_NUMBER>116355</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>56042</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>56042</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9056076</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>396</CFDA_CODE><CORE_PROJECT_NUM>R01CA192844</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01CA192844-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NCI:379015\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Hematology]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>ATLANTA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>066469933</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[EMORY UNIVERSITY]]></ORG_NAME><ORG_STATE>GA</ORG_STATE><ORG_ZIPCODE>303224250</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: CD86 is important for myeloma cell survival and we hypothesize that it contributes to both drug resistance as well as disease progression in myeloma. By determining how CD86 contributes to myeloma progression, we will provide the rationale for targeting this molecule for the treatment of this cancer. This can be achieved by repurposing an FDA-approved drug that is currently used for the treatment of rheumatoid arthritis.   
      

]]></PHR><PIS><PI><PI_NAME>BOISE, LAWRENCE H.</PI_NAME><PI_ID>1861212</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HOWCROFT, THOMAS K.</PROGRAM_OFFICER_NAME><PROJECT_START>12/23/2015</PROJECT_START><PROJECT_END>11/30/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Antigen-Presenting Cells]]></TERM><TERM><![CDATA[Autoimmunity]]></TERM><TERM><![CDATA[Autophagocytosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[BCL2 gene]]></TERM><TERM><![CDATA[Bone Marrow]]></TERM><TERM><![CDATA[cancer therapy]]></TERM><TERM><![CDATA[CD28 gene]]></TERM><TERM><![CDATA[CD80 gene]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Clinic]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[Cytoplasmic Tail]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dependence]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[established cell line]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Extramedullary]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic Polymorphism]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Graft Rejection]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune response]]></TERM><TERM><![CDATA[Immunity]]></TERM><TERM><![CDATA[Immunoglobulins]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Induction of Apoptosis]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Intravenous]]></TERM><TERM><![CDATA[Kidney Transplantation]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Target]]></TERM><TERM><![CDATA[multicatalytic endopeptidase complex]]></TERM><TERM><![CDATA[Multiple Myeloma]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organ Transplantation]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[outcome forecast]]></TERM><TERM><![CDATA[Passive Transfer of Immunity]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[personalized medicine]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Plasma Cells]]></TERM><TERM><![CDATA[Pre-Clinical Model]]></TERM><TERM><![CDATA[Proteasome Inhibition]]></TERM><TERM><![CDATA[Proteasome Inhibitor]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rheumatoid Arthritis]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Secretory Cell]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Molecule]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Tail]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[tumor growth]]></TERM><TERM><![CDATA[Vertebral column]]></TERM><TERM><![CDATA[Xenograft procedure]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Role of CD86 in Multiple Myeloma]]></PROJECT_TITLE><SERIAL_NUMBER>192844</SERIAL_NUMBER><STUDY_SECTION>BMCT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Basic Mechanisms  of Cancer Therapeutics Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>246633</DIRECT_COST_AMT><INDIRECT_COST_AMT>132382</INDIRECT_COST_AMT><TOTAL_COST>379015</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9193942</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>393</CFDA_CODE><CORE_PROJECT_NUM>R01CA079057</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-07-070</FOA_NUMBER><FULL_PROJECT_NUM>6R01CA079057-16</FULL_PROJECT_NUM><FUNDING_ICs>NCI:29616\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2013</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The goals of this project are to understand the functions of a major component of mammalian chromosomes called H1 linker histone. H1 is involved in many aspects of chromosome function including repair of DNA damage, recombination and silencing of genes and viruses. Thus, H1 is a key intermediate in processes that contribute to the development of numerous human diseases, including cancer.]]></PHR><PIS><PI><PI_NAME>SKOULTCHI, ARTHUR I</PI_NAME><PI_ID>1857785</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>OKANO, PAUL </PROGRAM_OFFICER_NAME><PROJECT_START>04/01/1998</PROJECT_START><PROJECT_END>07/31/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[In Vivo Analysis of Mouse H1 Histone Function]]></PROJECT_TITLE><SERIAL_NUMBER>079057</SERIAL_NUMBER><STUDY_SECTION>MGC</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Molecular Genetics C Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>16</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>17734</DIRECT_COST_AMT><INDIRECT_COST_AMT>11882</INDIRECT_COST_AMT><TOTAL_COST>29616</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198370</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000549</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-GH-11-191</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000549-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:1854567\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SEATTLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>605799469</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF WASHINGTON]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>981959472</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BARNHART, SCOTT </PI_NAME><PI_ID>8254617</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1191 IMPROVEMENT OF INTERGRATED HIV CLINICAL-BASED SERVICES ]]></PROJECT_TITLE><SERIAL_NUMBER>000549</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1854567</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9034768</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>EB</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>286</CFDA_CODE><CORE_PROJECT_NUM>R21EB020162</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-303</FOA_NUMBER><FULL_PROJECT_NUM>1R21EB020162-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIBIB:269869\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Diagnostic Radiology]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>073130411</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[MASSACHUSETTS GENERAL HOSPITAL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021142696</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The focus of this research proposal is to develop high-performance and cost-effective detectors for small animal PET imaging. The goal is develop sub-millimeter spatial resolution detectors with DOI capability while maintaining high sensitivity to the incident 511 keV gamma rays.   
      

]]></PHR><PIS><PI><PI_NAME>SABET, HAMID </PI_NAME><PI_ID>12179306</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SASTRE, ANTONIO </PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Biochemical Process]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[density]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[detector]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diamond]]></TERM><TERM><![CDATA[driving force]]></TERM><TERM><![CDATA[Elements]]></TERM><TERM><![CDATA[Emerging Technologies]]></TERM><TERM><![CDATA[Gamma Rays]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Image]]></TERM><TERM><![CDATA[Imagery]]></TERM><TERM><![CDATA[imaging system]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lasers]]></TERM><TERM><![CDATA[Lateral]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Mechanical Stress]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[millimeter]]></TERM><TERM><![CDATA[Modality]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[molecular imaging]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Optics]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Physics]]></TERM><TERM><![CDATA[Physiological Processes]]></TERM><TERM><![CDATA[Polishes (substance)]]></TERM><TERM><![CDATA[Positron-Emission Tomography]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Price]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[process optimization]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Refractive Indices]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Side]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[thermal stress]]></TERM><TERM><![CDATA[Thick]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Novel laser-processed scintillation detector for high-resolution PET scanners]]></PROJECT_TITLE><SERIAL_NUMBER>020162</SERIAL_NUMBER><STUDY_SECTION>BMIT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biomedical Imaging Technology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>157818</DIRECT_COST_AMT><INDIRECT_COST_AMT>112051</INDIRECT_COST_AMT><TOTAL_COST>269869</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9029513</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK105154</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01DK105154-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:826850\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Human Genome]]></CATEGORY><CATEGORY><![CDATA[Kidney Disease]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CAMBRIDGE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>623544785</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BROAD INSTITUTE, INC.]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021421401</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Kidney disease is a common and devastating complication of diabetes, and represents a major public health problem worldwide. The inherited, genetic factors that play a role in determining who will get this complication are beginning to be discovered, creating opportunities to understand the underlying biological basis of diabetic kidney disease, which will guide the development of improved treatments and preventive measures. We will combine and integrate data from several complementary approaches (genetics, epigenetics, gene expression analysis and studies in model systems) to identify genes and biological processes that influence the development of diabetic kidney disease.   
      

]]></PHR><PIS><PI><PI_NAME>FLOREZ, JOSE CARLOS</PI_NAME><PI_ID>1911463</PI_ID></PI><PI><PI_NAME>HIRSCHHORN, JOEL N (contact)</PI_NAME><PI_ID>1925105 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>RASOOLY, REBEKAH S</PROGRAM_OFFICER_NAME><PROJECT_START>12/23/2015</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Amputation]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biological Models]]></TERM><TERM><![CDATA[Biological Process]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biopsy]]></TERM><TERM><![CDATA[Blindness]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Candidate Disease Gene]]></TERM><TERM><![CDATA[Cell model]]></TERM><TERM><![CDATA[Chronic Kidney Failure]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Complication]]></TERM><TERM><![CDATA[Complications of Diabetes Mellitus]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[diabetic]]></TERM><TERM><![CDATA[Diabetic Nephropathy]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA Methylation]]></TERM><TERM><![CDATA[DNA Sequence]]></TERM><TERM><![CDATA[End stage renal failure]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[exome]]></TERM><TERM><![CDATA[exome sequencing]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Funding Mechanisms]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Gene Targeting]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic analysis]]></TERM><TERM><![CDATA[genetic approach]]></TERM><TERM><![CDATA[genetic association]]></TERM><TERM><![CDATA[genetic risk factor]]></TERM><TERM><![CDATA[Genetic study]]></TERM><TERM><![CDATA[genetic variant]]></TERM><TERM><![CDATA[genome wide association study]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[glycemic control]]></TERM><TERM><![CDATA[Guide prevention]]></TERM><TERM><![CDATA[Health Care Costs]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[human data]]></TERM><TERM><![CDATA[Hyperglycemia]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[International]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Ireland]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Kidney Diseases]]></TERM><TERM><![CDATA[Kidney Failure]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Letters]]></TERM><TERM><![CDATA[macrovascular disease]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Meta-Analysis]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Methylation]]></TERM><TERM><![CDATA[Microvascular Dysfunction]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[Northern Ireland]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Prevention strategy]]></TERM><TERM><![CDATA[Preventive]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[rare variant]]></TERM><TERM><![CDATA[Regulatory Element]]></TERM><TERM><![CDATA[Renal function]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sample Size]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Secondary to]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[stroke]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[trait]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Untranslated RNA]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Integrative genomic, epigenetic and functional studies in diabetic kidney disease]]></PROJECT_TITLE><SERIAL_NUMBER>105154</SERIAL_NUMBER><STUDY_SECTION>PBKD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Pathobiology of Kidney Disease Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>584312</DIRECT_COST_AMT><INDIRECT_COST_AMT>242538</INDIRECT_COST_AMT><TOTAL_COST>826850</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9187174</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH001052</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-13-311</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH001052-03S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:6500000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BAHIR DAR</ORG_CITY><ORG_COUNTRY>ETHIOPIA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>850498928</ORG_DUNS><ORG_FIPS>ET</ORG_FIPS><ORG_NAME><![CDATA[AMHARA REGIONAL HEALTH BUREAU]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>DERESE GETANEH, TESFA </PI_NAME><PI_ID>11789216</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2013</PROJECT_START><PROJECT_END>09/29/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH13-1311: STRENGTHENING LOCAL OWNERSHIP FOR THE SUSTAINABLE PROVISION]]></PROJECT_TITLE><SERIAL_NUMBER>001052</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>6500000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198279</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000388</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PUBLIC HEALTH]]></ED_INST_TYPE><FOA_NUMBER>RFA-GH-11-111</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000388-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:234304\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PUBLIC HEALTH & PREV MEDICINE]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>621889815</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[COLUMBIA UNIVERSITY HEALTH SCIENCES]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100320049</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>COLSON, PAUL W</PI_NAME><PI_ID>1906718</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[THE DEVELOPMENT AND ESTABLISHMENT OF AN INTERNATIONAL ACCREDITED TRAINING CENTER ]]></PROJECT_TITLE><SERIAL_NUMBER>000388</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>234304</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9187163</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000110</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-106</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000110-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:700000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DIRE DAWA</ORG_CITY><ORG_COUNTRY>ETHIOPIA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>850493328</ORG_DUNS><ORG_FIPS>ET</ORG_FIPS><ORG_NAME><![CDATA[DIRE DAWA ADMINISTRATIVE HEALTH BUREAU]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>HAILE, MULUKEN </PI_NAME><PI_ID>12545563</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1106: STRENGTHENING LOCAL OWNERSHIP FOR SUSTAINABLE PROVISION OF HIV/AIDS SERVICES]]></PROJECT_TITLE><SERIAL_NUMBER>000110</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>700000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198614</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000285</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-152</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000285-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:627115\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CAPE TOWN</ORG_CITY><ORG_COUNTRY>SOUTH AFRICA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>538450017</ORG_DUNS><ORG_FIPS>SF</ORG_FIPS><ORG_NAME><![CDATA[SHOUT IT NOW]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>FORGRIEVE, BRUCE </PI_NAME><PI_ID>10914469</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1152, S. Africa, STRENGTHENING PREVENTION TO EFF REDUCE HIV INCIDENCE THROUGH MOBILE HCT]]></PROJECT_TITLE><SERIAL_NUMBER>000285</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>627115</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8982893</APPLICATION_ID><ACTIVITY>F30</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>08/14/2015</AWARD_NOTICE_DATE><BUDGET_START>08/16/2015</BUDGET_START><BUDGET_END>08/15/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>F30HL126280</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[BIOMED ENGR/COL ENGR/ENGR STA]]></ED_INST_TYPE><FOA_NUMBER>PA-14-150</FOA_NUMBER><FULL_PROJECT_NUM>1F30HL126280-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:36541\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Lung]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>NASHVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOMEDICAL ENGINEERING]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>004413456</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VANDERBILT UNIVERSITY]]></ORG_NAME><ORG_STATE>TN</ORG_STATE><ORG_ZIPCODE>372122809</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Pulmonary hypertension, or high blood pressure in the lung vasculature, is an insidious illness with no effective treatment that ultimately progresses to righ heart failure and death. This project aims to identify the sequence of molecular changes that lead to pulmonary hypertension, opening the door for safe and effective therapies.   
      

]]></PHR><PIS><PI><PI_NAME>BLOODWORTH, NATHANIEL CRAIG</PI_NAME><PI_ID>12169334</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>COLOMBINI-HATCH, SANDRA </PROGRAM_OFFICER_NAME><PROJECT_START>08/16/2015</PROJECT_START><PROJECT_END>08/15/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biomechanics]]></TERM><TERM><![CDATA[BMPR2 gene]]></TERM><TERM><![CDATA[Categories]]></TERM><TERM><![CDATA[Cell membrane]]></TERM><TERM><![CDATA[cell motility]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Management]]></TERM><TERM><![CDATA[Cytoplasmic Tail]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Doxycycline]]></TERM><TERM><![CDATA[Drug Receptors]]></TERM><TERM><![CDATA[Dynamin]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Etiology]]></TERM><TERM><![CDATA[G-Protein-Coupled Receptors]]></TERM><TERM><![CDATA[GTP-Binding Proteins]]></TERM><TERM><![CDATA[Guanosine Triphosphate Phosphohydrolases]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Histologic]]></TERM><TERM><![CDATA[Histology]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[Hypoxia]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Mediator of activation protein]]></TERM><TERM><![CDATA[Microtubules]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Sequence Alteration]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Pathologic]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phosphorylation]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protein Kinase]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[pulmonary arterial hypertension]]></TERM><TERM><![CDATA[Pulmonary Hypertension]]></TERM><TERM><![CDATA[Pulmonary Vascular Resistance]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Recycling]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Serotonergic System]]></TERM><TERM><![CDATA[Serotonin]]></TERM><TERM><![CDATA[Serotonin Receptor 5-HT2B]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Systolic Pressure]]></TERM><TERM><![CDATA[Tail]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[trafficking]]></TERM><TERM><![CDATA[Up-Regulation (Physiology)]]></TERM><TERM><![CDATA[Ventricular]]></TERM><TERM><![CDATA[Vesicle]]></TERM><TERM><![CDATA[Vesicle Transport Pathway]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[The Intersection of Serotonergic and Hereditary Pulmonary Arterial Hypertension]]></PROJECT_TITLE><SERIAL_NUMBER>126280</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>36541</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>36541</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8985430</APPLICATION_ID><ACTIVITY>I01</ACTIVITY><ADMINISTERING_IC>VA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>I01RX002008</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-RX-15-003</FOA_NUMBER><FULL_PROJECT_NUM>1I01RX002008-01</FULL_PROJECT_NUM><FUNDING_ICs>VA:268009\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Veterans Affairs</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>SEATTLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>09</ORG_DISTRICT><ORG_DUNS>020232971</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VA PUGET SOUND HEALTHCARE SYSTEM]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>981081532</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:    
PROJECT NARRATIVE This study will investigate the effect of foot orthoses on two common conditions (ankle osteoarthritis and symptomatic adult onset flat feet) by using a custom biplane X-ray system our group has developed to very accurately and precisely quantify foot bone motion. We will vary the design of the orthoses and subjects will be examined to find out which are most effective at improving function. It has recently been shown that veterans have a significantly higher prevalence of foot problems, including arthritis and flatfoot, than non-veterans. In 2010, there were 308 million Americans, of which 21.8 million were veterans, including 9 million who were 65 or older. Demographically, most foot problems are more prevalent in older populations. The prevalence of diabetes is also higher in older populations. Therefore, veterans, in particular older veterans, are likely to suffer from foot problems such as arthritis, flatfoot or diabetes related tissue changes, at a higher prevalence than the general population, and as such, they stand to benefit from the research that our group is proposing.   
   
      

]]></PHR><PIS><PI><PI_NAME>LEDOUX, WILLIAM R.</PI_NAME><PI_ID>8428824</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2015</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Ankle]]></TERM><TERM><![CDATA[Arthritis]]></TERM><TERM><![CDATA[Articular Range of Motion]]></TERM><TERM><![CDATA[Automobile Driving]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biomechanics]]></TERM><TERM><![CDATA[bone]]></TERM><TERM><![CDATA[bone geometry]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical decision-making]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[Custom]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Degenerative polyarthritis]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Female]]></TERM><TERM><![CDATA[Flatfoot]]></TERM><TERM><![CDATA[Fluoroscopy]]></TERM><TERM><![CDATA[foot]]></TERM><TERM><![CDATA[foot bone]]></TERM><TERM><![CDATA[Foot Deformities]]></TERM><TERM><![CDATA[General Population]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[High Prevalence]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Influentials]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[joint loading]]></TERM><TERM><![CDATA[joint mobilization]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[kinematics]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Ligaments]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Lower Extremity]]></TERM><TERM><![CDATA[Manuals]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical pins]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Morphologic artifacts]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[muscle strength]]></TERM><TERM><![CDATA[Musculoskeletal]]></TERM><TERM><![CDATA[Older Population]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Orthotic Devices]]></TERM><TERM><![CDATA[Orthotic Medical Specialty]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Posterior Tibial Tendon Dysfunction]]></TERM><TERM><![CDATA[Posture]]></TERM><TERM><![CDATA[prescription procedure]]></TERM><TERM><![CDATA[pressure]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Regression Analysis]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Roentgen Rays]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Shoes]]></TERM><TERM><![CDATA[Skin]]></TERM><TERM><![CDATA[soft tissue]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Tarsal Bones]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Veterans]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Quantitative Prescription of Foot Orthoses: A Dose-Response Study of Kinematics in Patients with Foot and Ankle Pain using Biplane Fluoroscopy]]></PROJECT_TITLE><SERIAL_NUMBER>002008</SERIAL_NUMBER><STUDY_SECTION>RRD2</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Musculoskeletal/Orthopedic Rehabilitation  ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST></TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9196810</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>R01GM104213</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>6R01GM104213-04</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:290859\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[DNA damage that changes the overall gene complement of individual cells contributes to cancer and is
thought to occur in aging, increasing the frequency of age-related diseases. This project investigates the
mechanisms cells use to detect such genetic changes, and how individual damaged cells may then be
recognized and removed.]]></PHR><PIS><PI><PI_NAME>BAKER, NICHOLAS E</PI_NAME><PI_ID>1865094</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>REDDY, MICHAEL K.</PROGRAM_OFFICER_NAME><PROJECT_START>09/20/2013</PROJECT_START><PROJECT_END>07/31/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Cell Competition in Development and Homeostasis]]></PROJECT_TITLE><SERIAL_NUMBER>104213</SERIAL_NUMBER><STUDY_SECTION>CMAD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular Mechanisms in Aging and Development Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>174167</DIRECT_COST_AMT><INDIRECT_COST_AMT>116692</INDIRECT_COST_AMT><TOTAL_COST>290859</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9197933</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH001643</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-15-527</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH001643-01S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:12244327\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PORT AU  PRINCE</ORG_CITY><ORG_COUNTRY>HAITI</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>872038927</ORG_DUNS><ORG_FIPS>HA</ORG_FIPS><ORG_NAME><![CDATA[MOH/BUILD/STRENGTHEN/HAITI'S PLAN/PREVEN]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>PIERRE, LUC MOISE WEDNER</PI_NAME><PI_ID>12642249</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2015</PROJECT_START><PROJECT_END>09/29/2020</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH15-1527, Haiti:  Strengthening and Enhancing National HIV/AIDS Prevention, Diagnosis, Care,Treatment, Monitoring &Surveillance of Communicable & Non-communicable Diseases]]></PROJECT_TITLE><SERIAL_NUMBER>001643</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>12244327</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8969606</APPLICATION_ID><ACTIVITY>K01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>11/01/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>K01HL125504</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-HL-13-019</FOA_NUMBER><FULL_PROJECT_NUM>5K01HL125504-02</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:149778\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cardiovascular]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Heart Disease]]></CATEGORY><CATEGORY><![CDATA[Human Genome]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>HONOLULU</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>965088057</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF HAWAII AT MANOA]]></ORG_NAME><ORG_STATE>HI</ORG_STATE><ORG_ZIPCODE>968222234</ORG_ZIPCODE><PHR><![CDATA[HIV-positive individuals harbor monocytes that are hyper-responsive to inflammatory stimuli, which may
contribute to their heightened risk for cardiovascular disease (CVD). Epigenomic analyses integrated with
clinical and immunological indicators of CVD risk may reveal gene loci underlying this hyper-responsive
phenotype. These data may enable improved risk stratification strategies for CVD.]]></PHR><PIS><PI><PI_NAME>MAUNAKEA, ALIKA K</PI_NAME><PI_ID>7674310</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MEADOWS, TAWANNA </PROGRAM_OFFICER_NAME><PROJECT_START>11/15/2014</PROJECT_START><PROJECT_END>10/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[abstracting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[bead chip]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[bisulfite sequencing]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Blood specimen]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[cardiovascular disorder risk]]></TERM><TERM><![CDATA[CD14 gene]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Cohort Studies]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Coronary heart disease]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dialysis patients]]></TERM><TERM><![CDATA[differential expression]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Methylation]]></TERM><TERM><![CDATA[epigenetic marker]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[epigenomics]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[FCGR3B gene]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[genome-wide]]></TERM><TERM><![CDATA[Hawaii]]></TERM><TERM><![CDATA[High Prevalence]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Infections]]></TERM><TERM><![CDATA[HIV Seropositivity]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hyperlipidemia]]></TERM><TERM><![CDATA[IL6 gene]]></TERM><TERM><![CDATA[IL8 gene]]></TERM><TERM><![CDATA[immune activation]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[Interleukin-1]]></TERM><TERM><![CDATA[Interleukin-6]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Lipopolysaccharides]]></TERM><TERM><![CDATA[macrophage]]></TERM><TERM><![CDATA[Massive Parallel Sequencing]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[methylation pattern]]></TERM><TERM><![CDATA[methylome]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular Profiling]]></TERM><TERM><![CDATA[monocyte]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mRNA Precursor]]></TERM><TERM><![CDATA[Myelogenous]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[oxidized low density lipoprotein]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[peripheral blood]]></TERM><TERM><![CDATA[Peripheral Blood Mononuclear Cell]]></TERM><TERM><![CDATA[Persons]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Promoter Regions (Genetics)]]></TERM><TERM><![CDATA[Protein Isoforms]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[RNA Splicing]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Smoking]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Stratification]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[transcriptomics]]></TERM><TERM><![CDATA[trend]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Identifying epigenetic biomarkers of cardiovascular disease risk in humans]]></PROJECT_TITLE><SERIAL_NUMBER>125504</SERIAL_NUMBER><STUDY_SECTION>ZHL1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>138683</DIRECT_COST_AMT><INDIRECT_COST_AMT>11095</INDIRECT_COST_AMT><TOTAL_COST>149778</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9197393</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>R01NS091170</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01NS091170-02</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:335860\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Infantile spasms are age-specific epileptic seizures that manifest within a spectrum of early life epileptic encephalopathies of infancy with poor prognosis. There is a need for better understanding of their mechanisms and identification of more effective, age-appropriate treatments. Our preliminary studies indicate that age- specific interactions between GABAA receptor signaling and inflammatory processes are important in defining the age-specific susceptibility to infantile spasms and their progression. In this proposal, we will test this hypothesis and will try to identify new molecular targets for more effective therapeutic interventions for infantile spasms and test if these mechanisms also influence the development of epilepsies that persist through adulthood.   
      

]]></PHR><PIS><PI><PI_NAME>GALANOPOULOU, ARISTEA S</PI_NAME><PI_ID>6978554</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WHITTEMORE, VICKY R</PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2015</PROJECT_START><PROJECT_END>07/31/2020</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GABA-inflammation interplay in infantile spasms]]></PROJECT_TITLE><SERIAL_NUMBER>091170</SERIAL_NUMBER><STUDY_SECTION>CNNT</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Clinical Neuroplasticity and Neurotransmitters Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>201114</DIRECT_COST_AMT><INDIRECT_COST_AMT>134746</INDIRECT_COST_AMT><TOTAL_COST>335860</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9193943</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>09/12/2015</BUDGET_END><CFDA_CODE>398</CFDA_CODE><CORE_PROJECT_NUM>F31CA168337</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-112</FOA_NUMBER><FULL_PROJECT_NUM>6F31CA168337-04</FULL_PROJECT_NUM><FUNDING_ICs>NCI:42676\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2014</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[Head and neck squamous cell carcinoma is the sixth most common malignancy worldwide and the five-year survival rate for patients with HNSCC has shown little improvement over the last 30 years. The identification of prognostic biomarkers could lead to improved therapeutic strategies that may improve patient outcomes. From this project we anticipate gaining insight into how miR-375 expression levels can impact HNSCC patient outcome and incidence of distant metastasis through the exploration of its molecular mechanisms in HNSCC cell lines.]]></PHR><PIS><PI><PI_NAME>JIMENEZ, LIZANDRA </PI_NAME><PI_ID>10812936</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MCNEIL, NICOLE E</PROGRAM_OFFICER_NAME><PROJECT_START>09/13/2012</PROJECT_START><PROJECT_END>09/12/2015</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Role of miRNA-375 in Invasive Phenotype of Head and Neck Squamous Cell Carcinoma]]></PROJECT_TITLE><SERIAL_NUMBER>168337</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>42676</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>42676</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9194545</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH001068</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-13-322</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH001068-03S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:4710200\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>DAR ES SALAAM</ORG_CITY><ORG_COUNTRY>TANZANIA U REP</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>850501381</ORG_DUNS><ORG_FIPS>TZ</ORG_FIPS><ORG_NAME><![CDATA[TANZANIA HEALTH PROMOTION SUPPORT]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE>+255</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>MBATIA, REDEMPTA </PI_NAME><PI_ID>11355601</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2013</PROJECT_START><PROJECT_END>09/29/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[PROVISION OF COMPREHENSIVE HIV CARE AND TREATMENT PROGRAMS]]></PROJECT_TITLE><SERIAL_NUMBER>001068</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>4710200</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9189073</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>R01GM097752</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>6R01GM097752-05</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:79325\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[In general, this proposal will shed light on the assembly mechanism of small nucleolar ribonucleoproteins, which are important for such basic cellular processes as ribosome biogenesis and function, pre-mRNA splicing, genome integrity, and protein translation. Therefore, the proposed studies will promote our general understanding of cell physiology, which serves as basis for the treatment of many diseases. In particular, our studies are intended to shed light on the mechanism of the X-linked bone marrow failure syndrome dyskeratosis congenita and can eventually be exploited for the identification of drugs that will be beneficial to patients with dyskeratosis congenita.]]></PHR><PIS><PI><PI_NAME>MEIER, U THOMAS</PI_NAME><PI_ID>1964682</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BENDER, MICHAEL T.</PROGRAM_OFFICER_NAME><PROJECT_START>02/01/2012</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Biogenesis of H/ACA Ribonucleoproteins]]></PROJECT_TITLE><SERIAL_NUMBER>097752</SERIAL_NUMBER><STUDY_SECTION>NCSD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Nuclear and Cytoplasmic Structure/Function and Dynamics Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>47500</DIRECT_COST_AMT><INDIRECT_COST_AMT>31825</INDIRECT_COST_AMT><TOTAL_COST>79325</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8976211</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI098472</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>4R01AI098472-05</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:385635\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY><CATEGORY><![CDATA[Topical Microbicides]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAN FRANCISCO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>094878337</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA, SAN FRANCISCO]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>941186215</ORG_ZIPCODE><PHR><![CDATA[HIV medications (antiretrovirals) taken by HIV-negative people can reduce the risk of getting HIV through sex  in adults and through breastfeeding in infants.  However, HIV-uninfected individuals may not be motivated to  take medications every day.  Recent clinical trials in HIV prevention have shown that HIV-negative people  don't always tell investigators when they don't take the medications as prescribed, so ongoing prevention  trials need more objective ways to measure adherence, such as measuring drug levels.  We have proven that  measuring antiretroviral levels in small cut pieces of scalp hair are excellent measures of drug adherence.  Hair  samples are easy to collect, store and analyze.  Cutting small hair samples is painless and avoids drawing  blood, a particular advantage in babies.  This project will plug our hair measures into two ongoing large  HIV prevention trials in Africa and India (one in women and one in infants) to more accurately measure  adherence in these trials and in real-world HIV prevention programs.  Our innovative way of monitoring  medication levels in hair has public health relevance not only for HIV, but for many chronic disease states.]]></PHR><PIS><PI><PI_NAME>GANDHI, MONICA </PI_NAME><PI_ID>1925065</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ZHANG, HAO </PROGRAM_OFFICER_NAME><PROJECT_START>12/15/2011</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[absorption]]></TERM><TERM><![CDATA[Adherence (attribute)]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Africa]]></TERM><TERM><![CDATA[African]]></TERM><TERM><![CDATA[AIDS prevention]]></TERM><TERM><![CDATA[Anti-Retroviral Agents]]></TERM><TERM><![CDATA[antiretroviral therapy]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bedside Testings]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Blood]]></TERM><TERM><![CDATA[Breast Feeding]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Chronic Disease]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[drug testing]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[emtricitabine]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Futility]]></TERM><TERM><![CDATA[Gel]]></TERM><TERM><![CDATA[Hair]]></TERM><TERM><![CDATA[HIV]]></TERM><TERM><![CDATA[HIV Infections]]></TERM><TERM><![CDATA[HIV prevention trial]]></TERM><TERM><![CDATA[HIV Seropositivity]]></TERM><TERM><![CDATA[Human Milk]]></TERM><TERM><![CDATA[IMPAACT]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[India]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infant]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Liquid Chromatography]]></TERM><TERM><![CDATA[liquid chromatography mass spectrometry]]></TERM><TERM><![CDATA[Masks]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[medication compliance]]></TERM><TERM><![CDATA[Methodology]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[Mothers]]></TERM><TERM><![CDATA[Nevirapine]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Painless]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peripheral Blood Mononuclear Cell]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacology]]></TERM><TERM><![CDATA[pill (pharmacologic)]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Postpartum Period]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Prevention program]]></TERM><TERM><![CDATA[Prevention trial]]></TERM><TERM><![CDATA[Preventive Intervention]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[prophylactic]]></TERM><TERM><![CDATA[Prophylactic treatment]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Randomized Clinical Trials]]></TERM><TERM><![CDATA[Reproducibility]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Scalp structure]]></TERM><TERM><![CDATA[Sensitivity and Specificity]]></TERM><TERM><![CDATA[seroconversion]]></TERM><TERM><![CDATA[sex]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Surrogate Markers]]></TERM><TERM><![CDATA[tandem mass spectrometry]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Tenofovir]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thin Layer Chromatography]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Umbilical Cord Blood]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Vagina]]></TERM><TERM><![CDATA[Vaginal Gel]]></TERM><TERM><![CDATA[Vertical Disease Transmission]]></TERM><TERM><![CDATA[Viral Load result]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials]]></PROJECT_TITLE><SERIAL_NUMBER>098472</SERIAL_NUMBER><STUDY_SECTION>ACE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[AIDS Clinical Studies and Epidemiology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>314248</DIRECT_COST_AMT><INDIRECT_COST_AMT>71387</INDIRECT_COST_AMT><TOTAL_COST>385635</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9015763</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK052574</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK052574-17</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:94821\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>SAINT LOUIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>068552207</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON UNIVERSITY]]></ORG_NAME><ORG_STATE>MO</ORG_STATE><ORG_ZIPCODE>631304862</ORG_ZIPCODE><PHR><![CDATA[Mouse models of human digestive disease have been instrumental in allowing important scientific 
breakthroughs to be made. The WU-DDRCC Murine Models and Gnotobiotics Core will facilitate the 
production and use of mouse models relevant to human digestive disease to promote the research efforts of 
its membership.]]></PHR><PIS><PI><PI_NAME>MINER, JEFFREY H</PI_NAME><PI_ID>3102492</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[assisted reproduction]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Biomedical Research]]></TERM><TERM><![CDATA[blastocyst]]></TERM><TERM><![CDATA[Breeding]]></TERM><TERM><![CDATA[congenic]]></TERM><TERM><![CDATA[Control Animal]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Doxycycline]]></TERM><TERM><![CDATA[embryonic stem cell]]></TERM><TERM><![CDATA[Fertilization in Vitro]]></TERM><TERM><![CDATA[gastrointestinal system]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic pedigree]]></TERM><TERM><![CDATA[germ free condition]]></TERM><TERM><![CDATA[Germ-Free]]></TERM><TERM><![CDATA[Gnotobiotic]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Housing]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Injection of therapeutic agent]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Maintenance]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Morula]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Specific Pathogen Frees]]></TERM><TERM><![CDATA[Speed (motion)]]></TERM><TERM><![CDATA[Transgenes]]></TERM><TERM><![CDATA[Transgenic Mice]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Washington]]></TERM><TERM><![CDATA[zygote]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Core B: Murine Models and Gnotobiotics Core]]></PROJECT_TITLE><SERIAL_NUMBER>052574</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8140</SUBPROJECT_ID><SUPPORT_YEAR>17</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>62178</DIRECT_COST_AMT><INDIRECT_COST_AMT>32643</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>94821</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9198820</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000371</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-154</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000371-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:350000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>RONDEBOSCH</ORG_CITY><ORG_COUNTRY>SOUTH AFRICA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>568227214</ORG_DUNS><ORG_FIPS>SF</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CAPE TOWN]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE>7700</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>COHEN, KAREN </PI_NAME><PI_ID>12407138</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1154, S. Africa: STRENGTHENING HIV NATIONAL PHARMACOVIGILANCE SURVEILLANCE SYSTEM]]></PROJECT_TITLE><SERIAL_NUMBER>000371</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>350000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8912061</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>07/14/2015</AWARD_NOTICE_DATE><BUDGET_START>08/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>F31GM115223</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[GRADUATE SCHOOLS]]></ED_INST_TYPE><FOA_NUMBER>PA-14-148</FOA_NUMBER><FULL_PROJECT_NUM>1F31GM115223-01</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:39240\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>NEW HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[CHEMISTRY]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>043207562</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[YALE UNIVERSITY]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065208327</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: DNA polymerase beta (pol beta) is a human polymerase that is essential for repairing damaged DNA, thereby preventing cancer or cell death. Approximately 30% of human tumors have mutations in pol beta that either reduce the fidelity of the enzyme or completely knock out enzyme function. Here, I propose to measure how millisecond motions are related to the fidelity of pol beta in order to better understand how mutations in pol beta can lea to cancers in humans.   
   
   
      

]]></PHR><PIS><PI><PI_NAME>EAST, KYLE </PI_NAME><PI_ID>11587922</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GAILLARD, SHAWN R.</PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2015</PROJECT_START><PROJECT_END>07/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Base Excision Repairs]]></TERM><TERM><![CDATA[Base Pairing]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biochemical]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[C-terminal]]></TERM><TERM><![CDATA[Cataloging]]></TERM><TERM><![CDATA[Catalogs]]></TERM><TERM><![CDATA[Catalysis]]></TERM><TERM><![CDATA[Cell Death]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Circular Dichroism]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Deoxyribose]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA lesion]]></TERM><TERM><![CDATA[DNA Polymerase beta]]></TERM><TERM><![CDATA[DNA Repair]]></TERM><TERM><![CDATA[DNA Repair Enzymes]]></TERM><TERM><![CDATA[DNA Sequence]]></TERM><TERM><![CDATA[DNA-Directed DNA Polymerase]]></TERM><TERM><![CDATA[Drug Targeting]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Genomic DNA]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Gills]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Genome]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[inorganic phosphate]]></TERM><TERM><![CDATA[insertion/deletion mutation]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Knock-out]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Lyase]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mammalian Cell]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[metaplastic cell transformation]]></TERM><TERM><![CDATA[millisecond]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[N-terminal]]></TERM><TERM><![CDATA[NMR Spectroscopy]]></TERM><TERM><![CDATA[Nuclear Magnetic Resonance]]></TERM><TERM><![CDATA[Nucleotides]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Point Mutation]]></TERM><TERM><![CDATA[Polymerase]]></TERM><TERM><![CDATA[polymerization]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Protein Dynamics]]></TERM><TERM><![CDATA[protein structure]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Relaxation]]></TERM><TERM><![CDATA[repaired]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Solutions]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Transferase]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[tumor progression]]></TERM><TERM><![CDATA[tumorigenesis]]></TERM><TERM><![CDATA[Variant]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Perturbed Motions of DNAPolymeraseBeta Cancer Mutants Measured by NMR]]></PROJECT_TITLE><SERIAL_NUMBER>115223</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>39240</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>39240</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9021403</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/22/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R21AI121689</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[EARTH SCIENCES/RESOURCES]]></ED_INST_TYPE><FOA_NUMBER>RFA-AI-14-066</FOA_NUMBER><FULL_PROJECT_NUM>1R21AI121689-01</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:234034\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Antimicrobial Resistance]]></CATEGORY><CATEGORY><![CDATA[Hematology]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Lung]]></CATEGORY><CATEGORY><![CDATA[Pneumonia]]></CATEGORY><CATEGORY><![CDATA[Pneumonia & Influenza]]></CATEGORY><CATEGORY><![CDATA[Septicemia]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>COLLEGE STATION</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[VETERINARY SCIENCES]]></ORG_DEPT><ORG_DISTRICT>17</ORG_DISTRICT><ORG_DUNS>847205713</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[TEXAS A&M AGRILIFE RESEARCH]]></ORG_NAME><ORG_STATE>TX</ORG_STATE><ORG_ZIPCODE>778433578</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Bacterial pathogens that are resistant to multiple antibiotics are a major concern for public health, and one of the agents currently of most concern are carbapenemase-producing strains of Klebsiella pneumoniae. In this project, we propose to develop bacteriophages - naturally- occurring viruses that prey exclusively on bacteria - as a treatment for infections caused by these highly drug-resistant pathogens. Bacteriophages are non-toxic, bactericidal, specific for a particular strain or species of bacteria, and can replicateat the site of infection. We will collect and characterize bacteriophages that target these K. pneumoniae strains, and test them for treatment efficacy in mouse and rabbit models of infection. This work will have direct impact on our ability to use this treatment strategy in human
medicine.      

]]></PHR><PIS><PI><PI_NAME>GILL, JASON J. (contact)</PI_NAME><PI_ID>11692768 (contact)</PI_ID></PI><PI><PI_NAME>WALSH, THOMAS </PI_NAME><PI_ID>10795725</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>XU, ZUOYU </PROGRAM_OFFICER_NAME><PROJECT_START>12/22/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Alleles]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Antibiotic Resistance]]></TERM><TERM><![CDATA[Antibiotic Therapy]]></TERM><TERM><![CDATA[Antibiotics]]></TERM><TERM><![CDATA[antimicrobial]]></TERM><TERM><![CDATA[antimicrobial drug]]></TERM><TERM><![CDATA[Bacteremia]]></TERM><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[Bacterial Infections]]></TERM><TERM><![CDATA[bacterial resistance]]></TERM><TERM><![CDATA[bactericide]]></TERM><TERM><![CDATA[Bacteriophages]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Burkholderia]]></TERM><TERM><![CDATA[carbapenemase]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Characteristics]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinically relevant]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[combat]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Conduct Clinical Trials]]></TERM><TERM><![CDATA[Critical Illness]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[direct application]]></TERM><TERM><![CDATA[Drug resistance]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Enterobacteriaceae]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Food]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gram-Negative Bacteria]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immunocompromised Host]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Killings]]></TERM><TERM><![CDATA[Klebsiella pneumonia bacterium]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Lytic]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medicine]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[National Institute of Allergy and Infectious Disease]]></TERM><TERM><![CDATA[Organism]]></TERM><TERM><![CDATA[Oryctolagus cuniculus]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Personal Communication]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Pseudomonas aeruginosa]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[Resistance profile]]></TERM><TERM><![CDATA[resistant strain]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Sepsis]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Soil]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic development]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[treatment strategy]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Uropathogenic E. coli]]></TERM><TERM><![CDATA[Virulent]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[Water]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Development of therapeutic bacteriophages against carbapenemase-resistant Klebsiella pneumoniae]]></PROJECT_TITLE><SERIAL_NUMBER>121689</SERIAL_NUMBER><STUDY_SECTION>ZAI1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>174345</DIRECT_COST_AMT><INDIRECT_COST_AMT>59689</INDIRECT_COST_AMT><TOTAL_COST>234034</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198069</APPLICATION_ID><ACTIVITY>U51</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>05/01/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U51GH001191</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-14-401</FOA_NUMBER><FULL_PROJECT_NUM>3U51GH001191-02S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:413060\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WASHINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>98</ORG_DISTRICT><ORG_DUNS>066769738</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PAN AMERICAN HEALTH ORGANIZATION]]></ORG_NAME><ORG_STATE>DC</ORG_STATE><ORG_ZIPCODE>200372825</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>RUIZ, CUAUHTEMOC </PI_NAME><PI_ID>12536973</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>05/01/2014</PROJECT_START><PROJECT_END>04/30/2019</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[COOPERATIVE AGREEMENT WITH THE PAN AMERICAN HEALTH ORGANIZATION]]></PROJECT_TITLE><SERIAL_NUMBER>001191</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>413060</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9185135</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>K23AR063235</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCH ALLIED HEALTH PROFESSIONS]]></ED_INST_TYPE><FOA_NUMBER>PA-11-194</FOA_NUMBER><FULL_PROJECT_NUM>3K23AR063235-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:866\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Arthritis]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Osteoarthritis]]></CATEGORY><CATEGORY><![CDATA[Pain Conditions - Chronic]]></CATEGORY><CATEGORY><![CDATA[Pain Research]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHYSICAL MEDICINE & REHAB]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>049435266</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>022151390</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: We will study people with femoroacetabular impingement (FAI) and hip pain and people without hip pain to determine if people with painful FAI move differently than people without hip pain. We hope to demonstrate that people with FAI have fundamental differences in movement patterns compared to those without hip pain. The knowledge gained from this study may lead to improved physical therapy interventions for people with hip pain.]]></PHR><PIS><PI><PI_NAME>LEWIS, CARA L</PI_NAME><PI_ID>6795713</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PANAGIS, JAMES S.</PROGRAM_OFFICER_NAME><PROJECT_START>09/01/2013</PROJECT_START><PROJECT_END>08/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[acetabulum]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Arthroplasty]]></TERM><TERM><![CDATA[Articular Range of Motion]]></TERM><TERM><![CDATA[Back]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Cartilage]]></TERM><TERM><![CDATA[Case Study]]></TERM><TERM><![CDATA[cooking]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Degenerative polyarthritis]]></TERM><TERM><![CDATA[Dyskinetic syndrome]]></TERM><TERM><![CDATA[Femoral Neck Fractures]]></TERM><TERM><![CDATA[Femur]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hip Osteoarthritis]]></TERM><TERM><![CDATA[Hip Pain]]></TERM><TERM><![CDATA[Hip region structure]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[injured]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[joint injury]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[kinematics]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Leg]]></TERM><TERM><![CDATA[Limb structure]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Motion]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Nerve]]></TERM><TERM><![CDATA[neuromuscular]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[Paralysed]]></TERM><TERM><![CDATA[Patellofemoral Pain Syndrome]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Physical therapy]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Project Grants]]></TERM><TERM><![CDATA[Resected]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Rotation]]></TERM><TERM><![CDATA[Running]]></TERM><TERM><![CDATA[sex]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Structural defect]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[Walking]]></TERM><TERM><![CDATA[young adult]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Effect of femoroacetabular impingement (FAI) on hip motion in young adults]]></PROJECT_TITLE><SERIAL_NUMBER>063235</SERIAL_NUMBER><STUDY_SECTION>AMS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>802</DIRECT_COST_AMT><INDIRECT_COST_AMT>64</INDIRECT_COST_AMT><TOTAL_COST>866</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9022934</APPLICATION_ID><ACTIVITY>R03</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>393</CFDA_CODE><CORE_PROJECT_NUM>R03CA201951</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PAR-14-007</FOA_NUMBER><FULL_PROJECT_NUM>1R03CA201951-01</FULL_PROJECT_NUM><FUNDING_ICs>NCI:82000\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Diagnostic Radiology]]></CATEGORY><CATEGORY><![CDATA[Health Services]]></CATEGORY><CATEGORY><![CDATA[Lung]]></CATEGORY><CATEGORY><![CDATA[Lung Cancer]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY><CATEGORY><![CDATA[Smoking and Health]]></CATEGORY><CATEGORY><![CDATA[Substance Abuse]]></CATEGORY><CATEGORY><![CDATA[Tobacco]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>HERSHEY</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PUBLIC HEALTH & PREV MEDICINE]]></ORG_DEPT><ORG_DISTRICT>15</ORG_DISTRICT><ORG_DUNS>129348186</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[PENNSYLVANIA STATE UNIV HERSHEY MED CTR]]></ORG_NAME><ORG_STATE>PA</ORG_STATE><ORG_ZIPCODE>170332360</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  The goal of this project is to determine if a specific smoking nicotine dependence behavior, the time of day of the first cigarette, is associated with an earlier
detection of lung cancer in a clinical trial of smokers screened for lung cancer by low-dose computed tomography. The results will help identify smokers at high risk of lung cancer who can benefit from early detection and improved survival time.   
   
      

]]></PHR><PIS><PI><PI_NAME>MUSCAT, JOSHUA E (contact)</PI_NAME><PI_ID>6665602 (contact)</PI_ID></PI><PI><PI_NAME>ZHU, JUNJIA </PI_NAME><PI_ID>10664608</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>RIVERA, DONNA </PROGRAM_OFFICER_NAME><PROJECT_START>12/23/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Advisory Committees]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[American Cancer Society]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Cancer Etiology]]></TERM><TERM><![CDATA[cancer risk]]></TERM><TERM><![CDATA[Carcinogen exposure]]></TERM><TERM><![CDATA[Carcinogens]]></TERM><TERM><![CDATA[Chest]]></TERM><TERM><![CDATA[Cigarette]]></TERM><TERM><![CDATA[Cigarette Smoker]]></TERM><TERM><![CDATA[clinical risk]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Colorectal Cancer]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Costs and Benefits]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Dose]]></TERM><TERM><![CDATA[Early Diagnosis]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[inclusion criteria]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Low-Dose Spiral CT]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[Lung Neoplasms]]></TERM><TERM><![CDATA[Malignant neoplasm of lung]]></TERM><TERM><![CDATA[Malignant neoplasm of prostate]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[National Cancer Institute]]></TERM><TERM><![CDATA[Newly Diagnosed]]></TERM><TERM><![CDATA[Nicotine]]></TERM><TERM><![CDATA[Nicotine Dependence]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[predictive modeling]]></TERM><TERM><![CDATA[Preventive]]></TERM><TERM><![CDATA[Progression-Free Survivals]]></TERM><TERM><![CDATA[Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Radiation]]></TERM><TERM><![CDATA[randomized trial]]></TERM><TERM><![CDATA[Recommendation]]></TERM><TERM><![CDATA[Recording of previous events]]></TERM><TERM><![CDATA[Relative Risks]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Assessment]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Screening for Lung Cancer]]></TERM><TERM><![CDATA[Screening for Ovarian Cancer]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Smoke]]></TERM><TERM><![CDATA[Smoker]]></TERM><TERM><![CDATA[Smoking]]></TERM><TERM><![CDATA[Smoking History]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Survival Rate]]></TERM><TERM><![CDATA[Target Populations]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thoracic Radiography]]></TERM><TERM><![CDATA[Thoracic Surgical Procedures]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tobacco-Associated Carcinogen]]></TERM><TERM><![CDATA[Tobacco-Related Carcinoma]]></TERM><TERM><![CDATA[trend]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[X-Ray Computed Tomography]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Time to first cigarette and early detection in the National Lung Screening Trial]]></PROJECT_TITLE><SERIAL_NUMBER>201951</SERIAL_NUMBER><STUDY_SECTION>ZCA1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>50000</DIRECT_COST_AMT><INDIRECT_COST_AMT>32000</INDIRECT_COST_AMT><TOTAL_COST>82000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9141153</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>859</CFDA_CODE><CORE_PROJECT_NUM>R01GM079804</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[BIOMED ENGR/COL ENGR/ENGR STA]]></ED_INST_TYPE><FOA_NUMBER>PA-15-322</FOA_NUMBER><FULL_PROJECT_NUM>3R01GM079804-08S1</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:48914\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Emerging Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CHICAGO</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[ENGINEERING (ALL TYPES)]]></ORG_DEPT><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>098987217</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF ILLINOIS AT CHICAGO]]></ORG_NAME><ORG_STATE>IL</ORG_STATE><ORG_ZIPCODE>606127224</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Barrel membrane proteins are an important class of membrane proteins that are related to many infectious diseases and are important for cell homeostasis. The proposed work will generate computational tools for prediction of structures and protein-protein interactions of &#223;-barrel membrane proteins. These tools will be useful for developing anti-infectious and anti-cancer drugs, as well as vaccines, and will also enable design of effective bio-nanopores useful for low-cost DNA sequencing and for developing anti-cancer drugs.]]></PHR><PIS><PI><PI_NAME>LIANG, JIE </PI_NAME><PI_ID>6626092</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>CHIN, JEAN </PROGRAM_OFFICER_NAME><PROJECT_START>03/01/2007</PROJECT_START><PROJECT_END>08/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Acid Fast Bacillae Staining Method]]></TERM><TERM><![CDATA[Antibiotic Resistance]]></TERM><TERM><![CDATA[Antigens]]></TERM><TERM><![CDATA[Antineoplastic Agents]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Apoptosis Regulator]]></TERM><TERM><![CDATA[Archaea]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Bacillus anthracis]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[beta barrel]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Process]]></TERM><TERM><![CDATA[biophysical properties]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cereals]]></TERM><TERM><![CDATA[Chloroplasts]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Computer Simulation]]></TERM><TERM><![CDATA[computer studies]]></TERM><TERM><![CDATA[computerized tools]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Cytosol]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[DNA Sequence]]></TERM><TERM><![CDATA[Drug Delivery Systems]]></TERM><TERM><![CDATA[Encapsulated]]></TERM><TERM><![CDATA[Energy Metabolism]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Escherichia coli]]></TERM><TERM><![CDATA[Exotoxins]]></TERM><TERM><![CDATA[Family]]></TERM><TERM><![CDATA[Genus Mycobacterium]]></TERM><TERM><![CDATA[Geometry]]></TERM><TERM><![CDATA[Germany]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Gram-Negative Bacteria]]></TERM><TERM><![CDATA[Gram-Positive Bacteria]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hemolysin]]></TERM><TERM><![CDATA[High-Throughput DNA Sequencing]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Homo]]></TERM><TERM><![CDATA[Homologous Gene]]></TERM><TERM><![CDATA[Immunologic Surveillance]]></TERM><TERM><![CDATA[Induction of Apoptosis]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Integral Membrane Protein]]></TERM><TERM><![CDATA[Ion Transport]]></TERM><TERM><![CDATA[Israel]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Letters]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Membrane Proteins]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Mitochondria]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular Conformation]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mycobacterium tuberculosis]]></TERM><TERM><![CDATA[nanodevice]]></TERM><TERM><![CDATA[nanopore]]></TERM><TERM><![CDATA[Neisseria gonorrhoeae]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outer Mitochondrial Membrane]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[porin]]></TERM><TERM><![CDATA[protein protein interaction]]></TERM><TERM><![CDATA[protein structure]]></TERM><TERM><![CDATA[Protein translocation]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Space Models]]></TERM><TERM><![CDATA[Staphylococcus aureus]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Virulence]]></TERM><TERM><![CDATA[Voltage-Dependent Anion Channel]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Computational assembly of beta-barrel membrane proteins]]></PROJECT_TITLE><SERIAL_NUMBER>079804</SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>08</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>35130</DIRECT_COST_AMT><INDIRECT_COST_AMT>13784</INDIRECT_COST_AMT><TOTAL_COST>48914</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9016535</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK034987</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK034987-31</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:65567\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Induced Pluripotent Stem Cell]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Induced Pluripotent Stem Cell - Human]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Induced Pluripotent Stem Cell - Non-Human]]></CATEGORY><CATEGORY><![CDATA[Stem Cell Research - Nonembryonic - Human]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CHAPEL HILL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>608195277</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF NORTH CAROLINA CHAPEL HILL]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>275990001</ORG_ZIPCODE><PHR><![CDATA[RELEVANCE
In the past, studies of genetic, transcriptomic or proteomic changes have focused on isolated tissues or
specific cell populations. It is increasingly appreciated, particularly in the fields of stem cells, tumor initiating
cells and immune cells, that there are diverse and complex dynamics within cell populations that have been
under-appreciated. The Advanced Anal)1:ics Core provides members with access to instrumentation to provide
single cell analysis, high throughout quantitative analyses in very small amounts of RNA or DNA isolated from
biopsies or enteroids/colonoids derived from stem cell biopsy or crypt cultures, and immunotechnology
services.]]></PHR><PIS><PI><PI_NAME>MAGNESS, SCOTT T</PI_NAME><PI_ID>6530567</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Anus]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biopsy]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Client]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Consultations]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnostic]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Enzyme-Linked Immunosorbent Assay]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Gastrointestinal tract structure]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Expression Profile]]></TERM><TERM><![CDATA[Gene Expression Profiling]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Genetic study]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Heterogeneity]]></TERM><TERM><![CDATA[high throughput screening]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immunoassay]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[instrumentation]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[microbial]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[Natural regeneration]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phosphoproteins]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[progenitor]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[single cell analysis]]></TERM><TERM><![CDATA[SNP genotyping]]></TERM><TERM><![CDATA[stem]]></TERM><TERM><![CDATA[Stem cells]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[tissue culture]]></TERM><TERM><![CDATA[Tissue Extracts]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[transcriptomics]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Tumor Stem Cells]]></TERM><TERM><![CDATA[Validation]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[ADVANCED ANALYTICS CORE]]></PROJECT_TITLE><SERIAL_NUMBER>034987</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8827</SUBPROJECT_ID><SUPPORT_YEAR>31</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>41796</DIRECT_COST_AMT><INDIRECT_COST_AMT>23771</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>65567</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9016534</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK034987</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK034987-31</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:89783\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Human Genome]]></CATEGORY><CATEGORY><![CDATA[Infant Mortality/ (LBW)]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Perinatal - Birth - Preterm (LBW)]]></CATEGORY><CATEGORY><![CDATA[Perinatal Period - Conditions Originating in Perinatal Period]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CHAPEL HILL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>608195277</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF NORTH CAROLINA CHAPEL HILL]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>275990001</ORG_ZIPCODE><PHR><![CDATA[RELEVANCE 
The microbiota is the community of microorganisms that live in or on the human body. It is becoming 
increasingly clear that the microbiome (the microbiota's collective genomic information) contributes to GI 
health and disease. In order for the CGIBD to fulfill its mission, it is imperative that CGIBD members have 
access to state-of-the-art methods for analyzing microbial communities in the context of GI health and disease. 
The UNC Microbiome Core, a facility almost solely dedicated to the analysis of host-associated microbiota, has 
assisted 66 principal investigators from CGIBD and elsewhere on 157 projects since it was established as a 
recharge facility in 2009. Many of the completed projects were relevant for human GI related diseases like 
necrotizing enterocolitis (NEC), irritable bowel syndrome (IBS), and colorectal adenomas.]]></PHR><PIS><PI><PI_NAME>AZCARTE-PERIL, ANDREA </PI_NAME><PI_ID>12315630</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Bacteria]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[Colorectal Adenoma]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Consult]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[cost effective]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human body]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[Informatics]]></TERM><TERM><![CDATA[instrument]]></TERM><TERM><![CDATA[Irritable Bowel Syndrome]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Metadata]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microbe]]></TERM><TERM><![CDATA[microbial community]]></TERM><TERM><![CDATA[Microbiology]]></TERM><TERM><![CDATA[microbiome]]></TERM><TERM><![CDATA[microorganism]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Necrotizing Enterocolitis]]></TERM><TERM><![CDATA[next generation sequencing]]></TERM><TERM><![CDATA[Phylogenetic Analysis]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[rat Ran 2 protein]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[Reading]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Restriction Fragment Length Polymorphism Analysis]]></TERM><TERM><![CDATA[Ribosomal RNA]]></TERM><TERM><![CDATA[rRNA Genes]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[Taxon]]></TERM><TERM><![CDATA[Taxonomy]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[transcriptome sequencing]]></TERM><TERM><![CDATA[Universities]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[MICROBIOME CORE]]></PROJECT_TITLE><SERIAL_NUMBER>034987</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8061</SUBPROJECT_ID><SUPPORT_YEAR>31</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>65123</DIRECT_COST_AMT><INDIRECT_COST_AMT>24660</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>89783</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9193951</APPLICATION_ID><ACTIVITY>F30</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>398</CFDA_CODE><CORE_PROJECT_NUM>F30CA200411</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-150</FOA_NUMBER><FULL_PROJECT_NUM>6F30CA200411-02</FULL_PROJECT_NUM><FUNDING_ICs>NCI:42981\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Non-ablative focused ultrasound therapy can modulate the tumor cells, causing them to induce a robust anti-tumor immune response. This therapy can also be combined with current immunotherapies, such as a dendritic cell vaccine or a Listeria-based vaccine, enhancing their effect.   
      

]]></PHR><PIS><PI><PI_NAME>SKALINA, KARIN ALEXANDRA</PI_NAME><PI_ID>11018469</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2015</PROJECT_START><PROJECT_END>06/30/2019</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Optimization of Non-Ablative Focused Ultrasound Therapy for Tumor Immunity]]></PROJECT_TITLE><SERIAL_NUMBER>200411</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>42981</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>42981</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9035932</APPLICATION_ID><ACTIVITY>R21</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>12/24/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>395</CFDA_CODE><CORE_PROJECT_NUM>R21CA194826</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF ARTS AND SCIENCES]]></ED_INST_TYPE><FOA_NUMBER>PA-12-179</FOA_NUMBER><FULL_PROJECT_NUM>1R21CA194826-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NCI:176763\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Aging]]></CATEGORY><CATEGORY><![CDATA[Breast Cancer]]></CATEGORY><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Complementary and Alternative Medicine]]></CATEGORY><CATEGORY><![CDATA[Estrogen]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Obesity]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>AUSTIN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NONE]]></ORG_DEPT><ORG_DISTRICT>25</ORG_DISTRICT><ORG_DUNS>170230239</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF TEXAS, AUSTIN]]></ORG_NAME><ORG_STATE>TX</ORG_STATE><ORG_ZIPCODE>787121532</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE Obesity correlates with worse outcome on hormone therapy agents, most notably aromatase inhibitors (AI), contributing to the higher mortality rates associated with obesity. This is especially troublesome since obesity is most prevalent in the postmenopausal setting, when AIs are most likely to be prescribed and are now moving into the preventive setting. Understanding how obesity promotes resistance and developing novel, non-toxic approaches to improve response in an ever increasing patient population will have an immediate and significant impact on patient outcomes.   
      

]]></PHR><PIS><PI><PI_NAME>BRENNER, ANDREW JACOB</PI_NAME><PI_ID>9487595</PI_ID></PI><PI><PI_NAME>DEGRAFFENRIED, LINDA A (contact)</PI_NAME><PI_ID>7066329 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>XI, DAN </PROGRAM_OFFICER_NAME><PROJECT_START>12/24/2015</PROJECT_START><PROJECT_END>11/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[adipokines]]></TERM><TERM><![CDATA[arm]]></TERM><TERM><![CDATA[Aromatase]]></TERM><TERM><![CDATA[Aromatase Inhibitors]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Breast Cancer Cell]]></TERM><TERM><![CDATA[Breast Cancer Patient]]></TERM><TERM><![CDATA[cancer cell]]></TERM><TERM><![CDATA[Cancer Prognosis]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Comorbidity]]></TERM><TERM><![CDATA[comparative]]></TERM><TERM><![CDATA[cyclooxygenase 2]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diagnosis]]></TERM><TERM><![CDATA[Dinoprostone]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[disorder later incidence prevention]]></TERM><TERM><![CDATA[Eicosanoids]]></TERM><TERM><![CDATA[Emergency Department patient]]></TERM><TERM><![CDATA[Epithelial]]></TERM><TERM><![CDATA[Estrogen Receptors]]></TERM><TERM><![CDATA[Fish Oils]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Growth Factor]]></TERM><TERM><![CDATA[hormone therapy]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[Inflammatory Response]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Interleukin-1]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Intervention Studies]]></TERM><TERM><![CDATA[Intervention Trial]]></TERM><TERM><![CDATA[Leptin]]></TERM><TERM><![CDATA[malignant breast neoplasm]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mammary gland]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[metabolomics]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[Non obese]]></TERM><TERM><![CDATA[Non-Steroidal Anti-Inflammatory Agents]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Omega-3 Fatty Acids]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[patient population]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Postmenopause]]></TERM><TERM><![CDATA[pre-clinical]]></TERM><TERM><![CDATA[Premenopause]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Preventive]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Prognostic Marker]]></TERM><TERM><![CDATA[prospective]]></TERM><TERM><![CDATA[Prostaglandin-Endoperoxide Synthase]]></TERM><TERM><![CDATA[PTGS2 gene]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Publishing]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resistance development]]></TERM><TERM><![CDATA[resistance mechanism]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Retrospective Studies]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Supplementation]]></TERM><TERM><![CDATA[Tamoxifen]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[tumor microenvironment]]></TERM><TERM><![CDATA[Tumor Necrosis Factor-alpha]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Omega-3 Fatty Acid Modulation of Obesity-Induced Aromatase Expression]]></PROJECT_TITLE><SERIAL_NUMBER>194826</SERIAL_NUMBER><STUDY_SECTION>CDP</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Chemo/Dietary Prevention Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>126363</DIRECT_COST_AMT><INDIRECT_COST_AMT>50400</INDIRECT_COST_AMT><TOTAL_COST>176763</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8976160</APPLICATION_ID><ACTIVITY>K99</ACTIVITY><ADMINISTERING_IC>EY</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>867</CFDA_CODE><CORE_PROJECT_NUM>K99EY025007</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-042</FOA_NUMBER><FULL_PROJECT_NUM>5K99EY025007-02</FULL_PROJECT_NUM><FUNDING_ICs>NEI:94133\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL EYE INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Eye Disease and Disorders of Vision]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CLEVELAND</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHARMACOLOGY]]></ORG_DEPT><ORG_DISTRICT>11</ORG_DISTRICT><ORG_DUNS>077758407</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CASE WESTERN RESERVE UNIVERSITY]]></ORG_NAME><ORG_STATE>OH</ORG_STATE><ORG_ZIPCODE>441067000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The green cone pigment is critical for proper trichromatic vision. However, the mechanism which allows this pigment specifically to absorb green light has not been experimentally determined. By understanding this mechanism and characterizing how certain pathogenic mutations affect the pigment, new avenues for developing therapeutics will be opened.]]></PHR><PIS><PI><PI_NAME>ALEXANDER, NATHAN </PI_NAME><PI_ID>9546493</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>AGARWAL, NEERAJ </PROGRAM_OFFICER_NAME><PROJECT_START>12/02/2014</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[11 cis Retinal]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Process]]></TERM><TERM><![CDATA[chemical property]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[chromophore]]></TERM><TERM><![CDATA[Color]]></TERM><TERM><![CDATA[Color Visions]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[computer studies]]></TERM><TERM><![CDATA[Cone]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Crystallization]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[electronic structure]]></TERM><TERM><![CDATA[Electrostatics]]></TERM><TERM><![CDATA[Endoplasmic Reticulum]]></TERM><TERM><![CDATA[Eye]]></TERM><TERM><![CDATA[G-Protein-Coupled Receptors]]></TERM><TERM><![CDATA[Geometry]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[High Performance Computing]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hybrids]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Ions]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[laboratory facility]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[light intensity]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[loss of function]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Methyl Green]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Conformation]]></TERM><TERM><![CDATA[molecular mechanics]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutate]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Ophthalmology]]></TERM><TERM><![CDATA[Opsin]]></TERM><TERM><![CDATA[Organized by Structure Protein]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pharmacology]]></TERM><TERM><![CDATA[Photons]]></TERM><TERM><![CDATA[Pigments]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[protein folding]]></TERM><TERM><![CDATA[protein misfolding]]></TERM><TERM><![CDATA[protein structure prediction]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[quantum]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Resolution]]></TERM><TERM><![CDATA[Retina]]></TERM><TERM><![CDATA[Retinal]]></TERM><TERM><![CDATA[Retinal Pigments]]></TERM><TERM><![CDATA[Rhodopsin]]></TERM><TERM><![CDATA[Schiff Bases]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Structural Models]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[theories]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic development]]></TERM><TERM><![CDATA[three dimensional structure]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Transducin]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[Vision research]]></TERM><TERM><![CDATA[Visual]]></TERM><TERM><![CDATA[Visual Perception]]></TERM><TERM><![CDATA[Water]]></TERM><TERM><![CDATA[X ray diffraction analysis]]></TERM><TERM><![CDATA[X-Ray Crystallography]]></TERM><TERM><![CDATA[X-Ray Diffraction]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Structural investigations of native and mutant human green cone pigment]]></PROJECT_TITLE><SERIAL_NUMBER>025007</SERIAL_NUMBER><STUDY_SECTION>ZEY1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>87160</DIRECT_COST_AMT><INDIRECT_COST_AMT>6973</INDIRECT_COST_AMT><TOTAL_COST>94133</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9016533</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>P30DK034987</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK034987-31</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:348918\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHAPEL HILL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>608195277</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF NORTH CAROLINA CHAPEL HILL]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>275990001</ORG_ZIPCODE><PHR><![CDATA[RELEVANCE
The Administrative Core provides operational and financial oversight for the DDRCC. The Core is
responsible for assuring that the Center is in compliance with federal regulations, that reports are
submitted, and that the budget is balanced. The Administrative Core manages an active Enrichment
Program of seminars and symposia. The Core helps Center investigators conduct research to prevent or
manage disease.]]></PHR><PIS><PI><PI_NAME>SANDLER, ROBERT S</PI_NAME><PI_ID>10675515</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START></PROJECT_START><PROJECT_END></PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Administrator]]></TERM><TERM><![CDATA[Back]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Budgets]]></TERM><TERM><![CDATA[Capital]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[charge expenditure]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Facilities and Administrative Costs]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Oral]]></TERM><TERM><![CDATA[posters]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Review Committee]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Visit]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Administrative Core and Enrichment Program]]></PROJECT_TITLE><SERIAL_NUMBER>034987</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID>8060</SUBPROJECT_ID><SUPPORT_YEAR>31</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>228211</DIRECT_COST_AMT><INDIRECT_COST_AMT>120707</INDIRECT_COST_AMT><TOTAL_COST /><TOTAL_COST_SUB_PROJECT>348918</TOTAL_COST_SUB_PROJECT></row>
<row><APPLICATION_ID>9134331</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL118734</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-12-149</FOA_NUMBER><FULL_PROJECT_NUM>3R01HL118734-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:46830\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[American Indians / Alaska Natives]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Cardiovascular]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Clinical Trials and Supportive Activities]]></CATEGORY><CATEGORY><![CDATA[Diabetes]]></CATEGORY><CATEGORY><![CDATA[Health Services]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY><CATEGORY><![CDATA[Obesity]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>ALBUQUERQUE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PEDIATRICS]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>829868723</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR]]></ORG_NAME><ORG_STATE>NM</ORG_STATE><ORG_ZIPCODE>871310001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Healthy People 2020 has set objectives to: 1) increase the proportion of health care providers who regularly assess body mass index (BMI) in their adolescent patients, 2) increase the proportion of health care visits that include counseling related to nutrition, weight and physical activity, 3) reduce the proportion of adolescents who are obese, 4) prevent inappropriate weight gain in youth, 5) improve adolescent diet to include more fruits, vegetable and whole grains and less fats and added sugars, and 6) increase the proportion of adolescents who are physically active. The proposed project, ACTION PAC (Adolescents Committed to Improvement of Nutrition and Physical Activity), will address all of the above objectives by evaluating a method to motivate high school students to eat healthier, be physically active and achieve or maintain a healthy weight. Primary health care providers in school-based health centers will assess adolescents' BMI and work with them to adopt healthier behaviors to prevent access weight gain and assist those who are overweight or obese with weight management.]]></PHR><PIS><PI><PI_NAME>KONG, ALBERTA SUM-YU</PI_NAME><PI_ID>8945898</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PRATT, CHARLOTTE </PROGRAM_OFFICER_NAME><PROJECT_START>12/23/2015</PROJECT_START><PROJECT_END>07/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adolescent]]></TERM><TERM><![CDATA[adolescent patient]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[Adoption]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[American Indians]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Body mass index]]></TERM><TERM><![CDATA[cardiometabolic risk]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[Central obesity]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Child Rearing]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[community based participatory research]]></TERM><TERM><![CDATA[comparison group]]></TERM><TERM><![CDATA[Consumption]]></TERM><TERM><![CDATA[Counseling]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[Dietary Fiber]]></TERM><TERM><![CDATA[Dietary intake]]></TERM><TERM><![CDATA[Dyslipidemias]]></TERM><TERM><![CDATA[Eating]]></TERM><TERM><![CDATA[Eating Behavior]]></TERM><TERM><![CDATA[efficacy testing]]></TERM><TERM><![CDATA[eleventh grade]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epidemic]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Fatty acid glycerol esters]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[fruits and vegetables]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[group intervention]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Care Visit]]></TERM><TERM><![CDATA[health disparity]]></TERM><TERM><![CDATA[Health Personnel]]></TERM><TERM><![CDATA[Health Services]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Healthy People 2020]]></TERM><TERM><![CDATA[healthy weight]]></TERM><TERM><![CDATA[high school]]></TERM><TERM><![CDATA[High School Student]]></TERM><TERM><![CDATA[Hispanics]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Hypertension]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Incidence]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[insulin sensitivity]]></TERM><TERM><![CDATA[Intake]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[intervention program]]></TERM><TERM><![CDATA[Intervention Studies]]></TERM><TERM><![CDATA[Intervention Trial]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Life Cycle Stages]]></TERM><TERM><![CDATA[Low income]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic syndrome]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Minority]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[motivational enhancement therapy]]></TERM><TERM><![CDATA[National Heart, Lung, and Blood Institute]]></TERM><TERM><![CDATA[New Mexico]]></TERM><TERM><![CDATA[ninth grade]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[nutrition]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[obesity in children]]></TERM><TERM><![CDATA[obesity prevention]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Outcomes Research]]></TERM><TERM><![CDATA[Overweight]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[Physical activity]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Prediabetes syndrome]]></TERM><TERM><![CDATA[Pregnancy]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Prevention program]]></TERM><TERM><![CDATA[Preventive Intervention]]></TERM><TERM><![CDATA[Primary Health Care]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Provider]]></TERM><TERM><![CDATA[Randomized]]></TERM><TERM><![CDATA[Randomized Controlled Trials]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[satisfaction]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[Students]]></TERM><TERM><![CDATA[sugar]]></TERM><TERM><![CDATA[sweetened beverage]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Teenagers]]></TERM><TERM><![CDATA[tenth grade]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[treatment as usual]]></TERM><TERM><![CDATA[Treatment Efficacy]]></TERM><TERM><![CDATA[trial design]]></TERM><TERM><![CDATA[twelfth grade]]></TERM><TERM><![CDATA[Underrepresented Minority]]></TERM><TERM><![CDATA[Uninsured]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Weight]]></TERM><TERM><![CDATA[Weight Gain]]></TERM><TERM><![CDATA[Weight maintenance regimen]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[young adult]]></TERM><TERM><![CDATA[Youth]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Clinician Comfort and Teen Satisfaction with Motivational Interviewing]]></PROJECT_TITLE><SERIAL_NUMBER>118734</SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>31000</DIRECT_COST_AMT><INDIRECT_COST_AMT>15830</INDIRECT_COST_AMT><TOTAL_COST>46830</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198602</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000809</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-12-251</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000809-04S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:1250000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PORT-AU-PRINCE</ORG_CITY><ORG_COUNTRY>HAITI</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>872038919</ORG_DUNS><ORG_FIPS>HA</ORG_FIPS><ORG_NAME><![CDATA[MINISTRY OF HEALTH BLOOD SAFETY PROGRAM]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ERNST, NOEL </PI_NAME><PI_ID>11383573</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2012</PROJECT_START><PROJECT_END>09/29/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH12-1251, HAITI, SUPPORTING THE NATIONAL BLOOD SAFETY PROGRAM (NBSP)]]></PROJECT_TITLE><SERIAL_NUMBER>000809</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>1250000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198300</APPLICATION_ID><ACTIVITY>U38</ACTIVITY><ADMINISTERING_IC>CD</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>07/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U38OT000161</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-OT-13-302</FOA_NUMBER><FULL_PROJECT_NUM>3U38OT000161-03S3</FULL_PROJECT_NUM><FUNDING_ICs>ODCDC:12285\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Office of Public Health Research (OPHR) FMO/ PGO/MISO/MASO users</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>ARLINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>08</ORG_DISTRICT><ORG_DUNS>106735830</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ASSOCIATION OF STATE/TERR HLTH OFFICIALS]]></ORG_NAME><ORG_STATE>VA</ORG_STATE><ORG_ZIPCODE>222023711</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>JARRIS, PAUL E</PI_NAME><PI_ID>9180129</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2013</PROJECT_START><PROJECT_END>06/30/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[ Title: PPHF 2013: OSTLTS Partnerships - CBA of the Public Health System]]></PROJECT_TITLE><SERIAL_NUMBER>000161</SERIAL_NUMBER><STUDY_SECTION>ZOT1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S3</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>12285</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9001130</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/18/2015</AWARD_NOTICE_DATE><BUDGET_START>12/22/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK107474</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01DK107474-01</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:307312\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Digestive Diseases]]></CATEGORY><CATEGORY><![CDATA[Emerging Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Nutrition]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LONG BEACH</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>47</ORG_DISTRICT><ORG_DUNS>622027209</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SOUTHERN CALIFORNIA INST FOR RES/EDUC]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>908225201</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Vitamin C is essential for human well-being and must be obtained from the diet via intestinal absorption. The objectives of the studies proposed in this application are to gain further insight into the physiology and pathophysiology of the intestinal absorption process of this essential micronutrient with the ultimate goal to design effective ways to optimize its level in the human body.   
      

]]></PHR><PIS><PI><PI_NAME>SUBRAMANIAN, VEEDAMALI S</PI_NAME><PI_ID>7075326</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MARUVADA, PADMA </PROGRAM_OFFICER_NAME><PROJECT_START>12/22/2015</PROJECT_START><PROJECT_END>11/30/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[absorption]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Antioxidants]]></TERM><TERM><![CDATA[apical membrane]]></TERM><TERM><![CDATA[Ascorbic Acid]]></TERM><TERM><![CDATA[Ascorbic Acid Deficiency]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[bone]]></TERM><TERM><![CDATA[Caco-2 Cells]]></TERM><TERM><![CDATA[Cardiovascular Diseases]]></TERM><TERM><![CDATA[Cataract]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Co-Immunoprecipitations]]></TERM><TERM><![CDATA[cofactor]]></TERM><TERM><![CDATA[Colon]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Connective Tissue]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diet]]></TERM><TERM><![CDATA[enteric pathogen]]></TERM><TERM><![CDATA[Enterocytes]]></TERM><TERM><![CDATA[enteropathogenic Escherichia coli]]></TERM><TERM><![CDATA[enterotoxigenic Escherichia coli]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Epithelial Cells]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gall Bladder Diseases]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[histone modification]]></TERM><TERM><![CDATA[Homeostasis]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human body]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[Impaired wound healing]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intestinal Absorption]]></TERM><TERM><![CDATA[intestinal epithelium]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[jejunum]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mass Spectrum Analysis]]></TERM><TERM><![CDATA[Micronutrients]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[pathogenic bacteria]]></TERM><TERM><![CDATA[Personal Satisfaction]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Proteomics]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Scurvy]]></TERM><TERM><![CDATA[Sodium]]></TERM><TERM><![CDATA[sodium DEPENDENDENT vitamin C transporter 1]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Untranslated Regions]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Vasomotor]]></TERM><TERM><![CDATA[Vitamins]]></TERM><TERM><![CDATA[Western Blotting]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Physiology/pathophysiology of intestinal vitC uptake: Cell/molecular mechanisms]]></PROJECT_TITLE><SERIAL_NUMBER>107474</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>251100</DIRECT_COST_AMT><INDIRECT_COST_AMT>56212</INDIRECT_COST_AMT><TOTAL_COST>307312</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198295</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000424</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PUBLIC HEALTH]]></ED_INST_TYPE><FOA_NUMBER>RFA-GH-11-108</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000424-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:19519535\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PUBLIC HEALTH & PREV MEDICINE]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>621889815</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[COLUMBIA UNIVERSITY HEALTH SCIENCES]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100320049</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>EL-SADR, WAFAA M.</PI_NAME><PI_ID>1871336</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-11108:  TECHNICAL ASSISTANCE TO THE MOH FOR HIV SVC (PEPFAR) - Mozambique]]></PROJECT_TITLE><SERIAL_NUMBER>000424</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>19519535</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9181223</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>K23AR062099</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-194</FOA_NUMBER><FULL_PROJECT_NUM>3K23AR062099-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:972\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Aging]]></CATEGORY><CATEGORY><![CDATA[Arthritis]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Osteoarthritis]]></CATEGORY><CATEGORY><![CDATA[Pain Conditions - Chronic]]></CATEGORY><CATEGORY><![CDATA[Pain Research]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>GAINESVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>969663814</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF FLORIDA]]></ORG_NAME><ORG_STATE>FL</ORG_STATE><ORG_ZIPCODE>326115500</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Osteoarthritis is a prevalent condition and a leading cause of disability. We will evaluate changes in pain, functioning, and biological measures reflecting system burden over a four year period in a large group of ethnically diverse older adults with and without knee osteoarthritis. This information will provide an improved understanding of individual differences in osteoarthritis symptoms, help identify targets for prevention and treatment, and provide a measure for evaluating the efficacy of clinical interventions.]]></PHR><PIS><PI><PI_NAME>SIBILLE, KIMBERLY THERESA</PI_NAME><PI_ID>10674060</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>LESTER, GAYLE E.</PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2013</PROJECT_START><PROJECT_END>03/31/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acute Pain]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[African American]]></TERM><TERM><![CDATA[allostatic load]]></TERM><TERM><![CDATA[American]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Arthritis]]></TERM><TERM><![CDATA[behavioral/social science]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Factors]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[Biological Process]]></TERM><TERM><![CDATA[biological systems]]></TERM><TERM><![CDATA[biopsychosocial]]></TERM><TERM><![CDATA[Capsicum]]></TERM><TERM><![CDATA[Cardiovascular system]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Cell Aging]]></TERM><TERM><![CDATA[Chromosomes]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[chronic pain]]></TERM><TERM><![CDATA[Chronic stress]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical efficacy]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[coping]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Degenerative polyarthritis]]></TERM><TERM><![CDATA[Dentistry]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Discrimination (Psychology)]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[Doctor of Medicine]]></TERM><TERM><![CDATA[Doctor of Philosophy]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Elderly]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[ethnic difference]]></TERM><TERM><![CDATA[Ethnic group]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[field study]]></TERM><TERM><![CDATA[Florida]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[functional decline]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health application]]></TERM><TERM><![CDATA[Hyperalgesia]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[Immunology]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[indexing]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Individual Differences]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Interest Group]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Knee]]></TERM><TERM><![CDATA[Knee Osteoarthritis]]></TERM><TERM><![CDATA[knowledge base]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Leukocytes]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Manuscripts]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Medical]]></TERM><TERM><![CDATA[Medical Research]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[Mentored Patient-Oriented Research Career Development Award]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[Musculoskeletal Diseases]]></TERM><TERM><![CDATA[National Institute of Arthritis and Musculoskeletal and Skin Diseases]]></TERM><TERM><![CDATA[Neurosecretory Systems]]></TERM><TERM><![CDATA[Not Hispanic or Latino]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[optimism]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[pain inhibition]]></TERM><TERM><![CDATA[Pain Measurement]]></TERM><TERM><![CDATA[Pain Research]]></TERM><TERM><![CDATA[patient oriented research]]></TERM><TERM><![CDATA[Patient Self-Report]]></TERM><TERM><![CDATA[Persistent pain]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Prospective Studies]]></TERM><TERM><![CDATA[Proxy]]></TERM><TERM><![CDATA[Psychosocial Factor]]></TERM><TERM><![CDATA[Psychosocial Stress]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research and development]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[resilience]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Scholarship]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Severity of illness]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[skin disorder]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[stressor]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[telomere]]></TERM><TERM><![CDATA[Telomere Shortening]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[treatment response]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Biological Markers of System Burden in Symptomatic Knee OA: A Prospective Study]]></PROJECT_TITLE><SERIAL_NUMBER>062099</SERIAL_NUMBER><STUDY_SECTION>AMS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>900</DIRECT_COST_AMT><INDIRECT_COST_AMT>72</INDIRECT_COST_AMT><TOTAL_COST>972</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9181119</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>AR</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/23/2015</BUDGET_START><BUDGET_END>01/31/2016</BUDGET_END><CFDA_CODE>846</CFDA_CODE><CORE_PROJECT_NUM>K23AR062069</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCH ALLIED HEALTH PROFESSIONS]]></ED_INST_TYPE><FOA_NUMBER>PA-11-194</FOA_NUMBER><FULL_PROJECT_NUM>3K23AR062069-03S1</FULL_PROJECT_NUM><FUNDING_ICs>NIAMS:927\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Physical Rehabilitation]]></CATEGORY><CATEGORY><![CDATA[Rehabilitation]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>LEXINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PHYSICAL MEDICINE & REHAB]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>939017877</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF KENTUCKY]]></ORG_NAME><ORG_STATE>KY</ORG_STATE><ORG_ZIPCODE>405060057</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Identification of the underlying cellular and myofiber adaptations that contribute to the loss of quadriceps strength after an ACL reconstruction is essential to develop improved physical therapy interventions and functional outcomes.]]></PHR><PIS><PI><PI_NAME>NOEHREN, BRIAN </PI_NAME><PI_ID>10137938</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BOYCE, AMANDA T.</PROGRAM_OFFICER_NAME><PROJECT_START>02/01/2013</PROJECT_START><PROJECT_END>01/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Anterior]]></TERM><TERM><![CDATA[anterior cruciate ligament reconstruction]]></TERM><TERM><![CDATA[Architecture]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biomechanics]]></TERM><TERM><![CDATA[Biophysics]]></TERM><TERM><![CDATA[Biopsy]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[clinically significant]]></TERM><TERM><![CDATA[cohort]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Degenerative polyarthritis]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Diffusion]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[evidence base]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Fascicle]]></TERM><TERM><![CDATA[Fiber]]></TERM><TERM><![CDATA[Fibrosis]]></TERM><TERM><![CDATA[follow-up]]></TERM><TERM><![CDATA[functional outcomes]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Head]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Sciences]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[interest]]></TERM><TERM><![CDATA[Intervention]]></TERM><TERM><![CDATA[joint loading]]></TERM><TERM><![CDATA[Joints]]></TERM><TERM><![CDATA[Kentucky]]></TERM><TERM><![CDATA[Knee]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Left]]></TERM><TERM><![CDATA[Leg]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Ligaments]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mechanics]]></TERM><TERM><![CDATA[Mentored Patient-Oriented Research Career Development Award]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Mentorship]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Microscopic]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Morphology]]></TERM><TERM><![CDATA[Muscle]]></TERM><TERM><![CDATA[Muscle Fibers]]></TERM><TERM><![CDATA[Muscle function]]></TERM><TERM><![CDATA[Muscle Weakness]]></TERM><TERM><![CDATA[muscular structure]]></TERM><TERM><![CDATA[non-invasive imaging]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Operative Surgical Procedures]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Patient Outcomes Assessments]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Physical therapy]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[Quadriceps Muscle of the Thigh]]></TERM><TERM><![CDATA[reconstruction]]></TERM><TERM><![CDATA[Recovery]]></TERM><TERM><![CDATA[rehabilitation strategy]]></TERM><TERM><![CDATA[Rehabilitation therapy]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[response to injury]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Senior Scientist]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[strength training]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[United States National Institutes of Health]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[vastus lateralis]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Prolonged alterations to muscle following knee surgery and physical therapy]]></PROJECT_TITLE><SERIAL_NUMBER>062069</SERIAL_NUMBER><STUDY_SECTION>ZAR1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>858</DIRECT_COST_AMT><INDIRECT_COST_AMT>69</INDIRECT_COST_AMT><TOTAL_COST>927</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8993908</APPLICATION_ID><ACTIVITY>U10</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>U10HD055925</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-HD-14-018</FOA_NUMBER><FULL_PROJECT_NUM>5U10HD055925-08</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:3869101\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Contraception/Reproduction]]></CATEGORY><CATEGORY><![CDATA[Patient Safety]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>NEW HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PUBLIC HEALTH & PREV MEDICINE]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>043207562</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[YALE UNIVERSITY]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065208327</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The RMN has an important mission to enhance conception, live birth, and the health of children born to women and men with impaired fertility, and more broadly, to improve public health policy and practice. We at the DCC serve many of the RMN central functions in order to achieve the RMN aims, and hence play a significant role in advancing reproductive sciences and improving the clinical practice for infertility treatment.]]></PHR><PIS><PI><PI_NAME>ZHANG, HEPING </PI_NAME><PI_ID>1896292</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DE PAOLO, LOUIS V</PROGRAM_OFFICER_NAME><PROJECT_START>08/24/2007</PROJECT_START><PROJECT_END>11/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Administrator]]></TERM><TERM><![CDATA[Adverse event]]></TERM><TERM><![CDATA[Archives]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[biobank]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Preservation]]></TERM><TERM><![CDATA[Case Report Form]]></TERM><TERM><![CDATA[Cataloging]]></TERM><TERM><![CDATA[Catalogs]]></TERM><TERM><![CDATA[Child health care]]></TERM><TERM><![CDATA[Clinical and Translational Science Awards]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[clinical research site]]></TERM><TERM><![CDATA[Clinical Sciences]]></TERM><TERM><![CDATA[Clinical Trials Data Monitoring Committees]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Computer Assisted]]></TERM><TERM><![CDATA[Conceptions]]></TERM><TERM><![CDATA[Conduct Clinical Trials]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Data Analyses]]></TERM><TERM><![CDATA[Data Collection]]></TERM><TERM><![CDATA[Data Coordinating Center]]></TERM><TERM><![CDATA[data management]]></TERM><TERM><![CDATA[Data Quality]]></TERM><TERM><![CDATA[Data Set]]></TERM><TERM><![CDATA[Data Storage and Retrieval]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Dedications]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Devices]]></TERM><TERM><![CDATA[Electronics]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Equipment]]></TERM><TERM><![CDATA[Expenditure]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Fertility]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Policy]]></TERM><TERM><![CDATA[health practice]]></TERM><TERM><![CDATA[Human Resources]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Infertility]]></TERM><TERM><![CDATA[Informatics]]></TERM><TERM><![CDATA[Information Technology]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Investigational Drugs]]></TERM><TERM><![CDATA[Letters]]></TERM><TERM><![CDATA[Live Birth]]></TERM><TERM><![CDATA[Logistics]]></TERM><TERM><![CDATA[Manuals]]></TERM><TERM><![CDATA[Manuscripts]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Mission]]></TERM><TERM><![CDATA[Monitor]]></TERM><TERM><![CDATA[National Institute of Child Health and Human Development]]></TERM><TERM><![CDATA[Occupational activity of managing finances]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Paper]]></TERM><TERM><![CDATA[Patient Care]]></TERM><TERM><![CDATA[Performance]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Policies]]></TERM><TERM><![CDATA[Preparation]]></TERM><TERM><![CDATA[Principal Investigator]]></TERM><TERM><![CDATA[Procedures]]></TERM><TERM><![CDATA[Productivity]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[protocol development]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[quality assurance]]></TERM><TERM><![CDATA[Quality Control]]></TERM><TERM><![CDATA[Report (document)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[repository]]></TERM><TERM><![CDATA[reproductive]]></TERM><TERM><![CDATA[reproductive epidemiology]]></TERM><TERM><![CDATA[Reproductive Medicine]]></TERM><TERM><![CDATA[Research Design]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Resource Sharing]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[sample collection]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Specimen]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Summary Reports]]></TERM><TERM><![CDATA[Surveys]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Talents]]></TERM><TERM><![CDATA[Teleconferences]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[Update]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[web page]]></TERM><TERM><![CDATA[web site]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Writing]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Data Coordination Center for the RMN]]></PROJECT_TITLE><SERIAL_NUMBER>055925</SERIAL_NUMBER><STUDY_SECTION>ZHD1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>08</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>3510001</DIRECT_COST_AMT><INDIRECT_COST_AMT>359100</INDIRECT_COST_AMT><TOTAL_COST>3869101</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9027002</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/18/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>08/31/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>R01HD083270</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-118</FOA_NUMBER><FULL_PROJECT_NUM>1R01HD083270-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:571294\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Basic Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Pain Conditions - Chronic]]></CATEGORY><CATEGORY><![CDATA[Pain Research]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>076593722</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CHILDREN'S HOSPITAL CORPORATION]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021155724</ORG_ZIPCODE><PHR><![CDATA[PROJECT NARRATIVE
Public Health Relevance: 3.5 million youth in the US suffer from chronic pain and associated disability. Fear
is a salient influence on pain outcomes. Defining the behavioral and neurobiological mechanisms of fear
learning and extinction in adolescents with chronic pain will advance our understanding and treatment of these
patients and potentially prevent the persistence of pain into adulthood.]]></PHR><PIS><PI><PI_NAME>SIMONS, LAURA E</PI_NAME><PI_ID>9817338</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HAVERKOS, LYNNE </PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>08/31/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adolescence]]></TERM><TERM><![CDATA[Adolescent]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Aftercare]]></TERM><TERM><![CDATA[Amygdaloid structure]]></TERM><TERM><![CDATA[Anterior]]></TERM><TERM><![CDATA[avoidance behavior]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Behavioral Mechanisms]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Chronic]]></TERM><TERM><![CDATA[chronic pain]]></TERM><TERM><![CDATA[cognitive control]]></TERM><TERM><![CDATA[conditioning]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Coupling]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[depressive symptoms]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[disability]]></TERM><TERM><![CDATA[Distress]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Extinction (Psychology)]]></TERM><TERM><![CDATA[fear memory]]></TERM><TERM><![CDATA[Fright]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Functional Magnetic Resonance Imaging]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health care service utilization]]></TERM><TERM><![CDATA[Hour]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Insula of Reil]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[learning extinction]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[neurobiological mechanism]]></TERM><TERM><![CDATA[Neurobiology]]></TERM><TERM><![CDATA[neuroimaging]]></TERM><TERM><![CDATA[neuromechanism]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[parental influence]]></TERM><TERM><![CDATA[Parents]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Persistent pain]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Prefrontal Cortex]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[protective behavior]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[psychologic]]></TERM><TERM><![CDATA[Psychological reinforcement]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Proposals]]></TERM><TERM><![CDATA[resilience]]></TERM><TERM><![CDATA[Resistance]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Risk Factors]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Safety]]></TERM><TERM><![CDATA[Schools]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[Youth]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Fear learning in adolescents with chronic pain: Neural and behavioral mechanisms]]></PROJECT_TITLE><SERIAL_NUMBER>083270</SERIAL_NUMBER><STUDY_SECTION>BMIO</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Behavioral Medicine, Interventions and Outcomes Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>355523</DIRECT_COST_AMT><INDIRECT_COST_AMT>215771</INDIRECT_COST_AMT><TOTAL_COST>571294</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9184873</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DA</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>279</CFDA_CODE><CORE_PROJECT_NUM>R01DA036445</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-12-281</FOA_NUMBER><FULL_PROJECT_NUM>6R01DA036445-04</FULL_PROJECT_NUM><FUNDING_ICs>NIDA:676287\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE ON DRUG ABUSE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The epidemic of cigarette smoking is fueling an alarming rise in lung and other cancers in persons living with HIV (PLWH). Smokers living with HIV have few, if any, cessation resources available to them that address their particular needs, and HIV care providers have virtually no evidence base to guide their approach to tobacco treatment. The proposal, if funded, will conduct a definitive study of a group therapy intervention for PLWH smokers that showed promise in a pilot trial.]]></PHR><PIS><PI><PI_NAME>SHUTER, JONATHAN </PI_NAME><PI_ID>8726176</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KAHANA, SHOSHANA Y</PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2013</PROJECT_START><PROJECT_END>07/31/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[A trial of Positively Smoke Free group therapy for HIV-infected smokers]]></PROJECT_TITLE><SERIAL_NUMBER>036445</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>472894</DIRECT_COST_AMT><INDIRECT_COST_AMT>203393</INDIRECT_COST_AMT><TOTAL_COST>676287</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9196512</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000422</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-108</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000422-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:17955338\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>WASHINGTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>98</ORG_DISTRICT><ORG_DUNS>007041168</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ELIZABETH GLASER PEDIATRIC AIDS FDN]]></ORG_NAME><ORG_STATE>DC</ORG_STATE><ORG_ZIPCODE>200364028</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>ALTERESCU, XAVIER </PI_NAME><PI_ID>14123850</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-11108 TECH ASSIST TO THE MOH FOR HIV SVC & PROG TRANS(FORTALECER PROJECT)]]></PROJECT_TITLE><SERIAL_NUMBER>000422</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>17955338</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9197362</APPLICATION_ID><ACTIVITY>R13</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>R13NS093882</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-347</FOA_NUMBER><FULL_PROJECT_NUM>6R13NS093882-02</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:3000\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Neurodevelopmental disorders affect 1-2% of the world population and are a major cause of morbidity and societal costs. Christianson syndrome is among the most common X-linked developmental brain disorders, and has relevance to a wide array of more common developmental and degenerative disorders. In spite of this importance, Christianson syndrome has to date received little attention outside of a few clinics and research labs. The meeting supported by this proposal is the first to bring together all stake holders in understanding this disease, from clinicians and researchers to the families and individuals affected by this disorder.   
   
      

]]></PHR><PIS><PI><PI_NAME>MORROW, ERIC M</PI_NAME><PI_ID>8735036</PI_ID></PI><PI><PI_NAME>WALKLEY, STEVEN UPSHAW (contact)</PI_NAME><PI_ID>1885756 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WHITTEMORE, VICKY R</PROGRAM_OFFICER_NAME><PROJECT_START>07/15/2015</PROJECT_START><PROJECT_END>06/30/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Support for the 1st International Basic Science and Clinical Conference on Christianson Syndrome]]></PROJECT_TITLE><SERIAL_NUMBER>093882</SERIAL_NUMBER><STUDY_SECTION>NSD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[National Institute of Neurological Disorders and Stroke Initial Review Group ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>3000</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>3000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9184922</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>DA</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>279</CFDA_CODE><CORE_PROJECT_NUM>K23DA034541</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-194</FOA_NUMBER><FULL_PROJECT_NUM>6K23DA034541-05</FULL_PROJECT_NUM><FUNDING_ICs>NIDA:152165\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE ON DRUG ABUSE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[With the high rates of relapse to substance use upon release from correctional facilities, our project seeks to link opioid-addicted former inmates to buprenorphine treatment through peer mentorship. We will tailor a previously developed intervention to target former inmates and to use peer mentors. Ultimately, this intervention has the potential to increase initiation of buprenorphine treatment, an effective treatment for opioid addiction, and reduce HIV risk behaviors, overdose-related deaths, and re-incarceration. This study's findings will be used to guide a large-scale study of our intervention.]]></PHR><PIS><PI><PI_NAME>FOX, AARON D</PI_NAME><PI_ID>10660903</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WILEY, TISHA R. A.</PROGRAM_OFFICER_NAME><PROJECT_START>07/15/2012</PROJECT_START><PROJECT_END>06/30/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Buprenorphine Facilitated Access and Supportive Treatment in Former Inmates]]></PROJECT_TITLE><SERIAL_NUMBER>034541</SERIAL_NUMBER><STUDY_SECTION>NIDA</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Human Development Research Subcommittee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>140894</DIRECT_COST_AMT><INDIRECT_COST_AMT>11271</INDIRECT_COST_AMT><TOTAL_COST>152165</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8976161</APPLICATION_ID><ACTIVITY>K99</ACTIVITY><ADMINISTERING_IC>EY</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/25/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>867</CFDA_CODE><CORE_PROJECT_NUM>K99EY025026</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-042</FOA_NUMBER><FULL_PROJECT_NUM>5K99EY025026-02</FULL_PROJECT_NUM><FUNDING_ICs>NEI:94392\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL EYE INSTITUTE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LA JOLLA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>49</ORG_DISTRICT><ORG_DUNS>078731668</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[SALK INSTITUTE FOR BIOLOGICAL STUDIES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>920371002</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: In our daily lives, we rely critically on the ability to attend to relevant features of a vast amount of information present in a complex visual scene. The breakdown of these abilities can be observed in various neuropathologies such as attention-deficit disorder, autism and schizophrenia, as well as in patients with Traumatic Brain Injury (TBI). Studying the neural circuits that determine these abilities is thus crucial, not only to understand the fundamental computations underlying normal attention, but also to inform efforts to develop novel therapies for cortical dysfunction.]]></PHR><PIS><PI><PI_NAME>JADI, MONIKA P.</PI_NAME><PI_ID>11331514</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>AGARWAL, NEERAJ </PROGRAM_OFFICER_NAME><PROJECT_START>12/02/2014</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Acetylcholine]]></TERM><TERM><![CDATA[Achievement]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[area striata]]></TERM><TERM><![CDATA[area V1]]></TERM><TERM><![CDATA[area V4]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Attention Deficit Disorder]]></TERM><TERM><![CDATA[attentional modulation]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[biophysical model]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[Cataloging]]></TERM><TERM><![CDATA[Catalogs]]></TERM><TERM><![CDATA[cell type]]></TERM><TERM><![CDATA[cellular targeting]]></TERM><TERM><![CDATA[Chemicals]]></TERM><TERM><![CDATA[cholinergic]]></TERM><TERM><![CDATA[Cholinergic Receptors]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[computer studies]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Dendrites]]></TERM><TERM><![CDATA[Diffuse]]></TERM><TERM><![CDATA[Diffusion]]></TERM><TERM><![CDATA[direct application]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Extracellular Space]]></TERM><TERM><![CDATA[flexibility]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[GABA Receptor]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[information processing]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[molecular modeling]]></TERM><TERM><![CDATA[Molecular Models]]></TERM><TERM><![CDATA[Molecular Neurobiology]]></TERM><TERM><![CDATA[Morphology]]></TERM><TERM><![CDATA[nerve supply]]></TERM><TERM><![CDATA[network models]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[neural correlate]]></TERM><TERM><![CDATA[Neurobiology]]></TERM><TERM><![CDATA[Neuromuscular Junction]]></TERM><TERM><![CDATA[neuronal excitability]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neuropathology]]></TERM><TERM><![CDATA[Neurosciences]]></TERM><TERM><![CDATA[Neurotransmitter Receptor]]></TERM><TERM><![CDATA[Neurotransmitters]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Output]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Phase]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[Positioning Attribute]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Psychological Techniques]]></TERM><TERM><![CDATA[Reaction]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[receptor expression]]></TERM><TERM><![CDATA[relating to nervous system]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Schizophrenia]]></TERM><TERM><![CDATA[second messenger]]></TERM><TERM><![CDATA[Second Messenger Systems]]></TERM><TERM><![CDATA[Sensory]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Spatial Distribution]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Synapses]]></TERM><TERM><![CDATA[Synaptic Transmission]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[TBI Patients]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[transmission process]]></TERM><TERM><![CDATA[Vision research]]></TERM><TERM><![CDATA[Visual]]></TERM><TERM><![CDATA[Visual Cortex]]></TERM><TERM><![CDATA[visual process]]></TERM><TERM><![CDATA[visual processing]]></TERM><TERM><![CDATA[Visual system structure]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Cholinergic modulation of cortical visual processing]]></PROJECT_TITLE><SERIAL_NUMBER>025026</SERIAL_NUMBER><STUDY_SECTION>ZEY1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>87400</DIRECT_COST_AMT><INDIRECT_COST_AMT>6992</INDIRECT_COST_AMT><TOTAL_COST>94392</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9134379</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>02/01/2015</BUDGET_START><BUDGET_END>01/31/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>R01NS049119</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-249</FOA_NUMBER><FULL_PROJECT_NUM>3R01NS049119-09S1</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:23775\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Epilepsy]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Neurodegenerative]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>HOUSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROLOGY]]></ORG_DEPT><ORG_DISTRICT>09</ORG_DISTRICT><ORG_DUNS>051113330</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BAYLOR COLLEGE OF MEDICINE]]></ORG_NAME><ORG_STATE>TX</ORG_STATE><ORG_ZIPCODE>770303411</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Proteins called ion channels create the electrical signals in the brain that are the physical basis for activities such as thinking, sensation, and body movement. Ion channel variants can be responsible for several types of epilepsy which begin early after birth and are sometime followed by severe developmental delay. This study will analyze how variation in the ion channel called KCNQ2 cause such symptoms and test new strategies for treating and curing affected individuals, by using molecular biology, and studies of
cells in culture and mice.   
   
      

]]></PHR><PIS><PI><PI_NAME>COOPER, EDWARD C</PI_NAME><PI_ID>1887167</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>WHITTEMORE, VICKY R</PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2004</PROJECT_START><PROJECT_END>01/31/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Action Potentials]]></TERM><TERM><![CDATA[Acute]]></TERM><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Antiepileptic Agents]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavioral]]></TERM><TERM><![CDATA[Benign]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biophysics]]></TERM><TERM><![CDATA[Birth]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Central Nervous System Diseases]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[comparative efficacy]]></TERM><TERM><![CDATA[Custom]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Developmental Delay Disorders]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Dominant-Negative Mutation]]></TERM><TERM><![CDATA[early onset]]></TERM><TERM><![CDATA[Early treatment]]></TERM><TERM><![CDATA[effective therapy]]></TERM><TERM><![CDATA[Electrophysiology (science)]]></TERM><TERM><![CDATA[Encephalopathies]]></TERM><TERM><![CDATA[Epigenetic Process]]></TERM><TERM><![CDATA[Epilepsy]]></TERM><TERM><![CDATA[Esthesia]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[FDA approved]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[genetic pedigree]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hippocampal Formation]]></TERM><TERM><![CDATA[Hippocampus (Brain)]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[human tissue]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Inherited]]></TERM><TERM><![CDATA[Injury]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Ion Channel]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Molecular Biology]]></TERM><TERM><![CDATA[Motor]]></TERM><TERM><![CDATA[Movement]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[mutant]]></TERM><TERM><![CDATA[Mutant Strains Mice]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Myokymia]]></TERM><TERM><![CDATA[Neocortex]]></TERM><TERM><![CDATA[neocortical]]></TERM><TERM><![CDATA[Neonatal]]></TERM><TERM><![CDATA[Neuromuscular Diseases]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[North America]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Pain]]></TERM><TERM><![CDATA[patch clamp]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[postnatal]]></TERM><TERM><![CDATA[preclinical efficacy]]></TERM><TERM><![CDATA[preclinical safety]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Ranvier's Nodes]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[safety testing]]></TERM><TERM><![CDATA[Seizures]]></TERM><TERM><![CDATA[Severities]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Site]]></TERM><TERM><![CDATA[Slice]]></TERM><TERM><![CDATA[somatosensory]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Status Epilepticus]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Thinking, function]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Transfection]]></TERM><TERM><![CDATA[Transgenic Animals]]></TERM><TERM><![CDATA[Transgenic Organisms]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Variation (Genetics)]]></TERM><TERM><![CDATA[Voltage-Gated Potassium Channel]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[KCNQ2/3 channels in neonatal-onset epilepsy and encephalopathy]]></PROJECT_TITLE><SERIAL_NUMBER>049119</SERIAL_NUMBER><STUDY_SECTION></STUDY_SECTION><STUDY_SECTION_NAME xsi:nil='true' /><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>09</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>15000</DIRECT_COST_AMT><INDIRECT_COST_AMT>8775</INDIRECT_COST_AMT><TOTAL_COST>23775</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9193684</APPLICATION_ID><ACTIVITY>T32</ACTIVITY><ADMINISTERING_IC>AG</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>866</CFDA_CODE><CORE_PROJECT_NUM>T32AG000279</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-11-184</FOA_NUMBER><FULL_PROJECT_NUM>3T32AG000279-14S1</FULL_PROJECT_NUM><FUNDING_ICs>NIA:1\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INSTITUTIONAL</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE ON AGING</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Aging]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>AURORA</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>06</ORG_DISTRICT><ORG_DUNS>041096314</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF COLORADO DENVER]]></ORG_NAME><ORG_STATE>CO</ORG_STATE><ORG_ZIPCODE>800452570</ORG_ZIPCODE><PHR><![CDATA[The overall objective of this University of Colorado NRSA is to attract and mentor outstanding pre- (Ph.D.) and postdoctoral (Ph.D. and M.D.) trainees in the Integrative Physiology of Aging. These trainees will be equipped with the skills to become successful, independent academic leaders in the field of aging research.]]></PHR><PIS><PI><PI_NAME>SCHWARTZ, ROBERT S</PI_NAME><PI_ID>1869199</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ELDADAH, BASIL A.</PROGRAM_OFFICER_NAME><PROJECT_START>05/01/2001</PROJECT_START><PROJECT_END>04/30/2017</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Aging]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Training]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Integrative Physiology of Aging Training Grant]]></PROJECT_TITLE><SERIAL_NUMBER>000279</SERIAL_NUMBER><STUDY_SECTION>ZAG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>14</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>39147</DIRECT_COST_AMT><INDIRECT_COST_AMT>3132</INDIRECT_COST_AMT><TOTAL_COST>1</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9008479</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>CA</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>395</CFDA_CODE><CORE_PROJECT_NUM>R01CA200900</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01CA200900-01</FULL_PROJECT_NUM><FUNDING_ICs>NCI:644550\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL CANCER INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Bioengineering]]></CATEGORY><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Cancer]]></CATEGORY><CATEGORY><![CDATA[Gene Therapy]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Lung]]></CATEGORY><CATEGORY><![CDATA[Lung Cancer]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>BOSTON</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>030811269</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BRIGHAM AND WOMEN'S HOSPITAL]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021156110</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Lung cancer is the leading cause of cancer-related death in both men and women in the United States, and the estimated new cases and deaths in 2014 are 224,210 and 159,260, respectively. In particular, the 5-year survival rate of non-small cell lung cancer that accounts for ~ 85% of lung cancer cases is very low at late stages (14% for stage IIIA, 5% for stage IIIB, and 1% for stage IV). This project aims to develop effective, nanotechnology-based delivery methods for RNA-derived therapies, which will allow silencing of cancer- promoting genes as well as introduction of cancer suppressing genes to potentially reduce tumor burden and enhance the survival rate of patients with advanced lung cancer.   
   
      

]]></PHR><PIS><PI><PI_NAME>SHI, JINJUN </PI_NAME><PI_ID>10646072</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KONDAPAKA, SUDHIR B</PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>11/30/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adverse effects]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[antibody inhibitor]]></TERM><TERM><![CDATA[anticancer research]]></TERM><TERM><![CDATA[antitumor effect]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biodistribution]]></TERM><TERM><![CDATA[biomacromolecule]]></TERM><TERM><![CDATA[Blood Circulation]]></TERM><TERM><![CDATA[cancer cell]]></TERM><TERM><![CDATA[Cancer Etiology]]></TERM><TERM><![CDATA[cancer genome]]></TERM><TERM><![CDATA[cancer therapy]]></TERM><TERM><![CDATA[cell growth]]></TERM><TERM><![CDATA[Cell Survival]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[Charge]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Dissociation]]></TERM><TERM><![CDATA[DNA]]></TERM><TERM><![CDATA[DNA Sequence Alteration]]></TERM><TERM><![CDATA[Drug Formulations]]></TERM><TERM><![CDATA[Drug Kinetics]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Excretory function]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Face]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Gene Mutation]]></TERM><TERM><![CDATA[Gene Silencing]]></TERM><TERM><![CDATA[Generations]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genetically Engineered Mouse]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[humanized antibody]]></TERM><TERM><![CDATA[Hybrids]]></TERM><TERM><![CDATA[In Vitro]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Kidney]]></TERM><TERM><![CDATA[Kinetics]]></TERM><TERM><![CDATA[Label]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[macromolecule]]></TERM><TERM><![CDATA[Malignant neoplasm of lung]]></TERM><TERM><![CDATA[Malignant Neoplasms]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Messenger RNA]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Mononuclear]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[nanoparticle]]></TERM><TERM><![CDATA[Nanotechnology]]></TERM><TERM><![CDATA[neoplastic cell]]></TERM><TERM><![CDATA[Non-Small-Cell Lung Carcinoma]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[nuclease]]></TERM><TERM><![CDATA[Nucleic Acids]]></TERM><TERM><![CDATA[Oncogenes]]></TERM><TERM><![CDATA[Particle Size]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Phagocytes]]></TERM><TERM><![CDATA[phase I trial]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Polymers]]></TERM><TERM><![CDATA[Predisposition]]></TERM><TERM><![CDATA[Property]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[PTEN gene]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[research and development]]></TERM><TERM><![CDATA[restoration]]></TERM><TERM><![CDATA[RNA]]></TERM><TERM><![CDATA[self assembly]]></TERM><TERM><![CDATA[Small Interfering RNA]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[smoking cessation]]></TERM><TERM><![CDATA[Solid]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[STK11 gene]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Survival Rate]]></TERM><TERM><![CDATA[Synthetic Vaccines]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[targeted treatment]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[therapeutic target]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Translating]]></TERM><TERM><![CDATA[tumor]]></TERM><TERM><![CDATA[Tumor Biology]]></TERM><TERM><![CDATA[Tumor Burden]]></TERM><TERM><![CDATA[tumor growth]]></TERM><TERM><![CDATA[Tumor Suppressor Proteins]]></TERM><TERM><![CDATA[Tumor Tissue]]></TERM><TERM><![CDATA[United States]]></TERM><TERM><![CDATA[uptake]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Woman]]></TERM><TERM><![CDATA[Xenograft procedure]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Systemic RNA Delivery to Tumors]]></PROJECT_TITLE><SERIAL_NUMBER>200900</SERIAL_NUMBER><STUDY_SECTION>GDD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Gene and Drug Delivery Systems Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>506702</DIRECT_COST_AMT><INDIRECT_COST_AMT>137848</INDIRECT_COST_AMT><TOTAL_COST>644550</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9114842</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>AI</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>08/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>855</CFDA_CODE><CORE_PROJECT_NUM>R01AI113103</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R01AI113103-03</FULL_PROJECT_NUM><FUNDING_ICs>NIAID:373558\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW HAVEN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>03</ORG_DISTRICT><ORG_DUNS>043207562</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[YALE UNIVERSITY]]></ORG_NAME><ORG_STATE>CT</ORG_STATE><ORG_ZIPCODE>065208327</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Research outlined in this grant proposal will help define the type of immune response desired in a future Chlamydia vaccine. Identification of markers for protective vaccine-generated immune responses will foster development of a vaccine to reduce Chlamydia infections and their complications including infertility and potentially fatal tubal pregnancies.]]></PHR><PIS><PI><PI_NAME>BRUNHAM, ROBERT CONRAD</PI_NAME><PI_ID>8869260</PI_ID></PI><PI><PI_NAME>JOHNSON, RAYMOND MORRIS (contact)</PI_NAME><PI_ID>1862295 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DAVID, HAGIT S.</PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2015</PROJECT_START><PROJECT_END>06/30/2019</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Role of Plac8 in natural and vaccine-generated immunity against Chlamydia infections]]></PROJECT_TITLE><SERIAL_NUMBER>113103</SERIAL_NUMBER><STUDY_SECTION>VMD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Vaccines Against Microbial Diseases ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>258212</DIRECT_COST_AMT><INDIRECT_COST_AMT>115346</INDIRECT_COST_AMT><TOTAL_COST>373558</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9052923</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/22/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>R01HD084500</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>1R01HD084500-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:348621\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Arthritis]]></CATEGORY><CATEGORY><![CDATA[Autoimmune Disease]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Immunization]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Intellectual and Developmental Disabilities (IDD)]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurodegenerative]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY><CATEGORY><![CDATA[Rett Syndrome]]></CATEGORY><CATEGORY><![CDATA[Vaccine Related]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>NASHVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PEDIATRICS]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>004413456</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VANDERBILT UNIVERSITY]]></ORG_NAME><ORG_STATE>TN</ORG_STATE><ORG_ZIPCODE>372122809</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: MECP2 duplication syndrome is an X-linked disorder associated with distinct clinical outcomes including regression/loss of skills, but it is not yet known why some individuals convert to a path of decline while others maintain/gain milestones. In this study, we will identify the clinical signs, immune markers, and stress markers of regression so we can implement better guidelines for yearly vaccines, and so that we can lay the foundation for a future treatment study testing whether drugs known to improve immune functioning normalize or improve clinical course, normalize stress markers, and therefore improve quality of life. This study may have impact for other disorders with high rates of regression such as Rett syndrome and autism, where immune-mediated factors may contribute to clinical outcomes, and for autoimmune disorders associated with MeCP2 overexpression, including lupus, Sj&#246;gren's syndrome, and rheumatoid arthritis.   
      

]]></PHR><PIS><PI><PI_NAME>PETERS, SARIKA U</PI_NAME><PI_ID>7834953</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PARISI, MELISSA </PROGRAM_OFFICER_NAME><PROJECT_START>12/22/2015</PROJECT_START><PROJECT_END>11/30/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Accounting]]></TERM><TERM><![CDATA[Adolescence]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Age]]></TERM><TERM><![CDATA[Antibodies]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[Autoimmune Diseases]]></TERM><TERM><![CDATA[Autoimmune Process]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Biological Markers]]></TERM><TERM><![CDATA[boys]]></TERM><TERM><![CDATA[CCR6 gene]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cessation of life]]></TERM><TERM><![CDATA[chemokine]]></TERM><TERM><![CDATA[chemokine receptor]]></TERM><TERM><![CDATA[Childhood]]></TERM><TERM><![CDATA[Chorea]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical assessments]]></TERM><TERM><![CDATA[Clinical Markers]]></TERM><TERM><![CDATA[Clinical Paths]]></TERM><TERM><![CDATA[clinical practice]]></TERM><TERM><![CDATA[Cognition]]></TERM><TERM><![CDATA[CXCR3 gene]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Progression]]></TERM><TERM><![CDATA[emerging adult]]></TERM><TERM><![CDATA[Flow Cytometry]]></TERM><TERM><![CDATA[Foundations]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gene Duplication]]></TERM><TERM><![CDATA[Genes]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[girls]]></TERM><TERM><![CDATA[Guidelines]]></TERM><TERM><![CDATA[Hemagglutination]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Hydrocortisone]]></TERM><TERM><![CDATA[hypothalamic-pituitary-adrenal axis]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[immune function]]></TERM><TERM><![CDATA[Immunologic Markers]]></TERM><TERM><![CDATA[Immunotherapy]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[improved functioning]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[infancy]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[inflammatory marker]]></TERM><TERM><![CDATA[Influenza virus vaccine]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Intellectual functioning disability]]></TERM><TERM><![CDATA[Interferon Type II]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Longitudinal Studies]]></TERM><TERM><![CDATA[Lupus]]></TERM><TERM><![CDATA[male]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[Methyl-CpG-Binding Protein 2]]></TERM><TERM><![CDATA[motor control]]></TERM><TERM><![CDATA[Motor Skills]]></TERM><TERM><![CDATA[Muscle hypotonia]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Neurologic]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[overexpression]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[predictive marker]]></TERM><TERM><![CDATA[Prevention]]></TERM><TERM><![CDATA[Protein Overexpression]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Quality of life]]></TERM><TERM><![CDATA[Recurrence]]></TERM><TERM><![CDATA[research clinical testing]]></TERM><TERM><![CDATA[respiratory]]></TERM><TERM><![CDATA[Respiratory Tract Infections]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rett Syndrome]]></TERM><TERM><![CDATA[Rheumatoid Arthritis]]></TERM><TERM><![CDATA[Salivary]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[Seizures]]></TERM><TERM><![CDATA[Serum]]></TERM><TERM><![CDATA[Sjogren's Syndrome]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Speech]]></TERM><TERM><![CDATA[Stress]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Systemic Lupus Erythematosus]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[T-Lymphocyte Subsets]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Th1 Cells]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[Vaccines]]></TERM><TERM><![CDATA[Withdrawal]]></TERM><TERM><![CDATA[Work]]></TERM><TERM><![CDATA[X-linked intellectual disability]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Markers of Disease Progression in MECP2 Duplication Syndrome]]></PROJECT_TITLE><SERIAL_NUMBER>084500</SERIAL_NUMBER><STUDY_SECTION>CPDD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Child Psychopathology and Developmental Disabilities Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>227804</DIRECT_COST_AMT><INDIRECT_COST_AMT>120817</INDIRECT_COST_AMT><TOTAL_COST>348621</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198141</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000181</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-11-114</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000181-05S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:3550810\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>12</ORG_DISTRICT><ORG_DUNS>076832765</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[CATHOLIC MEDICAL MISSION BOARD, INC.]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100115701</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>FRANCOIS, DIANNE JEAN</PI_NAME><PI_ID>10911271</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>09/29/2016</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1114, Strengthening HIV Clinical Care and Treatment]]></PROJECT_TITLE><SERIAL_NUMBER>000181</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>3550810</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9174097</APPLICATION_ID><ACTIVITY>R25</ACTIVITY><ADMINISTERING_IC>HG</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/18/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>10/31/2016</BUDGET_END><CFDA_CODE>172</CFDA_CODE><CORE_PROJECT_NUM>R25HG006682</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PAR-09-245</FOA_NUMBER><FULL_PROJECT_NUM>3R25HG006682-04S1</FULL_PROJECT_NUM><FUNDING_ICs>NHGRI:261129\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HUMAN GENOME RESEARCH INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Biotechnology]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Human Genome]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>CAMBRIDGE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>07</ORG_DISTRICT><ORG_DUNS>623544785</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[BROAD INSTITUTE, INC.]]></ORG_NAME><ORG_STATE>MA</ORG_STATE><ORG_ZIPCODE>021421401</ORG_ZIPCODE><PHR><![CDATA[This project will increase the diversity of our nation's research scientists. Our program will prepare and inspire under represented minority and disadvantaged high school students, undergraduates, postdoctoral and faculty trainees to pursue and succeed in research careers.]]></PHR><PIS><PI><PI_NAME>BIRREN, BRUCE W.</PI_NAME><PI_ID>1922265</PI_ID></PI><PI><PI_NAME>LANDER, ERIC S (contact)</PI_NAME><PI_ID>1876444 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>GATLIN, CHRISTINE L.</PROGRAM_OFFICER_NAME><PROJECT_START>03/13/2012</PROJECT_START><PROJECT_END>10/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Academic Training]]></TERM><TERM><![CDATA[Achievement]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Bachelor's Degree]]></TERM><TERM><![CDATA[career]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[chemical genetics]]></TERM><TERM><![CDATA[Collaborations]]></TERM><TERM><![CDATA[collaborative environment]]></TERM><TERM><![CDATA[college]]></TERM><TERM><![CDATA[Communication]]></TERM><TERM><![CDATA[Communities]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disadvantaged]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Educational aspects]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Engineering]]></TERM><TERM><![CDATA[Ensure]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[experimental analysis]]></TERM><TERM><![CDATA[Experimental Designs]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[genetic technology]]></TERM><TERM><![CDATA[Genome]]></TERM><TERM><![CDATA[Genomics]]></TERM><TERM><![CDATA[Graduate Degree]]></TERM><TERM><![CDATA[High School Student]]></TERM><TERM><![CDATA[Home environment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Institutes]]></TERM><TERM><![CDATA[Institution]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[Mentors]]></TERM><TERM><![CDATA[Minority]]></TERM><TERM><![CDATA[minority trainee]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[next generation]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[outreach]]></TERM><TERM><![CDATA[Participant]]></TERM><TERM><![CDATA[post-doctoral training]]></TERM><TERM><![CDATA[Postdoctoral Fellow]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[Recruitment Activity]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Science]]></TERM><TERM><![CDATA[Science, Technology, Engineering and Mathematics Education]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Secure]]></TERM><TERM><![CDATA[skills]]></TERM><TERM><![CDATA[Source]]></TERM><TERM><![CDATA[Staging]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Teacher Professional Development]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Training]]></TERM><TERM><![CDATA[Training Programs]]></TERM><TERM><![CDATA[twelfth grade]]></TERM><TERM><![CDATA[undergraduate research]]></TERM><TERM><![CDATA[Underrepresented Minority]]></TERM><TERM><![CDATA[underrepresented minority student]]></TERM><TERM><![CDATA[Universities]]></TERM><TERM><![CDATA[Visit]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Achieving diversity in genomics: Research education for URM scientists]]></PROJECT_TITLE><SERIAL_NUMBER>006682</SERIAL_NUMBER><STUDY_SECTION>ZHG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>241786</DIRECT_COST_AMT><INDIRECT_COST_AMT>19343</INDIRECT_COST_AMT><TOTAL_COST>261129</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9016529</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>P30DK034987</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK034987-31</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:958973\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CHAPEL HILL</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>04</ORG_DISTRICT><ORG_DUNS>608195277</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIV OF NORTH CAROLINA CHAPEL HILL]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>275990001</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>SANDLER, ROBERT S.</PI_NAME><PI_ID>1863678</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PERRIN, PETER J</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/1996</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Center for Gastrointestinal Biology and Disease]]></PROJECT_TITLE><SERIAL_NUMBER>034987</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>31</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>703258</DIRECT_COST_AMT><INDIRECT_COST_AMT>255715</INDIRECT_COST_AMT><TOTAL_COST>958973</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9050106</APPLICATION_ID><ACTIVITY>F31</ACTIVITY><ADMINISTERING_IC>LM</ADMINISTERING_IC><APPLICATION_TYPE>1</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>09/17/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>12/20/2016</BUDGET_END><CFDA_CODE>879</CFDA_CODE><CORE_PROJECT_NUM>F31LM012176</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCH ALLIED HEALTH PROFESSIONS]]></ED_INST_TYPE><FOA_NUMBER>PA-14-147</FOA_NUMBER><FULL_PROJECT_NUM>1F31LM012176-01A1</FULL_PROJECT_NUM><FUNDING_ICs>NLM:36613\</FUNDING_ICs><FUNDING_MECHANISM>TRAINING, INDIVIDUAL</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL LIBRARY OF MEDICINE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Emerging Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Genetics]]></CATEGORY><CATEGORY><![CDATA[Infectious Diseases]]></CATEGORY><CATEGORY><![CDATA[Influenza]]></CATEGORY><CATEGORY><![CDATA[Networking and Information Technology R&D]]></CATEGORY><CATEGORY><![CDATA[Pneumonia & Influenza]]></CATEGORY><CATEGORY><![CDATA[Prevention]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>TEMPE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOMEDICAL ENGINEERING]]></ORG_DEPT><ORG_DISTRICT>09</ORG_DISTRICT><ORG_DUNS>943360412</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ARIZONA STATE UNIVERSITY-TEMPE CAMPUS]]></ORG_NAME><ORG_STATE>AZ</ORG_STATE><ORG_ZIPCODE>852876011</ORG_ZIPCODE><PHR><![CDATA[Project Narrative
I will develop and evaluate a spatial decision support system to support surveillance of zoonotic viruses in both
human and animal populations. I will use approaches from bioinformatics and public health to integrate genetic
sequence data from the virus with data from cases of reported infectious diseases and associated
environmental data. A surveillance system that considers the genetics and environment of the virus along with
public health data will assist public health officials in making informed decisions regarding risk of infectious
diseases.]]></PHR><PIS><PI><PI_NAME>BEARD, RACHEL </PI_NAME><PI_ID>12293508</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SIM, HUA-CHUAN </PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>12/20/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Academia]]></TERM><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Agriculture]]></TERM><TERM><![CDATA[Algorithm Design]]></TERM><TERM><![CDATA[Algorithms]]></TERM><TERM><![CDATA[Animals]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[Biodiversity]]></TERM><TERM><![CDATA[Bioinformatics]]></TERM><TERM><![CDATA[Case Study]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[clinical decision-making]]></TERM><TERM><![CDATA[Cluster Analysis]]></TERM><TERM><![CDATA[Communicable Diseases]]></TERM><TERM><![CDATA[Computer software]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[data acquisition]]></TERM><TERM><![CDATA[Databases]]></TERM><TERM><![CDATA[Decision Support Systems]]></TERM><TERM><![CDATA[Detection]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Disease Outbreaks]]></TERM><TERM><![CDATA[disorder risk]]></TERM><TERM><![CDATA[Ecology]]></TERM><TERM><![CDATA[Environment]]></TERM><TERM><![CDATA[Epidemiology]]></TERM><TERM><![CDATA[Evaluation]]></TERM><TERM><![CDATA[Evolution]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Genbank]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Geographic Information Systems]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[health data]]></TERM><TERM><![CDATA[high risk]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Genetics]]></TERM><TERM><![CDATA[Infection]]></TERM><TERM><![CDATA[Influenza]]></TERM><TERM><![CDATA[Influenza A virus]]></TERM><TERM><![CDATA[Influenza A Virus, H7N9 Subtype]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Literature]]></TERM><TERM><![CDATA[Location]]></TERM><TERM><![CDATA[Machine Learning]]></TERM><TERM><![CDATA[Maps]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Metadata]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Molecular Epidemiology]]></TERM><TERM><![CDATA[Molecular Evolution]]></TERM><TERM><![CDATA[novel virus]]></TERM><TERM><![CDATA[pathogen]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[personalized medicine]]></TERM><TERM><![CDATA[Population]]></TERM><TERM><![CDATA[prevent]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[Public Health Practice]]></TERM><TERM><![CDATA[Questionnaire Designs]]></TERM><TERM><![CDATA[Questionnaires]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Resources]]></TERM><TERM><![CDATA[respiratory]]></TERM><TERM><![CDATA[Retrospective Studies]]></TERM><TERM><![CDATA[Risk]]></TERM><TERM><![CDATA[Satellite Viruses]]></TERM><TERM><![CDATA[satisfaction]]></TERM><TERM><![CDATA[Scanning]]></TERM><TERM><![CDATA[seasonal influenza]]></TERM><TERM><![CDATA[Sequence Alignment]]></TERM><TERM><![CDATA[spatiotemporal]]></TERM><TERM><![CDATA[statistics]]></TERM><TERM><![CDATA[success]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[System]]></TERM><TERM><![CDATA[Time]]></TERM><TERM><![CDATA[tool]]></TERM><TERM><![CDATA[Translations]]></TERM><TERM><![CDATA[usability]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Validity and Reliability]]></TERM><TERM><![CDATA[Viral]]></TERM><TERM><![CDATA[Viral Genome]]></TERM><TERM><![CDATA[Virus]]></TERM><TERM><![CDATA[virus classification]]></TERM><TERM><![CDATA[Virus Diseases]]></TERM><TERM><![CDATA[virus genetics]]></TERM><TERM><![CDATA[West Nile virus]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Integrating Bioinformatics and Clustering Analysis for Disease Surveillance]]></PROJECT_TITLE><SERIAL_NUMBER>012176</SERIAL_NUMBER><STUDY_SECTION>BLR</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biomedical Library and Informatics Review Committee ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>01</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>36613</DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>36613</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9188024</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/30/2015</BUDGET_START><BUDGET_END>09/29/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000834</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>RFA-GH-12-222</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000834-04S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:3800000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>HAWASSA</ORG_CITY><ORG_COUNTRY>ETHIOPIA</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT></ORG_DISTRICT><ORG_DUNS>850514612</ORG_DUNS><ORG_FIPS>ET</ORG_FIPS><ORG_NAME><![CDATA[SOUTHERN NATIONS/NAT/PEOPLE HLTH BUREAU]]></ORG_NAME><ORG_STATE></ORG_STATE><ORG_ZIPCODE></ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>GEBREMICHAEL, HABTAMU </PI_NAME><PI_ID>11401994</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2012</PROJECT_START><PROJECT_END>09/29/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH12-1222: STRENGTHENING LOCAL OWNERSHIP FOR THE SUSTAINABLE PROVISION OF HIV/AIDS SERVICES ]]></PROJECT_TITLE><SERIAL_NUMBER>000834</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>3800000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9097941</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HL</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>12/24/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>837</CFDA_CODE><CORE_PROJECT_NUM>R01HL122554</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-12-149</FOA_NUMBER><FULL_PROJECT_NUM>3R01HL122554-02S1</FULL_PROJECT_NUM><FUNDING_ICs>NHLBI:66916\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Asthma]]></CATEGORY><CATEGORY><![CDATA[Clinical Research]]></CATEGORY><CATEGORY><![CDATA[Lung]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>NASHVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>004413456</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VANDERBILT UNIVERSITY]]></ORG_NAME><ORG_STATE>TN</ORG_STATE><ORG_ZIPCODE>372122809</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: We will determine how gender, estrogen, and progesterone affect protein secretion from immune cells, CD4+ Th17 cells and gamma delta T cells, associated with airway inflammation in severe asthma. Our research will provide critical mechanistic data which may aid in developing personalized treatments for patients with severe asthma, in particular women.]]></PHR><PIS><PI><PI_NAME>NEWCOMB, DAWN C</PI_NAME><PI_ID>9015443</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>NOEL, PATRICIA </PROGRAM_OFFICER_NAME><PROJECT_START>12/24/2015</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Adult]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[airway inflammation]]></TERM><TERM><![CDATA[Asthma]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[boys]]></TERM><TERM><![CDATA[Bronchoalveolar Lavage Fluid]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[CD4 Positive T Lymphocytes]]></TERM><TERM><![CDATA[Cell Differentiation process]]></TERM><TERM><![CDATA[Cell Separation]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Cellular biology]]></TERM><TERM><![CDATA[Child]]></TERM><TERM><![CDATA[Clinical Trials]]></TERM><TERM><![CDATA[cost]]></TERM><TERM><![CDATA[cytokine]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Estradiol]]></TERM><TERM><![CDATA[Estrogens]]></TERM><TERM><![CDATA[Female]]></TERM><TERM><![CDATA[Flow Cytometry]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[Gender]]></TERM><TERM><![CDATA[Gender Role]]></TERM><TERM><![CDATA[girls]]></TERM><TERM><![CDATA[Gonadal Steroid Hormones]]></TERM><TERM><![CDATA[Harvest]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Health Care Costs]]></TERM><TERM><![CDATA[Healthcare]]></TERM><TERM><![CDATA[Immune]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Inbred BALB C Mice]]></TERM><TERM><![CDATA[Infiltration]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[Inflammatory]]></TERM><TERM><![CDATA[inhibitor/antagonist]]></TERM><TERM><![CDATA[Interleukin-13]]></TERM><TERM><![CDATA[Interleukin-17]]></TERM><TERM><![CDATA[interleukin-23]]></TERM><TERM><![CDATA[Interleukin-4]]></TERM><TERM><![CDATA[Journals]]></TERM><TERM><![CDATA[Liquid substance]]></TERM><TERM><![CDATA[Lung]]></TERM><TERM><![CDATA[male]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Memory]]></TERM><TERM><![CDATA[memory CD4 T lymphocyte]]></TERM><TERM><![CDATA[men]]></TERM><TERM><![CDATA[Metaplasia]]></TERM><TERM><![CDATA[MicroRNAs]]></TERM><TERM><![CDATA[Monoclonal Antibodies]]></TERM><TERM><![CDATA[Morbidity - disease rate]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mucous body substance]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Ovalbumin]]></TERM><TERM><![CDATA[Ovarian hormone]]></TERM><TERM><![CDATA[Pathogenesis]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[personalized medicine]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Placebos]]></TERM><TERM><![CDATA[Prevalence]]></TERM><TERM><![CDATA[Production]]></TERM><TERM><![CDATA[Progesterone]]></TERM><TERM><![CDATA[protein expression]]></TERM><TERM><![CDATA[Protein Secretion]]></TERM><TERM><![CDATA[Puberty]]></TERM><TERM><![CDATA[Publications]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[T memory cell]]></TERM><TERM><![CDATA[T-Lymphocyte]]></TERM><TERM><![CDATA[T-Lymphocyte Subsets]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Th2 Cells]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[trend]]></TERM><TERM><![CDATA[Woman]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Role of Gender in TH17-Mediated Inflammation in Severe Asthma]]></PROJECT_TITLE><SERIAL_NUMBER>122554</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT>46840</DIRECT_COST_AMT><INDIRECT_COST_AMT>20076</INDIRECT_COST_AMT><TOTAL_COST>66916</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9196934</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>R01GM047892</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-11-260</FOA_NUMBER><FULL_PROJECT_NUM>6R01GM047892-24</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:235995\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: A small family of related transcription factors has been found to regulate cell proliferation and cell differentiation in a large number of tissues. Defects in thse proteins occur in multiple diseases including cancer, schizophrenia, diabetes, and eye diseases. This project investigates the properties of these proteins, with the ultimate goal of influencing their function to treat and prevent disease.]]></PHR><PIS><PI><PI_NAME>BAKER, NICHOLAS E</PI_NAME><PI_ID>1865094</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>HOODBHOY, TANYA </PROGRAM_OFFICER_NAME><PROJECT_START>08/01/1992</PROJECT_START><PROJECT_END>03/31/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Cell-Cell Interactions in Developing Retina]]></PROJECT_TITLE><SERIAL_NUMBER>047892</SERIAL_NUMBER><STUDY_SECTION>BVS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>24</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>141314</DIRECT_COST_AMT><INDIRECT_COST_AMT>94681</INDIRECT_COST_AMT><TOTAL_COST>235995</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9003042</APPLICATION_ID><ACTIVITY>P30</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>5</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/21/2015</AWARD_NOTICE_DATE><BUDGET_START>12/01/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>P30DK041301</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>RFA-DK-12-023</FOA_NUMBER><FULL_PROJECT_NUM>5P30DK041301-27</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:842809\</FUNDING_ICs><FUNDING_MECHANISM>RESEARCH CENTERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>LOS ANGELES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>33</ORG_DISTRICT><ORG_DUNS>092530369</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF CALIFORNIA LOS ANGELES]]></ORG_NAME><ORG_STATE>CA</ORG_STATE><ORG_ZIPCODE>900952000</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: The CURE DRRCC comprises a multidisciplinary research base dedicated to advancing our understanding of the biology, functional disorders and diseases of the digestive system. Scientific core facilities, Pilot and Feasibility Study awards an enrichment programs provide a platform of novel technologies, services and interactions to promote the collaborative research efforts of the CURE: DDRCC membership.]]></PHR><PIS><PI><PI_NAME>ROZENGURT, JUAN ENRIQUE</PI_NAME><PI_ID>6774619</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>PERRIN, PETER J</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/1996</PROJECT_START><PROJECT_END>11/30/2019</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Abnormal Cell]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Area]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Basic Science]]></TERM><TERM><![CDATA[Biocompatible Materials]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Biomedical Research]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[career development]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[cellular imaging]]></TERM><TERM><![CDATA[Clinical]]></TERM><TERM><![CDATA[Clinical Investigator]]></TERM><TERM><![CDATA[clinical material]]></TERM><TERM><![CDATA[Clinical Research]]></TERM><TERM><![CDATA[Core Facility]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Digestive System Disorders]]></TERM><TERM><![CDATA[Discipline]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Effectiveness]]></TERM><TERM><![CDATA[Faculty]]></TERM><TERM><![CDATA[Feasibility Studies]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[gastrointestinal]]></TERM><TERM><![CDATA[gastrointestinal system]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Healthcare Systems]]></TERM><TERM><![CDATA[Hormonal]]></TERM><TERM><![CDATA[Inflammation]]></TERM><TERM><![CDATA[innovation]]></TERM><TERM><![CDATA[Interdisciplinary Study]]></TERM><TERM><![CDATA[Intestines]]></TERM><TERM><![CDATA[Leadership]]></TERM><TERM><![CDATA[lecturer]]></TERM><TERM><![CDATA[Los Angeles]]></TERM><TERM><![CDATA[medical schools]]></TERM><TERM><![CDATA[meetings]]></TERM><TERM><![CDATA[member]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[molecular vector]]></TERM><TERM><![CDATA[multidisciplinary]]></TERM><TERM><![CDATA[National Institute of Diabetes and Digestive and Kidney Diseases]]></TERM><TERM><![CDATA[new technology]]></TERM><TERM><![CDATA[Normal Cell]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[operation]]></TERM><TERM><![CDATA[Pancreas]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[Peer Review Grants]]></TERM><TERM><![CDATA[Physicians]]></TERM><TERM><![CDATA[Physiology]]></TERM><TERM><![CDATA[Pilot Projects]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[professor]]></TERM><TERM><![CDATA[programs]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Receptor Signaling]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Research Infrastructure]]></TERM><TERM><![CDATA[Research Personnel]]></TERM><TERM><![CDATA[Research Support]]></TERM><TERM><![CDATA[Research Training]]></TERM><TERM><![CDATA[Resource Sharing]]></TERM><TERM><![CDATA[Scientist]]></TERM><TERM><![CDATA[Series]]></TERM><TERM><![CDATA[Services]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Signaling Protein]]></TERM><TERM><![CDATA[stem cell biology]]></TERM><TERM><![CDATA[Sum]]></TERM><TERM><![CDATA[symposium]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Technology]]></TERM><TERM><![CDATA[Training Activity]]></TERM><TERM><![CDATA[Training and Education]]></TERM><TERM><![CDATA[Translational Research]]></TERM><TERM><![CDATA[United States Department of Veterans Affairs]]></TERM><TERM><![CDATA[Vision]]></TERM><TERM><![CDATA[Visit]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[CURE: Digestive Diseases Research Center]]></PROJECT_TITLE><SERIAL_NUMBER>041301</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>27</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>631123</DIRECT_COST_AMT><INDIRECT_COST_AMT>211686</INDIRECT_COST_AMT><TOTAL_COST>842809</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9117890</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>GM</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>07/16/2015</BUDGET_START><BUDGET_END>04/30/2016</BUDGET_END><CFDA_CODE>999</CFDA_CODE><CORE_PROJECT_NUM>R01GM105646</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7R01GM105646-03</FULL_PROJECT_NUM><FUNDING_ICs>NIGMS:192236\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>MINNEAPOLIS</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[GENETICS]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>555917996</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MINNESOTA]]></ORG_NAME><ORG_STATE>MN</ORG_STATE><ORG_ZIPCODE>554552070</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE:  G-protein coupled receptors (GPCRs) are a family of proteins which communicate stimuli such as light, odorants and hormones to cells across the human body. GPCRs are a major target of modern drug therapy. An emerging paradigm in GPCR function, termed functional selectivity, significantly broadens the cellular effects of drugs that target GPCRs. We propose to develop new technologies to study GPCRs and use them to understand the molecular mechanisms that lead to functional selectivity. These studies will significantly enhance our understanding of GPCR function in diseases such as heart failure, diabetes and obesity. The novel technologies and insights gained through this research can be used to identify new drugs that exploit GPCR functional selectivity for improved treatments of these diseases.]]></PHR><PIS><PI><PI_NAME>SIVARAMAKRISHNAN, SIVARAJ </PI_NAME><PI_ID>8963539</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>DUNSMORE, SARAH </PROGRAM_OFFICER_NAME><PROJECT_START>07/01/2014</PROJECT_START><PROJECT_END>04/30/2018</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Address]]></TERM><TERM><![CDATA[Adopted]]></TERM><TERM><![CDATA[Adrenergic beta-Antagonists]]></TERM><TERM><![CDATA[Adrenergic Receptor]]></TERM><TERM><![CDATA[Affinity]]></TERM><TERM><![CDATA[Agonist]]></TERM><TERM><![CDATA[Arrestins]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[bimanes]]></TERM><TERM><![CDATA[Binding (Molecular Function)]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Cell Membrane Structures]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Complement]]></TERM><TERM><![CDATA[Coupled]]></TERM><TERM><![CDATA[Cyclic AMP]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Drug Targeting]]></TERM><TERM><![CDATA[Event]]></TERM><TERM><![CDATA[Fluorescence]]></TERM><TERM><![CDATA[Fluorescence Resonance Energy Transfer]]></TERM><TERM><![CDATA[Future]]></TERM><TERM><![CDATA[G Protein-Coupled Receptor Signaling]]></TERM><TERM><![CDATA[G-Protein-Coupled Receptors]]></TERM><TERM><![CDATA[genetic regulatory protein]]></TERM><TERM><![CDATA[GTP-Binding Proteins]]></TERM><TERM><![CDATA[Heart Diseases]]></TERM><TERM><![CDATA[Heart failure]]></TERM><TERM><![CDATA[Hormones]]></TERM><TERM><![CDATA[Human body]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Length]]></TERM><TERM><![CDATA[Life]]></TERM><TERM><![CDATA[Ligand Binding]]></TERM><TERM><![CDATA[Ligands]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Measurement]]></TERM><TERM><![CDATA[Membrane]]></TERM><TERM><![CDATA[Metoprolol]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Molecular Conformation]]></TERM><TERM><![CDATA[Molecular Probes]]></TERM><TERM><![CDATA[Nature]]></TERM><TERM><![CDATA[new technology]]></TERM><TERM><![CDATA[novel]]></TERM><TERM><![CDATA[Obesity]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Peptides]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacotherapy]]></TERM><TERM><![CDATA[Phosphotransferases]]></TERM><TERM><![CDATA[Preclinical Drug Evaluation]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[protein activation]]></TERM><TERM><![CDATA[Protein Family]]></TERM><TERM><![CDATA[protein protein interaction]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Radio]]></TERM><TERM><![CDATA[receptor]]></TERM><TERM><![CDATA[receptor function]]></TERM><TERM><![CDATA[Relative (related person)]]></TERM><TERM><![CDATA[Reporting]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[scaffold]]></TERM><TERM><![CDATA[sensor]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Specific qualifier value]]></TERM><TERM><![CDATA[Specificity]]></TERM><TERM><![CDATA[Stimulus]]></TERM><TERM><![CDATA[Structure]]></TERM><TERM><![CDATA[Surface]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic]]></TERM><TERM><![CDATA[Toxin]]></TERM><TERM><![CDATA[Validation]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Probing molecular mechanisms of GPCR functional selectivity in live cells]]></PROJECT_TITLE><SERIAL_NUMBER>105646</SERIAL_NUMBER><STUDY_SECTION>MIST</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Molecular and Integrative Signal Transduction Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>126471</DIRECT_COST_AMT><INDIRECT_COST_AMT>65765</INDIRECT_COST_AMT><TOTAL_COST>192236</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9178362</APPLICATION_ID><ACTIVITY>K23</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/18/2015</AWARD_NOTICE_DATE><BUDGET_START>12/21/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>K23MH103617</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-14-078</FOA_NUMBER><FULL_PROJECT_NUM>7K23MH103617-03</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:154919\</FUNDING_ICs><FUNDING_MECHANISM>OTHER RESEARCH-RELATED</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>EAST PROVIDENCE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>075706176</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[EMMA PENDLETON BRADLEY HOSPITAL]]></ORG_NAME><ORG_STATE>RI</ORG_STATE><ORG_ZIPCODE>029155061</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Chronic tics affect 1-3% of children and are often associated with marked psychosocial impairment and functional disability. Existing treatments target tic suppression but have limited efficacy because the mechanisms underlying tic suppression are poorly understood. The supplementary motor area (SMA), an area of the cortex that links contextual cues to motor actions, is thought to play a critical role in tic suppression. The role o SMA in tic suppression will be investigated using transcranial magnetic stimulation (TMS), a non- invasive procedure, in conjunction with a behavioral tic suppression task. This research will contribute to our understanding of the processes involved in tic suppression and pave the way for future treatment development.]]></PHR><PIS><PI><PI_NAME>CONELEA, CHRISTINE A</PI_NAME><PI_ID>10702353</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SARAMPOTE, CHRISTOPHER S.</PROGRAM_OFFICER_NAME><PROJECT_START>12/21/2015</PROJECT_START><PROJECT_END>06/30/2018</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Integrative Examination of Neurobehavioral Mechanisms in Tic Suppression]]></PROJECT_TITLE><SERIAL_NUMBER>103617</SERIAL_NUMBER><STUDY_SECTION>NPAS</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>03</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>143518</DIRECT_COST_AMT><INDIRECT_COST_AMT>11401</INDIRECT_COST_AMT><TOTAL_COST>154919</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9180473</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/19/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>06/30/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK098787</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[EARTH SCIENCES/RESOURCES]]></ED_INST_TYPE><FOA_NUMBER>RFA-DK-12-006</FOA_NUMBER><FULL_PROJECT_NUM>7R01DK098787-05</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:206553\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>PULLMAN</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[SOCIAL SCIENCES]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>041485301</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[WASHINGTON STATE UNIVERSITY]]></ORG_NAME><ORG_STATE>WA</ORG_STATE><ORG_ZIPCODE>991640001</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Rates of chronic and end-stage kidney disease are disproportionately high among American Indians, while rates of kidney donation and transplantation are the lowest of any racial or ethnic group in the U.S. New strategies are urgently needed to increase kidney donation and transplantation to improve the quality of life of this dramatically underserved population. Building on our previous work on kidney donation in tribal communities, and leveraging successful efforts by other researchers in racial minority groups, the proposed multi-level, multi-site study will return findings with immediate clinical and public health implications for healthcare facilities that serve American Indians.]]></PHR><PIS><PI><PI_NAME>BUCHWALD, DEDRA S</PI_NAME><PI_ID>1871775</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>MCBRYDE, KEVIN D</PROGRAM_OFFICER_NAME><PROJECT_START>09/21/2012</PROJECT_START><PROJECT_END>06/30/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[Culturally Adapted Strategies to Enhance Kidney Donation in Native Communities]]></PROJECT_TITLE><SERIAL_NUMBER>098787</SERIAL_NUMBER><STUDY_SECTION>ZDK1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>170000</DIRECT_COST_AMT><INDIRECT_COST_AMT>36553</INDIRECT_COST_AMT><TOTAL_COST>206553</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9171979</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>DK</ADMINISTERING_IC><APPLICATION_TYPE>7</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/24/2015</AWARD_NOTICE_DATE><BUDGET_START>12/24/2015</BUDGET_START><BUDGET_END>05/31/2016</BUDGET_END><CFDA_CODE>847</CFDA_CODE><CORE_PROJECT_NUM>R01DK073716</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-10-067</FOA_NUMBER><FULL_PROJECT_NUM>7R01DK073716-11</FULL_PROJECT_NUM><FUNDING_ICs>NIDDK:239736\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>CORAL GABLES</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[INTERNAL MEDICINE/MEDICINE]]></ORG_DEPT><ORG_DISTRICT>27</ORG_DISTRICT><ORG_DUNS>052780918</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[UNIVERSITY OF MIAMI SCHOOL OF MEDICINE]]></ORG_NAME><ORG_STATE>FL</ORG_STATE><ORG_ZIPCODE>331462926</ORG_ZIPCODE><PHR><![CDATA[Failure of ?-cells to expand or adapt to insulin resistance results in type 2 diabetes. The current evidence support the concept that mTORC1 is active in states of increased insulin demand and plays a major role in ?- cell adaptation to insulin resistance The goal of this application is to unravel how mTORC1 regulates ?-cell mass in an effort to develop strategies to identify pharmacological targets to improve ?-cell mass and function for the treatment of diabetes.]]></PHR><PIS><PI><PI_NAME>BERNAL-MIZRACHI, ERNESTO </PI_NAME><PI_ID>7844118</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>SILVA, CORINNE M</PROGRAM_OFFICER_NAME><PROJECT_START>12/01/2005</PROJECT_START><PROJECT_END>05/31/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Amino Acids]]></TERM><TERM><![CDATA[Apoptosis]]></TERM><TERM><![CDATA[Attenuated]]></TERM><TERM><![CDATA[attenuation]]></TERM><TERM><![CDATA[Award]]></TERM><TERM><![CDATA[Beta Cell]]></TERM><TERM><![CDATA[Cell Count]]></TERM><TERM><![CDATA[Cell Cycle Progression]]></TERM><TERM><![CDATA[Cell Cycle Regulation]]></TERM><TERM><![CDATA[cell growth regulation]]></TERM><TERM><![CDATA[Cell physiology]]></TERM><TERM><![CDATA[Cell Proliferation]]></TERM><TERM><![CDATA[Cell Size]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[design]]></TERM><TERM><![CDATA[diabetes management]]></TERM><TERM><![CDATA[Diabetes Mellitus]]></TERM><TERM><![CDATA[drug development]]></TERM><TERM><![CDATA[Equilibrium]]></TERM><TERM><![CDATA[Eukaryotic Initiation Factor-4E]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[extracellular]]></TERM><TERM><![CDATA[Failure (biologic function)]]></TERM><TERM><![CDATA[Feedback]]></TERM><TERM><![CDATA[Funding]]></TERM><TERM><![CDATA[Genetic Models]]></TERM><TERM><![CDATA[Glucose]]></TERM><TERM><![CDATA[Goals]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Growth Factor]]></TERM><TERM><![CDATA[human FRAP1 protein]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Insulin]]></TERM><TERM><![CDATA[Insulin Resistance]]></TERM><TERM><![CDATA[IRS1 gene]]></TERM><TERM><![CDATA[IRS2 gene]]></TERM><TERM><![CDATA[Knowledge]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Non-Insulin-Dependent Diabetes Mellitus]]></TERM><TERM><![CDATA[novel therapeutics]]></TERM><TERM><![CDATA[Nutrient]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[PDPK1 gene]]></TERM><TERM><![CDATA[Physiological]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Raptors]]></TERM><TERM><![CDATA[Regulation]]></TERM><TERM><![CDATA[research study]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Ribosomal Protein S6 Kinase]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Signal Pathway]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[TSC1/2 gene]]></TERM><TERM><![CDATA[Tuberous sclerosis protein complex]]></TERM><TERM><![CDATA[Uncertainty]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Akt/mTOR signaling and regulation of cell cycle in beta-cells]]></PROJECT_TITLE><SERIAL_NUMBER>073716</SERIAL_NUMBER><STUDY_SECTION>CADO</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Cellular Aspects of Diabetes and Obesity Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>11</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>156180</DIRECT_COST_AMT><INDIRECT_COST_AMT>83556</INDIRECT_COST_AMT><TOTAL_COST>239736</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9026858</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>HD</ADMINISTERING_IC><APPLICATION_TYPE>2</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>12/22/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>865</CFDA_CODE><CORE_PROJECT_NUM>R01HD064727</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>2R01HD064727-06A1</FULL_PROJECT_NUM><FUNDING_ICs>NICHD:432819\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &amp; HUMAN DEVELOPMENT</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Intellectual and Developmental Disabilities (IDD)]]></CATEGORY><CATEGORY><![CDATA[Neurodegenerative]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY><CATEGORY><![CDATA[Orphan Drug]]></CATEGORY><CATEGORY><![CDATA[Pediatric]]></CATEGORY><CATEGORY><![CDATA[Rare Diseases]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>NASHVILLE</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[BIOCHEMISTRY]]></ORG_DEPT><ORG_DISTRICT>05</ORG_DISTRICT><ORG_DUNS>004413456</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[VANDERBILT UNIVERSITY]]></ORG_NAME><ORG_STATE>TN</ORG_STATE><ORG_ZIPCODE>372122809</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: Smith-Lemli-Opitz syndrome (SLOS) is a devastating neurodevelopmental metabolic disorder caused by a defect in cholesterol biosynthesis that leads to a build up of toxic oxysterol compounds. Establishing assays for sterols and oxysterols in human fluids and understanding their fundamental neurobiology will shed light on SLOS and lead to therapies for this disorder and others that have altered cholesterol metabolism.   
      

]]></PHR><PIS><PI><PI_NAME>PORTER, NED ALLEN</PI_NAME><PI_ID>8288519</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>KROTOSKI, DANUTA </PROGRAM_OFFICER_NAME><PROJECT_START>04/01/2010</PROJECT_START><PROJECT_END>11/30/2020</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[7-dehydrocholesterol]]></TERM><TERM><![CDATA[7-dehydrocholesterol reductase]]></TERM><TERM><![CDATA[adduct]]></TERM><TERM><![CDATA[Affect]]></TERM><TERM><![CDATA[Alzheimer's Disease]]></TERM><TERM><![CDATA[Antioxidants]]></TERM><TERM><![CDATA[Autistic Disorder]]></TERM><TERM><![CDATA[AY9944]]></TERM><TERM><![CDATA[Biological]]></TERM><TERM><![CDATA[Biological Assay]]></TERM><TERM><![CDATA[Biology]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Cell Culture Techniques]]></TERM><TERM><![CDATA[Cell Line]]></TERM><TERM><![CDATA[Cells]]></TERM><TERM><![CDATA[Chemistry]]></TERM><TERM><![CDATA[Cholecalciferol]]></TERM><TERM><![CDATA[Cholesterol]]></TERM><TERM><![CDATA[cholesterol biosynthesis]]></TERM><TERM><![CDATA[Cholesterol Homeostasis]]></TERM><TERM><![CDATA[Collection]]></TERM><TERM><![CDATA[Complex]]></TERM><TERM><![CDATA[congenital anomaly]]></TERM><TERM><![CDATA[Control Groups]]></TERM><TERM><![CDATA[Defect]]></TERM><TERM><![CDATA[Desmosterol]]></TERM><TERM><![CDATA[Development]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Drug Exposure]]></TERM><TERM><![CDATA[Drug toxicity]]></TERM><TERM><![CDATA[Enzymes]]></TERM><TERM><![CDATA[Epoxy Compounds]]></TERM><TERM><![CDATA[Exhibits]]></TERM><TERM><![CDATA[Exposure to]]></TERM><TERM><![CDATA[Fibroblasts]]></TERM><TERM><![CDATA[Follow-Up Studies]]></TERM><TERM><![CDATA[Free Radicals]]></TERM><TERM><![CDATA[Frequencies (time pattern)]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[Gene Expression]]></TERM><TERM><![CDATA[Genetic]]></TERM><TERM><![CDATA[Grant]]></TERM><TERM><![CDATA[Health]]></TERM><TERM><![CDATA[Hereditary Disease]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Human Biology]]></TERM><TERM><![CDATA[human disease]]></TERM><TERM><![CDATA[human tissue]]></TERM><TERM><![CDATA[Huntington Disease]]></TERM><TERM><![CDATA[in vivo]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[Infant]]></TERM><TERM><![CDATA[Laboratories]]></TERM><TERM><![CDATA[Lanosterol]]></TERM><TERM><![CDATA[Lead]]></TERM><TERM><![CDATA[Libraries]]></TERM><TERM><![CDATA[Light]]></TERM><TERM><![CDATA[Link]]></TERM><TERM><![CDATA[lipid biosynthesis]]></TERM><TERM><![CDATA[Lipid Peroxidation]]></TERM><TERM><![CDATA[Lipids]]></TERM><TERM><![CDATA[Liquid substance]]></TERM><TERM><![CDATA[Measurable]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mental Retardation]]></TERM><TERM><![CDATA[Metabolic]]></TERM><TERM><![CDATA[Metabolic Diseases]]></TERM><TERM><![CDATA[Metabolism]]></TERM><TERM><![CDATA[Methods]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Modification]]></TERM><TERM><![CDATA[Molecular]]></TERM><TERM><![CDATA[Mortality Vital Statistics]]></TERM><TERM><![CDATA[mouse model]]></TERM><TERM><![CDATA[Mus]]></TERM><TERM><![CDATA[Mutant Strains Mice]]></TERM><TERM><![CDATA[Mutation]]></TERM><TERM><![CDATA[Nerve Degeneration]]></TERM><TERM><![CDATA[Neurobiology]]></TERM><TERM><![CDATA[neuroblastoma cell]]></TERM><TERM><![CDATA[Neurodegenerative Disorders]]></TERM><TERM><![CDATA[Neuronal Differentiation]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[Nuclear Receptors]]></TERM><TERM><![CDATA[Organ]]></TERM><TERM><![CDATA[oxidation]]></TERM><TERM><![CDATA[Oxidative Stress]]></TERM><TERM><![CDATA[Oxygen]]></TERM><TERM><![CDATA[Parkinson Disease]]></TERM><TERM><![CDATA[Pathology]]></TERM><TERM><![CDATA[Pathway interactions]]></TERM><TERM><![CDATA[Patients]]></TERM><TERM><![CDATA[peroxidation]]></TERM><TERM><![CDATA[Pharmaceutical Preparations]]></TERM><TERM><![CDATA[Pharmacologic Substance]]></TERM><TERM><![CDATA[Phenotype]]></TERM><TERM><![CDATA[Plasma]]></TERM><TERM><![CDATA[Play]]></TERM><TERM><![CDATA[postnatal]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Proteins]]></TERM><TERM><![CDATA[Protocols documentation]]></TERM><TERM><![CDATA[public health medicine (field)]]></TERM><TERM><![CDATA[public health relevance]]></TERM><TERM><![CDATA[Rattus]]></TERM><TERM><![CDATA[Records]]></TERM><TERM><![CDATA[Research]]></TERM><TERM><![CDATA[Rodent]]></TERM><TERM><![CDATA[Role]]></TERM><TERM><![CDATA[Sampling]]></TERM><TERM><![CDATA[screening]]></TERM><TERM><![CDATA[small molecule]]></TERM><TERM><![CDATA[Smith-Lemli-Opitz Syndrome]]></TERM><TERM><![CDATA[Standard Preparations]]></TERM><TERM><![CDATA[Sterol Biosynthesis Pathway]]></TERM><TERM><![CDATA[Sterols]]></TERM><TERM><![CDATA[Symptoms]]></TERM><TERM><![CDATA[Syndrome]]></TERM><TERM><![CDATA[Therapeutic Studies]]></TERM><TERM><![CDATA[tissue/cell culture]]></TERM><TERM><![CDATA[Tissues]]></TERM><TERM><![CDATA[Toxic effect]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[SLOS and Neuronal Oxidative Stress]]></PROJECT_TITLE><SERIAL_NUMBER>064727</SERIAL_NUMBER><STUDY_SECTION>NOMD</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Neural Oxidative Metabolism and Death Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>06</SUPPORT_YEAR><SUFFIX>A1</SUFFIX><DIRECT_COST_AMT>275681</DIRECT_COST_AMT><INDIRECT_COST_AMT>157138</INDIRECT_COST_AMT><TOTAL_COST>432819</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9198138</APPLICATION_ID><ACTIVITY>U2G</ACTIVITY><ADMINISTERING_IC>GH</ADMINISTERING_IC><APPLICATION_TYPE>3</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/23/2015</AWARD_NOTICE_DATE><BUDGET_START>04/01/2015</BUDGET_START><BUDGET_END>03/31/2016</BUDGET_END><CFDA_CODE></CFDA_CODE><CORE_PROJECT_NUM>U2GGH000119</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF PUBLIC HEALTH]]></ED_INST_TYPE><FOA_NUMBER>RFA-GH-11-116</FOA_NUMBER><FULL_PROJECT_NUM>3U2GGH000119-04S1</FULL_PROJECT_NUM><FUNDING_ICs>COGH:278000\</FUNDING_ICs><FUNDING_MECHANISM>OTHERS</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>Center for Global Health</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>NEW YORK</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[PUBLIC HEALTH & PREV MEDICINE]]></ORG_DEPT><ORG_DISTRICT>13</ORG_DISTRICT><ORG_DUNS>621889815</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[COLUMBIA UNIVERSITY HEALTH SCIENCES]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>100320049</ORG_ZIPCODE><PHR xsi:nil='true' /><PIS><PI><PI_NAME>BORTOLOTTI, VERONIQUE </PI_NAME><PI_ID>12474860</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME></PROGRAM_OFFICER_NAME><PROJECT_START>09/30/2011</PROJECT_START><PROJECT_END>03/31/2017</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[GH11-1116, Cote d'Ivoire:  IMPLEMENTATION OF PROGRAM FOR THE PREVENTION, CARE AND TREATMENT OF HIV/AIDS]]></PROJECT_TITLE><SERIAL_NUMBER>000119</SERIAL_NUMBER><STUDY_SECTION>ZGH1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>04</SUPPORT_YEAR><SUFFIX>S1</SUFFIX><DIRECT_COST_AMT></DIRECT_COST_AMT><INDIRECT_COST_AMT></INDIRECT_COST_AMT><TOTAL_COST>278000</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>8959934</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>MH</ADMINISTERING_IC><APPLICATION_TYPE>4</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/19/2015</AWARD_NOTICE_DATE><BUDGET_START>12/19/2015</BUDGET_START><BUDGET_END>11/30/2016</BUDGET_END><CFDA_CODE>242</CFDA_CODE><CORE_PROJECT_NUM>R01MH095894</CORE_PROJECT_NUM><ED_INST_TYPE><![CDATA[SCHOOLS OF MEDICINE]]></ED_INST_TYPE><FOA_NUMBER>PA-10-158</FOA_NUMBER><FULL_PROJECT_NUM>4R01MH095894-05</FULL_PROJECT_NUM><FUNDING_ICs>NIMH:278473\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2016</FY><IC_NAME>NATIONAL INSTITUTE OF MENTAL HEALTH</IC_NAME><NIH_SPENDING_CATS><CATEGORY><![CDATA[Autism]]></CATEGORY><CATEGORY><![CDATA[Basic Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Behavioral and Social Science]]></CATEGORY><CATEGORY><![CDATA[Brain Disorders]]></CATEGORY><CATEGORY><![CDATA[Intellectual and Developmental Disabilities (IDD)]]></CATEGORY><CATEGORY><![CDATA[Mental Health]]></CATEGORY><CATEGORY><![CDATA[Neurosciences]]></CATEGORY></NIH_SPENDING_CATS><ORG_CITY>DURHAM</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT><![CDATA[NEUROSCIENCES]]></ORG_DEPT><ORG_DISTRICT>01</ORG_DISTRICT><ORG_DUNS>044387793</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[DUKE UNIVERSITY]]></ORG_NAME><ORG_STATE>NC</ORG_STATE><ORG_ZIPCODE>277054673</ORG_ZIPCODE><PHR><![CDATA[Despite a broad continuum of phenotypic variation in behavior, individuals with autism spectrum disorders (ASD) share core deficits in social interaction. Here we propose that social dysfunction in ASD results, in part, from problems in deriving vicarious reward from others. We will use our new animal model of vicarious reward to discover how the brain signals vicarious reward, discover the impact of brain dysfunction on vicarious reward, and test how oxytocin, a potential therapy for ASD, might improve vicarious reward and brain function.]]></PHR><PIS><PI><PI_NAME>PLATT, MICHAEL L</PI_NAME><PI_ID>1965917</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>ROSSI, ANDREW </PROGRAM_OFFICER_NAME><PROJECT_START>02/21/2012</PROJECT_START><PROJECT_END>11/30/2016</PROJECT_END><PROJECT_TERMSX><TERM><![CDATA[Animal Model]]></TERM><TERM><![CDATA[Anterior]]></TERM><TERM><![CDATA[Attention]]></TERM><TERM><![CDATA[autism spectrum disorder]]></TERM><TERM><![CDATA[base]]></TERM><TERM><![CDATA[Behavior]]></TERM><TERM><![CDATA[Behavioral Model]]></TERM><TERM><![CDATA[Brain]]></TERM><TERM><![CDATA[Brain imaging]]></TERM><TERM><![CDATA[Caring]]></TERM><TERM><![CDATA[Cervical]]></TERM><TERM><![CDATA[cingulate cortex]]></TERM><TERM><![CDATA[classical conditioning]]></TERM><TERM><![CDATA[Code]]></TERM><TERM><![CDATA[Computers]]></TERM><TERM><![CDATA[Cues]]></TERM><TERM><![CDATA[Data]]></TERM><TERM><![CDATA[Disease]]></TERM><TERM><![CDATA[Electric Stimulation]]></TERM><TERM><![CDATA[electrical microstimulation]]></TERM><TERM><![CDATA[Ethics]]></TERM><TERM><![CDATA[experience]]></TERM><TERM><![CDATA[Functional disorder]]></TERM><TERM><![CDATA[gaze]]></TERM><TERM><![CDATA[Growth]]></TERM><TERM><![CDATA[Human]]></TERM><TERM><![CDATA[Impairment]]></TERM><TERM><![CDATA[improved]]></TERM><TERM><![CDATA[Individual]]></TERM><TERM><![CDATA[insight]]></TERM><TERM><![CDATA[Investigation]]></TERM><TERM><![CDATA[learned behavior]]></TERM><TERM><![CDATA[Learning]]></TERM><TERM><![CDATA[Lesion]]></TERM><TERM><![CDATA[Macaca mulatta]]></TERM><TERM><![CDATA[Measures]]></TERM><TERM><![CDATA[Mediating]]></TERM><TERM><![CDATA[microstimulation]]></TERM><TERM><![CDATA[Modeling]]></TERM><TERM><![CDATA[Monkeys]]></TERM><TERM><![CDATA[motivated behavior]]></TERM><TERM><![CDATA[National Institute of Mental Health (U.S.)]]></TERM><TERM><![CDATA[network dysfunction]]></TERM><TERM><![CDATA[neural circuit]]></TERM><TERM><![CDATA[neuromechanism]]></TERM><TERM><![CDATA[Neurons]]></TERM><TERM><![CDATA[neurophysiology]]></TERM><TERM><![CDATA[Neurophysiology - biologic function]]></TERM><TERM><![CDATA[neuropsychiatry]]></TERM><TERM><![CDATA[Operant Conditioning]]></TERM><TERM><![CDATA[Outcome]]></TERM><TERM><![CDATA[Oxytocin]]></TERM><TERM><![CDATA[Pattern]]></TERM><TERM><![CDATA[Penetration]]></TERM><TERM><![CDATA[preference]]></TERM><TERM><![CDATA[Process]]></TERM><TERM><![CDATA[Psychological reinforcement]]></TERM><TERM><![CDATA[Puncture procedure]]></TERM><TERM><![CDATA[Punishment]]></TERM><TERM><![CDATA[Reaction Time]]></TERM><TERM><![CDATA[Reference Values]]></TERM><TERM><![CDATA[response]]></TERM><TERM><![CDATA[Rewards]]></TERM><TERM><![CDATA[Saline]]></TERM><TERM><![CDATA[Shapes]]></TERM><TERM><![CDATA[Signal Transduction]]></TERM><TERM><![CDATA[social]]></TERM><TERM><![CDATA[Social Interaction]]></TERM><TERM><![CDATA[Techniques]]></TERM><TERM><![CDATA[Testing]]></TERM><TERM><![CDATA[Therapeutic Intervention]]></TERM><TERM><![CDATA[Variant]]></TERM><TERM><![CDATA[Visual]]></TERM><TERM><![CDATA[Work]]></TERM></PROJECT_TERMSX><PROJECT_TITLE><![CDATA[Neuronal Basis of Vicarious Reinforcement Dysfunction in Autism Spectrum Disorder]]></PROJECT_TITLE><SERIAL_NUMBER>095894</SERIAL_NUMBER><STUDY_SECTION>BRLE</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Biobehavioral Regulation, Learning and Ethology Study Section ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>05</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>180000</DIRECT_COST_AMT><INDIRECT_COST_AMT>98473</INDIRECT_COST_AMT><TOTAL_COST>278473</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
<row><APPLICATION_ID>9197387</APPLICATION_ID><ACTIVITY>R01</ACTIVITY><ADMINISTERING_IC>NS</ADMINISTERING_IC><APPLICATION_TYPE>6</APPLICATION_TYPE><ARRA_FUNDED>N</ARRA_FUNDED><AWARD_NOTICE_DATE>12/22/2015</AWARD_NOTICE_DATE><BUDGET_START>09/01/2015</BUDGET_START><BUDGET_END>07/31/2016</BUDGET_END><CFDA_CODE>853</CFDA_CODE><CORE_PROJECT_NUM>R01NS092466</CORE_PROJECT_NUM><ED_INST_TYPE xsi:nil='true'/><FOA_NUMBER>PA-13-302</FOA_NUMBER><FULL_PROJECT_NUM>6R01NS092466-02</FULL_PROJECT_NUM><FUNDING_ICs>NINDS:374435\</FUNDING_ICs><FUNDING_MECHANISM>Non-SBIR/STTR RPGs</FUNDING_MECHANISM><FY>2015</FY><IC_NAME>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</IC_NAME><NIH_SPENDING_CATS xsi:nil='true' /><ORG_CITY>BRONX</ORG_CITY><ORG_COUNTRY>UNITED STATES</ORG_COUNTRY><ORG_DEPT xsi:nil='true'/><ORG_DISTRICT>14</ORG_DISTRICT><ORG_DUNS>079783367</ORG_DUNS><ORG_FIPS>US</ORG_FIPS><ORG_NAME><![CDATA[ALBERT EINSTEIN COLLEGE OF MEDICINE, INC]]></ORG_NAME><ORG_STATE>NY</ORG_STATE><ORG_ZIPCODE>104611975</ORG_ZIPCODE><PHR><![CDATA[PUBLIC HEALTH RELEVANCE: This application, which is based on numerous previous findings by the applicants, will determine how the protein complex formed of gap junction proteins and their binding partners contribute to astrocyte physiology. Specific experiments will evaluate how connexins link to cytoskeletal and other proteins of astrocytes, how these interactions give rise to polarization of astrocytes and to establishment of the tight endothelial barrier and how both the astrocyte polarization and endothelial barrier are remodeled following disruption by ultrasound.   
      

]]></PHR><PIS><PI><PI_NAME>SCEMES, ELIANA </PI_NAME><PI_ID>2091199</PI_ID></PI><PI><PI_NAME>SPRAY, DAVID C (contact)</PI_NAME><PI_ID>1906080 (contact)</PI_ID></PI></PIS><PROGRAM_OFFICER_NAME>BOSETTI, FRANCESCA </PROGRAM_OFFICER_NAME><PROJECT_START>08/01/2015</PROJECT_START><PROJECT_END>07/31/2020</PROJECT_END><PROJECT_TERMSX xsi:nil='true' /><PROJECT_TITLE><![CDATA[The Astrocyte Nexus:  Cx43 Protein Interactions]]></PROJECT_TITLE><SERIAL_NUMBER>092466</SERIAL_NUMBER><STUDY_SECTION>ZRG1</STUDY_SECTION><STUDY_SECTION_NAME><![CDATA[Special Emphasis Panel ]]></STUDY_SECTION_NAME><SUBPROJECT_ID></SUBPROJECT_ID><SUPPORT_YEAR>02</SUPPORT_YEAR><SUFFIX></SUFFIX><DIRECT_COST_AMT>224213</DIRECT_COST_AMT><INDIRECT_COST_AMT>150222</INDIRECT_COST_AMT><TOTAL_COST>374435</TOTAL_COST><TOTAL_COST_SUB_PROJECT /></row>
</PROJECTS>
